CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

Annual Review of Immunology 16, 111-135 DOI: 10.1146/annurev.immunol.16.1.111

Citation Report

#	Article	IF	CITATIONS
1	Interactions between T lymphocytes and endothelial cells in allograft rejection. Current Opinion in Immunology, 1998, 10, 525-531.	2.4	85
2	Cytokine Actions in the Central Nervous System. Cytokine and Growth Factor Reviews, 1998, 9, 259-275.	3.2	340
3	Cellular interactions in the pathogenesis of lupus nephritis: The role of T cells and macrophages in the amplification of the inflammatory process in the kidney. Lupus, 1998, 7, 597-603.	0.8	86
4	Innate immune recognition and control of adaptive immune responses. Seminars in Immunology, 1998, 10, 351-353.	2.7	330
5	Tumor necrosis factor receptor family members in the immune system. Seminars in Immunology, 1998, 10, 423-434.	2.7	149
6	The TRAF Family of Signal Transducers Mediates NF-κB Activation by the TRANCE Receptor. Journal of Biological Chemistry, 1998, 273, 28355-28359.	1.6	424
7	Cell surface sialic acid and the regulation of immune cell interactions: the neuraminidase effect reconsidered. Glycobiology, 1999, 9, 267-275.	1.3	40
8	Nonlymphocyte-Derived Tumor Necrosis Factor Is Required for Induction of Colitis in Recombination Activating Gene (Rag)2â^'/âr' Mice upon Transfer of Cd4+Cd45rbhi T Cells. Journal of Experimental Medicine, 1999, 190, 1479-1492.	4.2	118
9	A Critical Role for Cd40–Cd40 Ligand Interactions in Amplification of the Mucosal Cd8 T Cell Response. Journal of Experimental Medicine, 1999, 190, 1275-1284.	4.2	74
10	TRANCE–RANK, a New Signal Pathway Involved in Lymphocyte Development and T Cell Activation. Journal of Experimental Medicine, 1999, 189, 1017-1020.	4.2	54
11	NF-ÂB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9136-9141.	3.3	505
12	CD8+ T Cells Mediate CD40-independent Maturation of Dendritic Cells In Vivo. Journal of Experimental Medicine, 1999, 189, 1875-1884.	4.2	140
13	Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response. Journal of Experimental Medicine, 1999, 190, 125-134.	4.2	168
14	BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth. Journal of Experimental Medicine, 1999, 189, 1747-1756.	4.2	1,213
15	Anti-Tumor Immunity Induced by in Vivo Adenovirus Vector-Mediated Expression of CD40 Ligand in Tumor Cells. Human Gene Therapy, 1999, 10, 1375-1387.	1.4	83
16	Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8132-8137.	3.3	405
17	TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand–independent T Helper Cell Activation. Journal of Experimental Medicine, 1999, 189, 1025-1031.	4.2	240
18	The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection. Current Opinion in Immunology, 1999, 11, 504-508.	2.4	67

		CITATION REPORT		
#	Article		IF	CITATIONS
19	The initiation of autoimmune diabetes. Current Opinion in Immunology, 1999, 11, 663	-669.	2.4	29
20	Regulation of MHC class II expression in the central nervous system. Microbes and Infe 893-902.	ction, 1999, 1,	1.0	23
21	Manipulation of TGF- $\hat{1}^2$ to control autoimmune and chronic inflammatory diseases. Mic Infection, 1999, 1, 1367-1380.	robes and	1.0	67
22	Aberrant expression and reverse signalling of CD70 on malignant B cells. British Journal Haematology, 1999, 106, 491-503.	of	1.2	125
23	Systematic characterization of porcine ileal Peyer's patch, II. A role for CD154 on T selection of immature porcine ileal Peyer's patch B cells. Immunology, 1999, 98, 62	cells in the positive 22-629.	2.0	12
24	CD40 expression on graft infiltrates and parenchymal CD154 (CD40L) induction in hur renal allograft rejection. Kidney International, 1999, 55, 1543-1552.	nan chronic	2.6	36
25	Two subsets of memory T lymphocytes with distinct homing potentials and effector fu Nature, 1999, 402, 34-38.	nctions.	13.7	19
26	Gene targeting in the analysis of mammalian apoptosis and TNF receptor superfamily s Immunological Reviews, 1999, 169, 283-302.	ignaling.	2.8	70
27	Regulation of the IL-12/IL-12R axis: a critical step in T-helper cell differentiation and effe Immunological Reviews, 1999, 170, 65-72.	ctor function.	2.8	131
28	Two subsets of memory T lymphocytes with distinct homing potentials and effector fu Nature, 1999, 401, 708-712.	nctions.	13.7	5,333
29	CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypas Nature Medicine, 1999, 5, 548-553.	sses T-cell help.	15.2	381
30	Tumor necrosis factor-a and the progression of diabetes in non-obese diabetic mice. Im Reviews, 1999, 169, 11-22.	munological	2.8	66
31	Generation of protective immunity against an immunogenic carcinoma requires CD40/ B7/CD28 interactions but not CD4 + T cells. Cancer Immunology, Immunotherapy, 199	CD40L and 19, 48, 336-341.	2.0	20
32	The development of CD4+ T effector cells during the type 2 immune response. Immuno 1999, 20, 55-65.	ologic Research,	1.3	20
33	Mechanisms and assessment of lectin-mediated mitogenesis. Molecular Biotechnology	, 1999, 11, 55-65.	1.3	42
34	Differential regulation of rheumatoid synovial cell interleukin-12 production by tumor r factor ? and CD40 signals. Arthritis and Rheumatism, 1999, 42, 1917-1926.	necrosis	6.7	25
35	CD40 cross-linking enhances the immunogenicity of Burkitt's-lymphoma cell lines. , 19	99, 83, 772-779.		8
36	TRAF2 Deficiency Results in Hyperactivity of Certain TNFR1 Signals and Impairment of Responses. Immunity, 1999, 11, 379-389.	CD40-Mediated	6.6	128

ARTICLE IF CITATIONS # OX40-Deficient Mice Are Defective in Th Cell Proliferation but Are Competent in Generating B Cell and 37 6.6 297 CTL Responses after Virus Infection. Immunity, 1999, 11, 699-708. On costimulatory signals and T cell tolerance: relevance for transplantation immunity. Transplantation Proceedings, 1999, 31, 25S-32S. 0.3 UPDATE OF DIAGNOSTIC AND PROGNOSTIC MARKERS IN CUTANEOUS MALIGNANT MELANOMA. 39 1.0 20 Dermatologic Clinics, 1999, 17, 631-643. Bone Marrow-Derived Cells Are Required for the Induction of a Pulmonary Inflammatory Response Mediated by CD40 Ligation. American Journal of Pathology, 1999, 154, 919-926. Costimulatory Markers in Muscle of Patients with Idiopathic Inflammatory Myopathies and in 41 1.4 87 Cultured Muscle Cells. Clinical Immunology, 1999, 92, 161-169. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. Journal of Leukocyte Biology, 1999, 65, 715-724. 1.5 188 Molecular Biology of Transplantation. Nephron, 2000, 86, 260-265. 43 0.9 6 The CD40/CD40 Ligand Interaction Is Required for Resistance to Toxoplasmic Encephalitis. Infection 44 1.0 and Immunity, 2000, 68, 1312-1318. 45 CD40-CD40 ligand. Journal of Leukocyte Biology, 2000, 67, 2-17. 1,219 1.5 Progress in the treatment of proliferative lupus nephritis. Current Opinion in Nephrology and 1.0 Hypertension, 2000, 9, 107-115. The role of costimulatory molecules as targets for new immunosuppressives in transplantation. 47 0.9 27 Current Opinion in Urológy, 2000, 10, 57-62. Marked immunosuppressive effects of the HIV-2 envelope protein in spite of the lower HIV-2 34 pathogenicity. Aids, 2000, 14, 2679-2686. Detection of membrane-bound tumor necrosis factor (TNF): An analysis of TNF-specific reagents. 49 1.2 17 Microscopy Research and Technique, 2000, 50, 243-250. The role of CD40 ligand and tumor necrosis factor \hat{l} ± signaling in the transgenic K/BxN mouse model of rheumatoid arthritis. Arthritis and Rheumatism, 2000, 43, 2571-2577. 6.7 Engagement of CD30 shapes the secretion of cytokines by human î³ î´T cells. European Journal of 51 1.6 22 Immunology, 2000, 30, 2172-2180. Bacterial CpG-DNA activates dendritic cellsin vivo: T helper cell-independent cytotoxic T cell 161 responses to soluble proteins. European Journal of Immunology, 2000, 30, 3591-3597. Potential of costimulation-based therapies for composite tissue allotransplantation. Microsurgery, 53 0.6 27 2000, 20, 430-434. 54 Strategies for tolerance induction to composite tissue allografts. Microsurgery, 2000, 20, 448-452.

#	Article	IF	CITATIONS
55	Blocking T-cell costimulation in transplantation: opportunities and challenges. Transfusion, 2000, 40, 139-142.	0.8	6
56	Absence of CD40-CD40 ligand interactions in X-linked hyper-IgM syndrome does not affect differentiation of T helper cell subsets. Clinical and Experimental Immunology, 2000, 121, 346-352.	1.1	7
57	Interleukin-15 up-regulates the expression of CD154 on synovial fluid T cells. Immunology, 2000, 100, 238-244.	2.0	15
58	Induction of functional CD154 (CD40 ligand) in neonatal T cells by cAMP-elevating agents. Immunology, 2000, 100, 432-440.	2.0	9
59	Fortifying B cells with CD154: an engaging tale of many hues. Immunology, 2000, 100, 269-280.	2.0	39
60	CD40-CD40 ligand (CD154) engagement is required but may not be sufficient for human T helper 1 cell induction of interleukin-2- or interleukin-15-driven, contact-dependent, interleukin-11² production by monocytes. Immunology, 2000, 99, 279-286.	2.0	31
61	p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nature Medicine, 2000, 6, 290-297.	15.2	216
62	Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nature Medicine, 2000, 6, 673-679.	15.2	109
63	Immunologic â€~ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nature Medicine, 2000, 6, 686-688.	15.2	412
64	Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells. Nature Medicine, 2000, 6, 1154-1159.	15.2	81
65	In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Therapy, 2000, 7, 1467-1476.	2.3	67
66	Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature, 2000, 408, 57-63.	13.7	1,099
67	NF-κB as a therapeutic target in chronic inflammation: recent advances. Trends in Molecular Medicine, 2000, 6, 441-448.	2.6	358
68	CD154 polymorphism in Spanish populations. Differences in the allelic distribution between Canary Islanders and Peninsulars. International Journal of Immunogenetics, 2000, 27, 141-144.	1.2	8
69	The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends in Cell Biology, 2000, 10, 542-550.	3.6	361
70	Active immunization of humans with dendritic cells. , 2000, 20, 167-174.		31
71	Improved dysgammaglobulinaemia in congenital rubella syndrome after immunoglobulin therapy: correlation with CD154 expression. European Journal of Pediatrics, 2000, 159, 764-766.	1.3	7
72	Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice. Hepatology, 2000, 31, 1266-1274.	3.6	103

#	Article	IF	CITATIONS
73	Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood, 2000, 96, 218-223.	0.6	242
74	Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood, 2000, 96, 91-99.	0.6	132
75	Immune regulation by CD40-CD40-L interactions - 2 Y2K update. Frontiers in Bioscience - Landmark, 2000, 5, d880-893.	3.0	6
76	Neonatal Tumor Necrosis Factor α Promotes Diabetes in Nonobese Diabetic Mice by Cd154-Independent Antigen Presentation to Cd8+ T Cells. Journal of Experimental Medicine, 2000, 191, 225-238.	4.2	71
77	Impairment of Antigen-Presenting Cell Function in Mice Lacking Expression of Ox40 Ligand. Journal of Experimental Medicine, 2000, 191, 365-374.	4.2	268
78	Immune regulation by CD40-CD40-L interactions - 2; Y2K update. Frontiers in Bioscience - Landmark, 2000, 5, d880.	3.0	42
79	The Role of CD40-CD154 Interactions in the Regulation of Cell Mediated Immunity. Immunological Investigations, 2000, 29, 111-114.	1.0	42
80	CD40-CD40 Ligand-Independent Activation of CD8+ T Cells Can Trigger Allograft Rejection. Journal of Immunology, 2000, 165, 1111-1118.	0.4	144
81	CD4+ T Lymphocytes with Constitutive CD40 Ligand in Preautoimmune (NZB × NZW)F1 Lupus-Prone Mice: Phenotype and Possible Role in Autoreactivity. Journal of Immunology, 2000, 165, 4095-4104.	0.4	31
82	Role of IL-6 in Directing the Initial Immune Response to Schistosome Eggs. Journal of Immunology, 2000, 164, 2419-2426.	0.4	61
83	Regulation of Cytokine Expression in Mice Immunized with Cryptococcal Polysaccharide, a Glucuronoxylomannan (GXM), Associated with Peritoneal Antigen-Presenting Cells (APC): Requirements for GXM, APC Activation, and Interleukin-12. Infection and Immunity, 2000, 68, 5146-5153.	1.0	10
84	IL-2 and IL-15 Regulate CD154 Expression on Activated CD4 T Cells. Journal of Immunology, 2000, 164, 3500-3505.	0.4	66
85	Requirement of B7 Costimulation for Th1-Mediated Inflammatory Bone Resorption in Experimental Periodontal Disease. Journal of Immunology, 2000, 164, 2102-2109.	0.4	144
86	IL-15 Is Highly Expressed in Inflammatory Bowel Disease and Regulates Local T Cell-Dependent Cytokine Production. Journal of Immunology, 2000, 164, 3608-3615.	0.4	177
87	Measles Virus Induces Abnormal Differentiation of CD40 Ligand-Activated Human Dendritic Cells. Journal of Immunology, 2000, 164, 1753-1760.	0.4	159
88	Human Vascular Endothelial Cells Stimulate Memory But Not Naive CD8+ T Cells to Differentiate into CTL Retaining an Early Activation Phenotype. Journal of Immunology, 2000, 164, 5146-5155.	0.4	94
89	Engagement of CD153 (CD30 Ligand) by CD30+T Cells Inhibits Class Switch DNA Recombination and Antibody Production in Human IgD+IgM+B Cells. Journal of Immunology, 2000, 165, 786-794.	0.4	89
90	Cytokines and Cell Surface Molecules Independently Induce CXCR4 Expression on CD4+ CCR7+ Human Memory T Cells. Journal of Immunology, 2000, 165, 716-724.	0.4	101

#	Article	IF	CITATIONS
91	Blockade of Costimulation Prevents Infection-Induced Immunopathology in Interleukin-10-Deficient Mice. Infection and Immunity, 2000, 68, 2837-2844.	1.0	30
92	Involvement of STAT-1 and Ets Family Members in Interferon-Î ³ Induction of CD40 Transcription in Microglia/Macrophages. Journal of Biological Chemistry, 2000, 275, 23674-23684.	1.6	141
93	Resting B Lymphocytes as APC for Naive T Lymphocytes: Dependence on CD40 Ligand/CD40. Journal of Immunology, 2000, 164, 688-697.	0.4	79
94	Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions. Journal of Immunology, 2000, 164, 6005-6014.	0.4	118
95	Treatment of Allograft Recipients with Donor-Specific Transfusion and Anti-CD154 Antibody Leads to Deletion of Alloreactive CD8+ T Cells and Prolonged Graft Survival in a CTLA4-Dependent Manner. Journal of Immunology, 2000, 164, 512-521.	0.4	201
96	Th2-Dependent B Cell Responses in the Absence of CD40-CD40 Ligand Interactions. Journal of Immunology, 2000, 164, 248-255.	0.4	18
97	CD40 Engagement on Synovial Fibroblast Up-Regulates Production of Vascular Endothelial Growth Factor. Journal of Immunology, 2000, 164, 5055-5061.	0.4	107
98	The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Advances in Cancer Research, 2000, 79, 157-173.	1.9	93
99	Follicular B Helper T Cells Express Cxc Chemokine Receptor 5, Localize to B Cell Follicles, and Support Immunoglobulin Production. Journal of Experimental Medicine, 2000, 192, 1545-1552.	4.2	1,284
100	Readministration of Adenovirus Vector in Nonhuman Primate Lungs by Blockade of CD40-CD40 Ligand Interactions. Journal of Virology, 2000, 74, 3345-3352.	1.5	59
101	Analysis of the Virus-Specific and Nonspecific B Cell Response to a Persistent B-Lymphotropic Gammaherpesvirus. Journal of Immunology, 2000, 164, 1820-1828.	0.4	109
102	CpC-DNA-Mediated Transient Lymphadenopathy Is Associated with a State of Th1 Predisposition to Antigen-Driven Responses. Journal of Immunology, 2000, 165, 1228-1235.	0.4	127
103	Regulatory role of mature B cells in a murine model of inflammatory bowel disease. International Immunology, 2000, 12, 597-605.	1.8	192
104	Role of Antigen-Presenting Cells in Mediating Tolerance and Autoimmunity. Journal of Experimental Medicine, 2000, 191, 2021-2028.	4.2	148
105	RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 11421-11426.	3.3	61
106	Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors. Journal of Immunology, 2000, 165, 7017-7024.	0.4	266
107	Tyrosine kinase activation in the decision between growth, differentiation, and death responses initiated from the B cell antigen receptor. Advances in Immunology, 2000, 75, 283-316.	1.1	67
108	CD40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth. International Immunology, 2000, 12, 787-795.	1.8	20

#	Article	IF	CITATIONS
109	Functional Maturation of Adult Mouse Resting Microglia into an APC Is Promoted by Granulocyte-Macrophage Colony-Stimulating Factor and Interaction with Th1 Cells. Journal of Immunology, 2000, 164, 1705-1712.	0.4	137
110	Proinflammatory and Th2-Derived Cytokines Modulate CD40-Mediated Expression of Inflammatory Mediators in Airway Epithelia: Implications for the Role of Epithelial CD40 in Airway Inflammation. Journal of Immunology, 2000, 165, 2214-2221.	0.4	66
111	CpG-DNA Activates In Vivo T Cell Epitope Presenting Dendritic Cells to Trigger Protective Antiviral Cytotoxic T Cell Responses. Journal of Immunology, 2000, 164, 2372-2378.	0.4	123
112	Human Immunodeficiency Virus Type 1 Infection Modulates the Interleukin (IL)–1β and ILâ€6 Responses of Human Macrophages to CD40 Ligand Stimulation. Journal of Infectious Diseases, 2000, 182, 776-784.	1.9	12
113	Amelioration of Experimental Autoimmune Uveoretinitis by Pretreatment with a Pathogenic Peptide in Liposome and Anti-CD40 Ligand Monoclonal Antibody. Journal of Immunology, 2000, 165, 2962-2969.	0.4	39
114	Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2000, 59, 190-195.	0.5	84
115	IL-4-Activated STAT-6 Inhibits IFN-Î ³ -Induced CD40 Gene Expression in Macrophages/Microglia. Journal of Immunology, 2000, 165, 6235-6243.	0.4	69
116	TTRAP, a Novel Protein That Associates with CD40, Tumor Necrosis Factor (TNF) Receptor-75 and TNF Receptor-associated Factors (TRAFs), and That Inhibits Nuclear Factor-κB Activation. Journal of Biological Chemistry, 2000, 275, 18586-18593.	1.6	120
117	Coupling of Peripheral Tolerance to Endogenous Interleukin 10 Promotes Effective Modulation of Myelin-Activated T Cells and Ameliorates Experimental Allergic Encephalomyelitis. Journal of Experimental Medicine, 2000, 191, 2039-2052.	4.2	64
118	Anti-CD154 (CD40L) prevents recurrence of diabetes in islet isografts in the DR-BB rat. Diabetes, 2000, 49, 1666-1670.	0.3	35
119	Potent Adjuvant Effect by Anti-CD40 in Collagen-induced Arthritis. Enhanced Disease is Accompanied by Increased Production of Collagen Type-II Reactive IgG2a and IFN-Î3. Journal of Autoimmunity, 2000, 14, 295-302.	3.0	29
120	Increased Expression of CD40 Ligand in Activated CD4+T Lymphocytes of Systemic Sclerosis Patients. Journal of Autoimmunity, 2000, 15, 61-66.	3.0	44
121	Viral Infection Abrogates CD8+ T-cell Deletion Induced by Costimulation Blockade. Journal of Surgical Research, 2000, 93, 63-69.	0.8	33
122	CD40 Ligation Induces Tissue Factor Expression in Human Vascular Smooth Muscle Cells. American Journal of Pathology, 2000, 156, 7-14.	1.9	142
123	CD154 (CD40 ligand). International Journal of Biochemistry and Cell Biology, 2000, 32, 687-693.	1.2	90
124	DAP12-Deficient Mice Fail to Develop Autoimmunity Due to Impaired Antigen Priming. Immunity, 2000, 13, 345-353.	6.6	221
125	CD40 Triggering of Heterodimeric IL-12 p70 Production by Dendritic Cells In Vivo Requires a Microbial Priming Signal. Immunity, 2000, 13, 453-462.	6.6	507
126	Global Expression Analysis of Extracellular Matrix–Integrin Interactions in Monocytes. Immunity, 2000, 13, 749-758.	6.6	68

#	Article	IF	CITATIONS
127	Abundant expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell histiocytosis lesions. European Journal of Cancer, 2000, 36, 2105-2110.	1.3	58
128	A polymorphic CD40 ligand (CD154) molecule mediates CD40-dependent signalling but interferes with the ability of soluble CD40 to functionally block CD154 : CD40 interactions. Immunology, 2000, 99, 54-61.	2.0	12
129	Cell fate decision: T-helper 1 and 2 subsets in immune responses. Arthritis Research, 2000, 2, 179.	2.0	113
130	1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation. Journal of Immunology, 2000, 164, 2405-2411.	0.4	1,146
131	The Roles of CD28 and CD40 Ligand in T Cell Activation and Tolerance. Journal of Immunology, 2000, 164, 4465-4470.	0.4	164
132	Rechazo de trasplantes. Medicine, 2000, 8, 1342-1349.	0.0	1
133	Chronic murine colitis is dependent on the CD154/CD40 pathway and can be attenuated by anti-CD154 administration. Gastroenterology, 2000, 119, 715-723.	0.6	90
134	Immunological memory and acquired immunodeficiency syndrome pathogenesis. Philosophical Transactions of the Royal Society B: Biological Sciences, 2000, 355, 381-390.	1.8	10
135	Host factors influencing viral persistence. Philosophical Transactions of the Royal Society B: Biological Sciences, 2000, 355, 1031-1041.	1.8	24
136	The Immune System. New England Journal of Medicine, 2000, 343, 108-117.	13.9	438
137	The lymphoid liver: Considerations on pathways to autoimmune injury. Gastroenterology, 2001, 120, 1485-1501.	0.6	148
138	EFFECT OF DIFFERENT ACTIVATION STIMULI ON THE CYTOKINE RESPONSE OF HUMAN MACROPHAGES TO CD40L. Cytokine, 2001, 16, 121-125.	1.4	4
139	Role of CD40-CD40L in Mouse Severe Malaria. American Journal of Pathology, 2001, 159, 733-742.	1.9	61
140	Measle Virus-Infected Dendritic Cells Develop Immunosuppressive and Cytotoxic Activities. Immunobiology, 2001, 204, 629-638.	0.8	31
141	Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochemistry International, 2001, 39, 381-391.	1.9	179
142	The role of TALL-1 and APRIL in immune regulation. Trends in Immunology, 2001, 22, 61-63.	2.9	31
143	CD62L Is Required on Effector Cells for Local Interactions in the CNS to Cause Myelin Damage in Experimental Allergic Encephalomyelitis. Immunity, 2001, 14, 291-302.	6.6	73
144	Enhanced CD4+ T Cell Proliferation and Th2 Cytokine Production in DR6-Deficient Mice. Immunity, 2001, 15, 23-34.	6.6	82

#	Article	IF	CITATIONS
145	Function of CD40/CD40L in peritubular capillary of renal allograft rejection. Transplantation Proceedings, 2001, 33, 407-408.	0.3	4
146	Induction of transplantation tolerance by 1,25-dihydroxyvitamin D3. Transplantation Proceedings, 2001, 33, 58-59.	0.3	9
147	Inhibition of costimulatory pathways for T-cell activation by 1,25-dihydroxyvitamin D3. Transplantation Proceedings, 2001, 33, 2083-2084.	0.3	14
148	The TNF and TNF Receptor Superfamilies. Cell, 2001, 104, 487-501.	13.5	3,271
149	Pathways for self-tolerance and the treatment of autoimmune diseases. Lancet, The, 2001, 357, 2115-2121.	6.3	79
150	CD154 DEFICIENCY AND RELATED SYNDROMES. Immunology and Allergy Clinics of North America, 2001, 21, 65-89.	0.7	10
151	CANCER VACCINES. Hematology/Oncology Clinics of North America, 2001, 15, 741-773.	0.9	25
152	Co-Stimulatory Blockade and Tolerance Induction in Transplantation. BioDrugs, 2001, 15, 491-500.	2.2	1
153	Novel approaches in the treatment of lupus nephritis. Expert Opinion on Investigational Drugs, 2001, 10, 1117-1130.	1.9	6
154	Gene therapy for paediatric leukaemia. Expert Opinion on Biological Therapy, 2001, 1, 663-674.	1.4	5
155	Human B Cell Activation by Autologous NK Cells Is Regulated by CD40-CD40 Ligand Interaction: Role of Memory B Cells and CD5+B Cells. Journal of Immunology, 2001, 167, 6132-6139.	0.4	87
156	Endothelium. , 2001, , 275-287.		1
157	Regulation of CD40 ligand expression in systemic lupus erythematosus. Current Opinion in Rheumatology, 2001, 13, 361-369.	2.0	56
158	T-lymphocyte coactivator molecules. Current Opinion in Hematology, 2001, 8, 5-11.	1.2	18
159	THE EFFECT OF CD28/B7 BLOCKADE ON ALLOREACTIVE T AND B CELLS AFTER LIVER CELL TRANSPLANTATION 1. Transplantation, 2001, 71, 801-811.	0.5	21
160	RAT XENOGRAFT SURVIVAL IN MICE TREATED WITH DONOR-SPECIFIC TRANSFUSION AND ANTI-CD154 ANTIBODY IS ENHANCED BY ELIMINATION OF HOST CD4+ CELLS1. Transplantation, 2001, 71, 319-327.	0.5	27
161	HUMAN CD154 INDUCES ACTIVATION OF PORCINE ENDOTHELIAL CELLS AND UP-REGULATION OF MHC CLASS II EXPRESSION. Transplantation, 2001, 72, 127-132.	0.5	16
162	New approaches in tolerance induction. Current Opinion in Organ Transplantation, 2001, 6, 89-94.	0.8	2

#	ARTICLE	IF	CITATIONS
163	Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood, 2001, 97, 2750-2757.	0.6	79
164	Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood, 2001, 97, 2777-2783.	0.6	299
165	Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood, 2001, 97, 2798-2807.	0.6	246
166	Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients. Journal of Clinical Oncology, 2001, 19, 3280-3287.	0.8	209
167	CD40 Signaling and Autoimmunity. , 2001, 5, 51-61.		12
168	Cytokine Regulation of Diabetes in Experimental Models. , 2001, 4, 193-217.		1
169	Cancer Gene Therapy by Adenovirus-Mediated Gene Transfer. Current Gene Therapy, 2001, 1, 101-122.	0.9	47
170	Th1 and Th2 cells. Current Opinion in Hematology, 2001, 8, 47-51.	1.2	135
171	Corneal Allograft Rejection: Current Understanding. Ophthalmologica, 2001, 215, 254-262.	1.0	23
172	Composite Tissue Transplantation: More Science and Patience Needed. Plastic and Reconstructive Surgery, 2001, 107, 1066-1070.	0.7	42
173	CD40 expression and function on human dermal microvascular endothelial cells: role in cutaneous inflammation. Clinical and Experimental Dermatology, 2001, 26, 434-440.	0.6	14
174	Treatment with ribavirin and interferon-αreduces interferon-γexpression in patients with chronic hepatitis C. Clinical and Experimental Immunology, 2001, 123, 459-464.	1.1	28
175	Inhibition of Dendritic Cell Differentiation by Fumaric Acid Esters. Journal of Investigative Dermatology, 2001, 116, 203-208.	0.3	101
176	Increased T cell expression of CD154 (CD40-ligand) in multiple sclerosis. European Journal of Neurology, 2001, 8, 321-328.	1.7	37
177	CD40/154 blockade and rejection of islet allografts in the streptozotocin and autoimmune diabetic rat. Pediatric Diabetes, 2001, 2, 178-183.	1.2	8
178	Immune function of astrocytes. Glia, 2001, 36, 180-190.	2.5	1,136
179	Alterations of dendritic cells in systemic lupus erythematosus: Phenotypic and functional deficiencies. Arthritis and Rheumatism, 2001, 44, 856-865.	6.7	98
180	Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis and Rheumatism, 2001, 44, 2097-2106.	6.7	211

#	Article	IF	CITATIONS
181	Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. European Journal of Immunology, 2001, 31, 3094-3100.	1.6	96
182	Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions. European Journal of Immunology, 2001, 31, 959-965.	1.6	121
183	Enforced and prolonged CD40 ligand expression triggers autoantibody productionin vivo. European Journal of Immunology, 2001, 31, 3484-3492.	1.6	16
184	Annotated References by Year. , 2001, , 651-770.		Ο
185	Reciprocal Induction of IL-10 and IL-12 from Macrophages by Low-Density Lipoprotein and Its Oxidized Forms. Cellular Immunology, 2001, 213, 45-51.	1.4	28
186	Anti-CD40 Treatment of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-Exposed C57Bl/6 Mice Induces Activation of Antigen Presenting Cells Yet Fails to Overcome TCDD-Induced Suppression of Allograft Immunity. Toxicology and Applied Pharmacology, 2001, 170, 10-22.	1.3	24
187	Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. Hepatology, 2001, 34, 72-81.	3.6	50
189	Transforming growth factor \hat{l}^2 enhances the expression of CD154 (CD40L) and production of tumor necrosis factor \hat{l}_{\pm} by human T lymphocytes. Immunology Letters, 2001, 78, 83-88.	1.1	22
190	Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells. Nature Immunology, 2001, 2, 150-156.	7.0	44
191	Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nature Immunology, 2001, 2, 223-228.	7.0	365
192	Importance of ICOS–B7RP-1 costimulation in acute and chronic allograft rejection. Nature Immunology, 2001, 2, 591-596.	7.0	301
193	Separable effector T cell populations specialized for B cell help or tissue inflammation. Nature Immunology, 2001, 2, 876-881.	7.0	120
194	Functional antigen-independent synapses formed between T cells and dendritic cells. Nature Immunology, 2001, 2, 925-931.	7.0	268
195	A self-immunomodulating myoblast cell line for erythropoietin delivery. Gene Therapy, 2001, 8, 58-66.	2.3	13
196	T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. Leukemia, 2001, 15, 1451-1457.	3.3	18
197	It takes more than two to tango. Nature, 2001, 409, 31-32.	13.7	17
198	Neonatal Exposure to Antigen Induces a Defective CD40 Ligand Expression that Undermines Both IL-12 Production by APC and IL-2 Receptor Up-Regulation on Splenic T Cells and Perpetuates IFN-Î ³ -Dependent T Cell Anergy. Journal of Immunology, 2001, 166, 5594-5603.	0.4	22
199	CD40 Signaling and Plaque Instability. Circulation Research, 2001, 89, 1092-1103.	2.0	527

#	Article	IF	CITATIONS
200	Costimulation-Dependent Modulation of Experimental Autoimmune Encephalomyelitis by Ligand Stimulation of V $\hat{l}\pm14$ NK T Cells. Journal of Immunology, 2001, 166, 662-668.	0.4	120
201	In Vivo CD40-CD154 (CD40 Ligand) Interaction Induces Integrated HIV Expression by APC in an HIV-1-Transgenic Mouse Model. Journal of Immunology, 2001, 166, 3210-3217.	0.4	19
202	CD40/CD40 Ligand Interactions Are Critical for Elicitation of Autoimmune-Mediated Fibrosis in the Lung. Journal of Immunology, 2001, 166, 3556-3563.	0.4	24
203	IL-1 Enhances T Cell-Dependent Antibody Production Through Induction of CD40 Ligand and OX40 on T Cells. Journal of Immunology, 2001, 167, 90-97.	0.4	106
204	CD8â^' Dendritic Cell Activation Status Plays an Integral Role in Influencing Th2 Response Development. Journal of Immunology, 2001, 167, 1982-1988.	0.4	269
205	Involvement of T-Lymphocytes in Periodontal Disease and in Direct and Indirect Induction of Bone Resorption. Critical Reviews in Oral Biology and Medicine, 2001, 12, 125-135.	4.4	262
206	Selective Immunointervention in Autoimmune Diseases: Lessons from Multiple Sclerosis. Journal of Chemotherapy, 2001, 13, 219-234.	0.7	22
207	CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity. International Journal of Oncology, 2001, 19, 791-8.	1.4	4
208	CD40 Ligand - An Anti-Apoptotic Molecule in Hodgkin's Disease. Cancer Biotherapy and Radiopharmaceuticals, 2001, 16, 85-92.	0.7	13
209	Role of CD40 Ligand Signaling in Defective Type 1 Cytokine Response in Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2001, 183, 1722-1731.	1.9	41
210	Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets, 2001, 12, 74-82.	1.1	247
211	Molecular Characterization of CD40 Signaling Intermediates. Journal of Biological Chemistry, 2001, 276, 43334-43342.	1.6	49
212	Lipopolysaccharide Modulation of Dendritic Cells Is Insufficient to Mature Dendritic Cells to Generate CTLs from Naive Polyclonal CD8+T Cells In Vitro, Whereas CD40 Ligation Is Essential. Journal of Immunology, 2001, 167, 6247-6255.	0.4	41
213	CD40 Activates NF-κB and c-Jun N-Terminal Kinase and Enhances Chemokine Secretion on Activated Human Hepatic Stellate Cells. Journal of Immunology, 2001, 166, 6812-6819.	0.4	146
214	An Antagonist IL-15/Fc Protein Prevents Costimulation Blockade-Resistant Rejection. Journal of Immunology, 2001, 167, 3478-3485.	0.4	76
215	CD4 T Cell-Mediated Alloresistance to Fully MHC-Mismatched Allogeneic Bone Marrow Engraftment Is Dependent on CD40-CD40 Ligand Interactions, and Lasting T Cell Tolerance Is Induced by Bone Marrow Transplantation with Initial Blockade of this Pathway. Journal of Immunology, 2001, 166, 2970-2981.	0.4	102
216	CD40 Signaling Converts a Minimally Immunogenic Antigen into a Potent Vaccine Against the Intracellular Pathogen <i>Listeria monocytogenes</i> . Journal of Immunology, 2001, 166, 5115-5121.	0.4	40
217	A Dual-Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer Induces T Cell-Mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice. Journal of Immunology, 2001, 167, 4560-4565.	0.4	104

#	Article	IF	CITATIONS
218	Autoimmune Intervention by CD154 Blockade Prevents T Cell Retention and Effector Function in the Target Organ. Journal of Immunology, 2001, 166, 1547-1553.	0.4	32
219	CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1166-1170.	3.3	359
220	T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 14565-14570.	3.3	357
221	The Development of a Th1-Type Response and Resistance toLeishmania majorInfection in the Absence of CD40-CD40L Costimulation. Journal of Immunology, 2001, 167, 5874-5879.	0.4	27
222	Regulation of Transcriptional Activity of the Murine CD40 Ligand Promoter in Response to Signals Through TCR and the Costimulatory Molecules CD28 and CD2. Journal of Immunology, 2001, 166, 4578-4585.	0.4	32
223	CD45 Is Required for CD40-induced Inhibition of DNA Synthesis and Regulation of c-Jun NH2-terminal Kinase and p38 in BAL-17 B Cells. Journal of Biological Chemistry, 2001, 276, 8550-8556.	1.6	10
224	Requirement for a Complex Array of Costimulators in the Negative Selection of Autoreactive Thymocytes In Vivo. Journal of Immunology, 2001, 166, 6050-6056.	0.4	39
225	Molecular Identification of IgE-Dependent Histamine-Releasing Factor as a B Cell Growth Factor. Journal of Immunology, 2001, 166, 6545-6554.	0.4	71
226	Neonatal Immunity Develops in a Transgenic TCR Transfer Model and Reveals a Requirement for Elevated Cell Input to Achieve Organ-Specific Responses. Journal of Immunology, 2001, 167, 2585-2594.	0.4	16
227	The Clinical Course of Experimental Autoimmune Encephalomyelitis and Inflammation Is Controlled by the Expression of Cd40 within the Central Nervous System. Journal of Experimental Medicine, 2001, 193, 967-974.	4.2	216
228	Cutting Edge: Critical Role of Inducible Costimulator in Germinal Center Reactions. Journal of Immunology, 2001, 166, 3659-3662.	0.4	190
229	CD40-Mediated Regulation of Immune Responses by TRAF-Dependent and TRAF-Independent Signaling Mechanisms. Advances in Immunology, 2001, 76, 61-178.	1.1	84
230	Critical Role for IL-4 in the Development of Transplant Arteriosclerosis in the Absence of CD40-CD154 Costimulation. Journal of Immunology, 2001, 167, 532-541.	0.4	43
231	Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-Â gene and protein expression in lupus T cells. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 2628-2633.	3.3	175
232	Regulation of CD40 function by its isoforms generated through alternative splicing. Proceedings of the United States of America, 2001, 98, 1751-1756.	3.3	132
233	Overexpression of Cd40 Ligand in Murine Epidermis Results in Chronic Skin Inflammation and Systemic Autoimmunity. Journal of Experimental Medicine, 2001, 194, 615-628.	4.2	158
234	Malaria Infection Induces Virus Expression in Human Immunodeficiency Virus Transgenic Mice by CD4 T Cell–Dependent Immune Activation. Journal of Infectious Diseases, 2001, 183, 1260-1268.	1.9	28
235	Recombinant Adenovirus Coexpressing Covalent Peptide/MHC Class II Complex and B7-1: In Vitro and In Vivo Activation of Myelin Basic Protein-Specific T Cells. Journal of Immunology, 2001, 167, 1297-1305.	0.4	16

#	Article	IF	CITATIONS
236	Influence of Costimulatory Molecules on Immune Response to Leishmania major by Human Cells In Vitro. Infection and Immunity, 2001, 69, 665-672.	1.0	28
237	Cross-Strain Protection against Clinical and Laboratory Strains ofPseudomonas aeruginosaMediated by Dendritic Cells Genetically Modified to Express CD40 Ligand and Pulsed with Specific Strains ofPseudomonas aeruginosa. Human Gene Therapy, 2001, 12, 1251-1263.	1.4	13
238	Signaling Lymphocytic Activation Molecule Is Expressed on CD40 Ligand-Activated Dendritic Cells and Directly Augments Production of Inflammatory Cytokines. Journal of Immunology, 2001, 167, 3174-3181.	0.4	102
239	Cytokines and the pathogenesis of atherosclerosis. Advances in Cell Aging and Gerontology, 2002, , 79-126.	0.1	2
240	Murine Neonatal CD4+Lymph Node Cells Are Highly Deficient in the Development of Antigen-Specific Th1 Function in Adoptive Adult Hosts. Journal of Immunology, 2002, 169, 4998-5004.	0.4	51
241	Critical Role of Tumor Necrosis Factor-α and NF-κB in Interferon-γ-induced CD40 Expression in Microglia/Macrophages. Journal of Biological Chemistry, 2002, 277, 13796-13803.	1.6	102
242	Allograft Rejection by Primed/Memory CD8+ T Cells Is CD154 Blockade Resistant: Therapeutic Implications for Sensitized Transplant Recipients. Journal of Immunology, 2002, 169, 4667-4673.	0.4	157
243	CD40 Ligation in the Presence of Self-Reactive CD8 T Cells Leads to Severe Immunopathology. Journal of Immunology, 2002, 168, 5124-5129.	0.4	23
244	NF-κB Family of Transcription Factors: Central Regulators of Innate and Adaptive Immune Functions. Clinical Microbiology Reviews, 2002, 15, 414-429.	5.7	456
245	Cutting Edge: Th2 Response Induction by Dendritic Cells: A Role for CD40. Journal of Immunology, 2002, 168, 537-540.	0.4	196
246	CD28, TNF Receptor, and IL-12 Are Critical for CD4-Independent Cross-Priming of Therapeutic Antitumor CD8+ T Cells. Journal of Immunology, 2002, 169, 4897-4904.	0.4	19
247	The Role of Sp1 and NF-κB in Regulating CD40 Gene Expression. Journal of Biological Chemistry, 2002, 277, 8890-8897.	1.6	65
248	CD40 Ligand and CTLA-4 Are Reciprocally Regulated in the Th1 Cell Proliferative Response Sustained by CD8+ Dendritic Cells. Journal of Immunology, 2002, 169, 1182-1188.	0.4	21
249	The Novel IgD Binding Protein from <i>Moraxella catarrhalis</i> Induces Human B Lymphocyte Activation and Ig Secretion in the Presence of Th2 Cytokines. Journal of Immunology, 2002, 168, 5582-5588.	0.4	51
250	T Cell Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody. Journal of Immunology, 2002, 168, 2720-2728.	0.4	79
251	The CD154-CD40 T Cell Costimulation Pathway Is Required for Host Sensitization of CD8+ T Cells by Skin Grafts Via Direct Antigen Presentation. Journal of Immunology, 2002, 169, 1270-1276.	0.4	39
252	Activated Intrahepatic Antigen-Presenting Cells Inhibit Hepatitis B Virus Replication in the Liver of Transgenic Mice. Journal of Immunology, 2002, 169, 5188-5195.	0.4	109
253	Mechanism of Action of Combined Short-Term CTLA4Ig and Anti-CD40 Ligand in Murine Systemic Lupus Erythematosus. Journal of Immunology, 2002, 168, 2046-2053.	0.4	96

#	Article	IF	CITATIONS
254	CD40 Ligand Functions Non-Cell Autonomously to Promote Deletion of Self-Reactive Thymocytes. Journal of Immunology, 2002, 168, 2759-2765.	0.4	39
255	Programmed Death-1 Targeting Can Promote Allograft Survival. Journal of Immunology, 2002, 169, 6546-6553.	0.4	219
256	Temporal Sequence and Functional Implications of Vβâ€Specific T Cell Receptor Downâ€regulation and Costimulatory Molecule Expression following In Vitro Stimulation with the Staphylococcal Superantigen Toxic Shock Syndrome Toxin–1. Journal of Infectious Diseases, 2002, 185, 555-560.	1.9	7
257	Essential Role for CD40 Ligand Interactions in T Lymphocyte-Mediated Modulation of the Murine Immune Response to Pneumococcal Capsular Polysaccharides. Journal of Immunology, 2002, 168, 2773-2781.	0.4	35
258	Impaired Th2 Development and Increased Mortality During <i>Schistosoma mansoni</i> Infection in the Absence of CD40/CD154 Interaction. Journal of Immunology, 2002, 168, 4643-4649.	0.4	81
259	Mechanism of TCDD-Induced Suppression of Antibody Production: Effect on T Cell-Derived Cytokine Production in the Primary Immune Reaction of Mice. Toxicological Sciences, 2002, 70, 46-54.	1.4	49
260	CD8 T Cells Are Required for the Formation of Ectopic Germinal Centers in Rheumatoid Synovitis. Journal of Experimental Medicine, 2002, 195, 1325-1336.	4.2	163
261	Upregulation of CD40 Expression on Endothelial Cells Infected with Human Cytomegalovirus. Journal of Virology, 2002, 76, 12803-12812.	1.5	20
262	CD40-mediated Activation of NF-κB in Airway Epithelial Cells. Journal of Biological Chemistry, 2002, 277, 37054-37063.	1.6	20
263	Apoptosis Induced by Pseudomonas aeruginosa in Antigen Presenting Cells Is Diminished by Genetic Modification with CD40 Ligand. Pediatric Research, 2002, 52, 636-644.	1.1	23
264	The Effects of Malignant Transformation on Susceptibility of Human Urothelial Cells to CD40-Mediated Apoptosis. Journal of the National Cancer Institute, 2002, 94, 1381-1395.	3.0	52
265	Increased CD4 and CCR5 Expression and Human Immunodeficiency Virus Type 1 Entry in CD40 Ligand–Stimulated Macrophages. Journal of Infectious Diseases, 2002, 185, 1567-1577.	1.9	13
266	Spleen Is a Primary Site for Activation of Platelet-Reactive T and B Cells in Patients with Immune Thrombocytopenic Purpura. Journal of Immunology, 2002, 168, 3675-3682.	0.4	139
267	CD154 and Typeâ€l Cytokine Response: From Hyper IgM Syndrometo Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2002, 185, S83-S89.	1.9	25
268	Levels of Soluble CD40 Ligand (CD154) in Serum Are Increased in Human Immunodeficiency Virus Type 1-Infected Patients and Correlate with CD4 + T-Cell Counts. Vaccine Journal, 2002, 9, 558-561.	3.2	35
269	A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory. Science, 2002, 297, 2060-2063.	6.0	586
270	Requirement for the Lymphocyte Semaphorin, CD100, in the Induction of Antigen-Specific T Cells and the Maturation of Dendritic Cells. Journal of Immunology, 2002, 169, 1175-1181.	0.4	144
271	Suppressor of Cytokine Signaling 1 Inhibits Cytokine Induction of CD40 Expression in Macrophages. Journal of Immunology, 2002, 169, 2354-2360.	0.4	62

#	Article	IF	CITATIONS
272	Dissection of B cell differentiation during primary immune responses in mice with altered CD40 signals. International Immunology, 2002, 14, 319-329.	1.8	38
273	Nuclear Factor κB–dependent Gene Expression Profiling of Hodgkin's Disease Tumor Cells, Pathogenetic Significance, and Link to Constitutive Signal Transducer and Activator of Transcription 5a Activity. Journal of Experimental Medicine, 2002, 196, 605-617.	4.2	244
274	CD2 Facilitates Differentiation of CD4 Th Cells Without Affecting Th1/Th2 Polarization. Journal of Immunology, 2002, 168, 1113-1122.	0.4	13
275	Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance. Journal of Experimental Medicine, 2002, 195, 423-435.	4.2	120
277	Dendritic Cells Cultured in Anti-CD40 Antibody-Immobilized Plates Elicit a Highly Efficient Peptide-Specific T-Cell Response. Journal of Immunotherapy, 2002, 25, 176-184.	1.2	12
278	Induction of donor-specific tolerance by adenovirus-mediated cd40ig gene therapy in rat liver transplantation1. Transplantation, 2002, 73, 1403-1410.	0.5	36
279	Differentiation and functional maturation of human cd14+ adherent peripheral blood monocytes by xenogeneic endothelial cells: up-regulation of costimulation, cytokine generation, and toll-like receptors1. Transplantation, 2002, 74, 243-252.	0.5	8
280	Anti-lymphocyte function-associated antigen-1 monoclonal antibody inhibits CD40 ligand-independent immune responses and prevents chronic vasculopathy in CD40 ligand-deficient mice1. Transplantation, 2002, 74, 35-41.	0.5	29
281	Cytokines and Th subsets in tolerance. Current Opinion in Organ Transplantation, 2002, 7, 13-17.	0.8	0
282	Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood, 2002, 99, 520-525.	0.6	71
283	Role of GITR in activation response of T lymphocytes. Blood, 2002, 100, 350-352.	0.6	172
284	Immunohistochemical Markers of Melanocytic Lesions. American Journal of Dermatopathology, 2002, 24, 270-281.	0.3	57
285	CD154-CD40 T-cell costimulation pathway is required in the mechanism of hepatic ischemia/reperfusion injury, and its blockade facilitates and depends on heme oxygenase-1 mediated cytoprotection. Transplantation, 2002, 74, 315-319.	0.5	118
286	Prevention of Autoimmune Diabetes in the DRBB Rat by CD40/154 Blockade. Journal of Autoimmunity, 2002, 19, 139-145.	3.0	13
287	Blockade of T cell Costimulatory Signals using Adenovirus Vectors Prevents both the Induction and the Progression of Experimental Autoimmune Myocarditis. Journal of Molecular and Cellular Cardiology, 2002, 34, 279-295.	0.9	34
288	Clast5/Stra13 Is a Negative Regulator of B Lymphocyte Activation. Biochemical and Biophysical Research Communications, 2002, 292, 121-127.	1.0	34
289	Aberrant Expression of the Costimulatory Molecule CD40 Ligand on Monocytes from Patients with Systemic Lupus Erythematosus. Clinical Immunology, 2002, 103, 54-62.	1.4	66
290	RANK-LANDRANK: T Cells, Bone Loss, and Mammalian Evolution. Annual Review of Immunology, 2002, 20, 795-823.	9.5	741

#	Article	IF	CITATIONS
291	Chronic lymphocytic leukaemia: a model for investigating potential new targets for the therapy of indolent lymphomas. Best Practice and Research in Clinical Haematology, 2002, 15, 563-575.	0.7	5
292	CD40-mediated p38 mitogen-activated protein kinase activation is required for immunoglobulin class switch recombination to IgE. Journal of Allergy and Clinical Immunology, 2002, 110, 421-428.	1.5	21
293	CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation. Journal of Allergy and Clinical Immunology, 2002, 110, 443-449.	1.5	36
294	CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition. Lupus, 2002, 11, 370-378.	0.8	39
295	Costimulatory Molecules and Autoimmune Thyroid Diseases. Autoimmunity, 2002, 35, 159-167.	1.2	44
296	Advances in Dendritic Cell-Based Vaccine of Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 601-619.	0.7	28
297	Malignant B Cells and Antigenic Receptor: Necessity or Habit?. Leukemia and Lymphoma, 2002, 43, 1383-1390.	0.6	2
298	Antitumor Immune Responses Derived from Transgenic Expression of CD40 Ligand in Myeloma Cells. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 11-18.	0.7	12
299	Adenovirus-mediated CD40lg expression attenuates chronic vascular rejection lesions in an aorta allotransplantation model. Transplantation Proceedings, 2002, 34, 743-744.	0.3	9
300	CD40 triggered human monocyte-derived dendritic cells convert to tolerogenic dendritic cells when JAK3 activity is inhibited. Transplantation Proceedings, 2002, 34, 1407-1408.	0.3	22
301	T-Cell costimulatory pathways relevant to transplant rejection and tolerance. Transplantation Reviews, 2002, 16, 205-219.	1.2	4
302	Recent Progress in the Understanding of the Structure- Function Relationships of the Globular Head Regions of C1q. Immunobiology, 2002, 205, 355-364.	0.8	88
303	CD154-Dependent Priming of Diabetogenic CD4+ T Cells Dissociated from Activation of Antigen-Presenting Cells. Immunity, 2002, 16, 719-732.	6.6	40
304	Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine and Growth Factor Reviews, 2002, 13, 341-355.	3.2	87
306	Diltiazem impairs maturation and functions of human dendritic cells. Human Immunology, 2002, 63, 524-533.	1.2	20
307	Cloning and expression of the ovine CD40 molecule and the inhibition of the mixed lymphocyte reaction by the ovine CD40e–EGFP fusion protein. Veterinary Immunology and Immunopathology, 2002, 89, 37-45.	0.5	1
308	CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Journal of Clinical Pathology, 2002, 55, 110-120.	2.1	58
309	Corneal Allograft Rejection: Current Understanding. Ophthalmologica, 2002, 216, 2-12.	1.0	27

ARTICLE IF CITATIONS Cd40 Activation as Potential Tool in Malignant Neoplasms. Tumori, 2002, 88, 361-366. 310 0.6 24 BLyS and B Cell Autoimmunity., 2002, 6, 21-37. Advances in classification and therapy of indolent B-cell malignancies. Seminars in Oncology, 2002, 29, 312 0.8 21 98-104. CD40 ligand (CD40L) does not stimulate proliferation of vascular smooth muscle cells. European Journal of Cell Biology, 2002, 81, 213-221. Differentiated Th1 autoreactive effector cells can induce experimental autoimmune encephalomyelitis 314 1.1 15 in the absence of IL-12 and CD40/CD40L interactions. Journal of Neuroimmunology, 2002, 122, 65-73. IL-18 is linked to raised IFN-Î³ in multiple sclerosis and is induced by activated CD4+ T cells via 1.1 CD40–CD40 ligand interactions. Journal of Neuroimmunology, 2002, 125, 134-140. Interaction of monocytes with vascular endothelial cells synergistically induces interferon 316 Î³-inducible protein 10 expression through activation of specific cell surface molecules and cytokines. 1.4 19 Cellular Immunology, 2002, 219, 131-139. Analysis of a CD40 ligand dinucleotide microsatellite in multiple sclerosis. International Journal of 1.2 Immunogenetics, 2002, 29, 81-85. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells Exploiting 318 0.2 39 cross-priming. Experimental Hematology, 2002, 30, 1355-1364. CD8 lethargy in the absence of CD4 help. European Journal of Immunology, 2002, 32, 2199. 1.6 123 Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is 320 impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis and Rheumatism, 6.7 78 2002, 46, 533-544. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis 321 and Rheumatism, 2002, 46, 1554-1562. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A 322 6.7 321 randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 2002, 46, 3251-3258. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. 2.3 International Journal of Cancer, 2002, 101, 61-68. Critical involvement of CD40 in protection against herpes simplex virus infection in a murine model 324 0.9 7 of genital herpes. Archives of Virology, 2002, 147, 187-194. Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic 2.0 cell-based treatment. Cancer Immunology, Immunotherapy, 2002, 51, 341-348. Macrophage Activation and Hemophagocytic Syndrome in Langerhans Cell Histiocytosis: Report of 30 327 0.5 74 Cases. Pediatric and Developmental Pathology, 2002, 5, 130-140. Simultaneous inhibition of B7 and LFA-1 signaling prevents rejection of discordant neural xenografts 328 1.6 in mice lacking CD40L. Xenotransplantation, 2002, 9, 68-76.

#	Article	IF	CITATIONS
329	Regulation of monocyte gene expression by the extracellular matrix and its functional implications. Immunological Reviews, 2002, 186, 208-220.	2.8	42
330	New regulatory co-receptors: inducible co-stimulator and PD-1. Current Opinion in Immunology, 2002, 14, 779-782.	2.4	221
331	Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library. Immunology, 2002, 106, 456-463.	2.0	17
332	Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. British Journal of Haematology, 2002, 118, 506-513.	1.2	5
333	CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren's syndrome patients indicating their intrinsic activation. Clinical and Experimental Immunology, 2002, 127, 386-392.	1.1	91
334	Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+T cellsin vivo. Clinical and Experimental Immunology, 2002, 130, 293-299.	1.1	4
335	Evaluation of the cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment. BJU International, 2002, 89, 635-635.	1.3	0
336	CD40, CD154, Bax and Bcl -2 Expression in SjĶgren's Syndrome Salivary Glands: a Putative Anti-Apoptotic Role During its Effector Phases. Scandinavian Journal of Immunology, 2002, 56, 561-571.	1.3	55
337	CD40 stimulation in vivo does not inhibit CD4+ T cell tolerance to soluble antigens. Immunology Letters, 2002, 84, 125-132.	1.1	10
339	Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology, 2002, 174, 53-65.	2.0	38
340	Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8+ cytotoxic T-cell activation and antitumor immunity. Cancer Gene Therapy, 2002, 9, 202-208.	2.2	44
341	Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40–CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector. Gene Therapy, 2002, 9, 537-546.	2.3	16
342	A non-immunogenic adenoviral vector, coexpressing CTLA4Ig and bilirubin-uridine-diphosphoglucuronateglucuronosyltransferase permits long-term, repeatable transgene expression in the Gunn rat model of Crigler–Najjar syndrome. Gene Therapy, 2002, 9, 981-990.	2.3	61
343	Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia, 2002, 16, 1637-1644.	3.3	45
344	Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nature Neuroscience, 2002, 5, 1288-1293.	7.1	196
345	BAFF: A fundamental survival factor for B cells. Nature Reviews Immunology, 2002, 2, 465-475.	10.6	619
346	Regulation and Function of Class II Major Histocompatibility Complex, CD40, and B7 Expression in Macrophages and Microglia: Implications in Neurological Diseases. Journal of NeuroVirology, 2002, 8, 496-512.	1.0	83
347	Immunobiology of Tumor Necrosis Factor Receptor Superfamily. Immunologic Research, 2002, 26, 323-336.	1.3	54

#	Article	IF	CITATIONS
348	CD154 Transcriptional Regulation in Primary Human CD4 T Cells. Immunologic Research, 2003, 27, 185-202.	1.3	42
349	Effector lymphocytes in islet cell autoimmunity. Reviews in Endocrine and Metabolic Disorders, 2003, 4, 271-280.	2.6	12
350	Reactive oxygen species play roles on B cell surface receptor CD40-mediated proximal and distal signaling events: effects of an antioxidant, N-acetyl-L-cysteine treatment. Molecular and Cellular Biochemistry, 2003, 252, 1-7.	1.4	18
351	Differential CD86 and CD40 co-stimulatory molecules and cytokine expression pattern induced by Trypanosoma cruzi in APCs from resistant or susceptible mice. Clinical and Experimental Immunology, 2003, 131, 41-47.	1.1	43
352	LMP1, a viral relative of the TNF receptor family, signals principally from intracellular compartments. EMBO Journal, 2003, 22, 3027-3038.	3.5	61
353	The master regulators of allergic inflammation: dendritic cells in Th2 sensitization. Current Opinion in Immunology, 2003, 15, 620-626.	2.4	84
354	Induction of tolerance for islet transplantation for type 1 diabetes. Current Diabetes Reports, 2003, 3, 329-335.	1.7	15
355	Therapeutic vaccination with tumor cells that engage CD137. Journal of Molecular Medicine, 2003, 81, 71-86.	1.7	26
356	Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. International Journal of Colorectal Disease, 2003, 18, 142-147.	1.0	51
357	Elevated circulating soluble CD40 ligand in patients with mixed connective tissue disease. Clinical Rheumatology, 2003, 22, 37-39.	1.0	9
358	CD40 and its viral mimic, LMP1: similar means to different ends. Cellular Signalling, 2003, 15, 9-16.	1.7	111
359	Dietary ribonucleotides increase antigen-specific type 1 T-helper cells in the regional draining lymph nodes in young BALB/cJ mice. Nutrition, 2003, 19, 41-46.	1.1	17
360	Prevention of CD40-Triggered Dendritic Cell Maturation and Induction of T-Cell Hyporeactivity by Targeting of Janus Kinase 3. American Journal of Transplantation, 2003, 3, 1341-1349.	2.6	33
361	Antigen presentation in graft-vs-host disease. Experimental Hematology, 2003, 31, 1187-1197.	0.2	55
362	Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presenting cells. Cellular Immunology, 2003, 221, 81-88.	1.4	14
363	CD154-CD40-induced reactivation of latent HIV-1 infection. Virology, 2003, 314, 261-270.	1.1	16
364	B cells in the aged: CD27, CD5, and CD40 expression. Mechanisms of Ageing and Development, 2003, 124, 389-393.	2.2	123
365	Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry, 2003, 52A, 101-109.	1.8	39

ARTICLE IF CITATIONS # Mini-review CD4 T cells are required for CD8 T cell memory generation. European Journal of 366 1.6 75 Immunology, 2003, 33, 3225-3231. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis and 6.7 Rheumatism, 2003, 48, 495-506. The role of inducible co-stimulator (ICOS)/B7-related protein-1 (B7RP-1) interaction in the functional 368 1.1 14 development of Peyer's patches. Immunology Letters, 2003, 88, 63-70. T cell anergy and costimulation. Immunological Reviews, 2003, 192, 161-180. Apoptosis and transplantation tolerance. Immunological Reviews, 2003, 193, 124-145. 370 2.8 22 Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by 371 cryptococcal polysaccharide-pulsed antigen-presenting cells. Immunology, 2003, 108, 158-166. A Salmonella typhi OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds 372 2.0 12 CD40 and activates a lymphoma B-cell line. Immunology, 2003, 110, 206-216. T-cell costimulatory pathways in allograft rejection and tolerance. Immunological Reviews, 2003, 196, 2.8 202 85-108. Role of the microenvironment in chronic lymphocytic leukaemia. British Journal of Haematology, 374 1.2 164 2003, 123, 380-388. Increased susceptibility to airway responses in CD40-deficient mice. Clinical and Experimental 1.1 Immunology, 2003, 133, 22-29. CD40 ligand is selectively expressed on CD4+T cells and platelets: implications for CD40-CD40L 376 2.1 63 signalling in atherosclerosis. Journal of Pathology, 2003, 201, 288-295. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Therapy, 2003, 10, 1-13. 2.2 160 Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using 378 2.2 14 retrovirus vector. Cancer Gene Therapy, 2003, 10, 833-839. Autoimmune regulator: from loss of function to autoimmunity. Genes and Immunity, 2003, 4, 12-21. 379 2.2 Attenuated Apoptosis of B Cell Activating Factor–Expressing Cells in Primary SjŶgren's Syndrome. 380 1.7 66 Laboratory Investigation, 2003, 83, 357-365. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than 134 costimulation blockade. Nature Medicine, 2003, 9, 1275-1280. Dendritic-cell control of pathogen-driven T-cell polarization. Nature Reviews Immunology, 2003, 3, 382 10.6 1,235 984-993. High-Efficiency Lentiviral Vector-Mediated Gene Transfer into Murine Macrophages and Activated 1.4 Splenic B Lymphocytes. Human Gene Therapy, 2003, 14, 385-391.

#	ARTICLE	IF	CITATIONS
384	LOCATION ISEVERYTHING: Lipid Rafts and Immune Cell Signaling. Annual Review of Immunology, 2003, 21, 457-481.	9.5	453
385	The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria. Gut, 2003, 52, 1522-1529.	6.1	201
386	Co-stimulation agonists as a new immunotherapy for autoimmune diseases. Trends in Molecular Medicine, 2003, 9, 483-489.	3.5	6
387	Mutations of CD40 ligand in two patients with hyper-IgM syndrome. Immunobiology, 2003, 207, 285-294.	0.8	15
388	CD8+ T cells induce graft vascular occlusion in a CD40 knockout donor/recipient combination. Journal of Heart and Lung Transplantation, 2003, 22, 177-183.	0.3	22
389	A CD40 Bridge between Innate and Adaptive Immunity. Immunity, 2003, 18, 724-725.	6.6	11
390	Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin. Immunity, 2003, 19, 849-861.	6.6	149
391	CD40 Ligation Releases Immature Dendritic Cells from the Control of Regulatory CD4+CD25+ T Cells. Immunity, 2003, 19, 877-889.	6.6	259
392	Monocyte response to Th1 stimulation and effector function toward human mesangial cells are not impaired in patients with lupus nephritis. Clinical Immunology, 2003, 106, 65-72.	1.4	19
393	Targeting of Costimulatory Molecules as a Therapeutic Approach in Inflammatory Bowel Disease. BioDrugs, 2003, 17, 395-411.	2.2	10
394	A crucial role of CD4 T cells as a functional source of CD154 in the initiation of insulin-dependent diabetes mellitus in the non-obese diabetic mouse. International Immunology, 2003, 15, 351-357.	1.8	12
395	Modulation of T-Cell Costimulation as Immunotherapy or Immunochemotherapy in Experimental Visceral Leishmaniasis. Infection and Immunity, 2003, 71, 6453-6462.	1.0	60
396	Cytokine balance in kidney tissue from lupus nephritis patients. British Journal of Rheumatology, 2003, 42, 935-938.	2.5	99
397	Characterization and Development of T-Cell Immune Responses in B-Cell-Deficient (Igh-6 â^'/â^') Mice with Salmonella enterica Serovar TyphimuriumInfection. Infection and Immunity, 2003, 71, 6808-6819.	1.0	71
398	Differential Requirements for Expression of CD80/86 and CD40 on B Cells for T-Dependent Antibody Responses In Vivo. Journal of Immunology, 2003, 170, 781-787.	0.4	43
399	Platelet-Activating Factor Mediates CD40-Dependent Angiogenesis and Endothelial-Smooth Muscle Cell Interaction. Journal of Immunology, 2003, 171, 5489-5497.	0.4	38
400	Signal 3 Determines Tolerance versus Full Activation of Naive CD8 T Cells. Journal of Experimental Medicine, 2003, 197, 1141-1151.	4.2	437
401	Intrinsic Renal Cell Expression of CD40 Directs Th1 Effectors Inducing Experimental Crescentic Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2003, 14, 2813-2822.	3.0	38

#	Article	IF	CITATIONS
402	CD40-dependent Activation of Phosphatidylinositol 3-Kinase/Akt Pathway Mediates Endothelial Cell Survival and in Vitro Angiogenesis. Journal of Biological Chemistry, 2003, 278, 18008-18014.	1.6	96
403	Infectious Nickel Tolerance: A Reciprocal Interplay of Tolerogenic APCs and T Suppressor Cells That Is Driven by Immunization. Journal of Immunology, 2003, 171, 2863-2872.	0.4	35
404	Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proceedings of the United States of America, 2003, 100, 6057-6062.	3.3	73
405	CD45-Positive Cells of the Retina and Their Responsiveness to In Vivo and In Vitro Treatment with IFN- \hat{I}^3 or Anti-CD40. , 2003, 44, 3083.		52
406	Delineation of a Novel Pathway That Regulates CD154 (CD40 Ligand) Expression. Molecular and Cellular Biology, 2003, 23, 510-525.	1.1	75
407	NF-κB Is Involved in Regulation of CD40 Ligand Expression on Mycobacterium bovis Bacillus Calmette-Guel∎in-Activated Human T Cells. Vaccine Journal, 2003, 10, 376-382.	3.2	4
408	Adenovirus-Mediated Gene Transfer of ICOSIg Fusion Protein Ameliorates Ongoing Experimental Autoimmune Myocarditis. Human Gene Therapy, 2003, 14, 521-532.	1.4	12
409	B Cell Developmental Requirement for the <i>G</i> α <i>i2</i> Gene. Journal of Immunology, 2003, 170, 1707-1715.	0.4	126
410	CD154–CD40â€independent upâ€regulation of B7â€2 on splenic antigenâ€presenting cells and efficient T cell priming by staphylococcal enterotoxin A. International Immunology, 2003, 15, 817-826.	1.8	4
411	Cutting Edge: CD40-Induced Expression of Recombination Activating Gene (RAG) 1 and RAG2: A Mechanism for the Generation of Autoaggressive T Cells in the Periphery. Journal of Immunology, 2003, 170, 3455-3459.	0.4	58
412	Short Term Administration of Costimulatory Blockade and Cyclophosphamide Induces Remission of Systemic Lupus Erythematosus Nephritis in NZB/W F1 Mice by a Mechanism Downstream of Renal Immune Complex Deposition. Journal of Immunology, 2003, 171, 489-497.	0.4	144
413	CD154 Blockade Results in Transient Reduction in Theiler's Murine Encephalomyelitis Virus-Induced Demyelinating Disease. Journal of Virology, 2003, 77, 2247-2250.	1.5	13
414	Cell-specific expression of B lymphocyte (APRIL, BLyS)- and Th2 (CD30L/CD153)-promoting tumor necrosis factor superfamily ligands in human placentas. Journal of Leukocyte Biology, 2003, 74, 81-87.	1.5	36
415	Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. British Journal of Cancer, 2003, 88, 586-592.	2.9	42
416	Blockade of CD40-Mediated Signaling Is Sufficient for Inducing Islet But Not Skin Transplantation Tolerance. Journal of Immunology, 2003, 170, 3015-3023.	0.4	30
417	Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase. Journal of Immunology, 2003, 171, 6396-6405.	0.4	39
418	CD40 Stimulation of Human Peripheral B Lymphocytes: Distinct Response from Naive and Memory Cells. Journal of Immunology, 2003, 171, 4621-4629.	0.4	69
419	CD154 Activates Macrophage Antimicrobial Activity in the Absence of IFN-Î ³ through a TNF-α-Dependent Mechanism. Journal of Immunology, 2003, 171, 6750-6756.	0.4	38

#	Article	IF	CITATIONS
420	Activation of Alloreactive CD8+ T Cells Operates Via CD4-Dependent and CD4-Independent Mechanisms and Is CD154 Blockade Sensitive. Journal of Immunology, 2003, 170, 3024-3028.	0.4	26
421	Cutting Edge: Induced Expression of a RhoA-Specific Guanine Nucleotide Exchange Factor, p190RhoCEF, Following CD40 Stimulation and WEHI 231 B Cell Activation. Journal of Immunology, 2003, 170, 19-23.	0.4	19
422	In Vivo Ligation of CD40 Enhances Priming Against the Endogenous Tumor Antigen and Promotes CD8+ T Cell Effector Function in SV40 T Antigen Transgenic Mice. Journal of Immunology, 2003, 171, 697-707.	0.4	74
423	Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo. International Journal of Oncology, 2003, 22, 345.	1.4	2
424	Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells. International Journal of Oncology, 2003, 23, 1697.	1.4	7
425	Efficacy of CD40 Ligand Gene Therapy in Malignant Mesothelioma. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 321-330.	1.4	36
426	Adaptive Immunity to NontypeableHaemophilus influenzae. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 587-592.	2.5	91
427	Mouse Endothelial CD40 Expression Does Not Play a Role During the Development of Transplant Arteriosclerosis. Endothelium: Journal of Endothelial Cell Research, 2003, 10, 111-117.	1.7	4
428	MONITORING IMMUNE RESPONSES IN CANCER PATIENTS RECEIVING TUMOR VACCINES. International Reviews of Immunology, 2003, 22, 283-319.	1.5	29
429	Maintenance of Long Term \hat{I}^3 -Herpesvirus B Cell Latency Is Dependent on CD40-Mediated Development of Memory B Cells. Journal of Immunology, 2003, 171, 886-892.	0.4	48
430	Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation, 2003, 75, 637-643.	0.5	118
431	Induction of operational tolerance to discordant dopaminergic porcine xenografts1. Transplantation, 2003, 75, 1448-1454.	0.5	24
432	Clearance of <i>Pneumocystis carinii</i> in Mice Is Dependent on B Cells But Not on <i>P. carinii</i> -Specific Antibody. Journal of Immunology, 2003, 171, 1423-1430.	0.4	101
433	Platelets and Anti-platelet Therapy. Journal of Pharmacological Sciences, 2003, 93, 381-396.	1.1	88
434	CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood, 2003, 101, 1962-1969.	0.6	139
435	Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood, 2003, 101, 758-765.	0.6	280
436	Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood, 2003, 101, 1430-1438.	0.6	85
437	T Cell Costimulatory Molecules in Anti-Viral Immunity: Potential Role in Immunotherapeutic Vaccines. Canadian Journal of Infectious Diseases & Medical Microbiology, 2003, 14, 221-229.	0.3	5

#	Article	IF	CITATIONS
438	Novel approaches and cutting edge immunotherapies in multiple sclerosis. Frontiers in Bioscience - Landmark, 2004, 9, 2302.	3.0	5
439	Endotracheal Colonization at Birth Is Associated with a Pathogen-Dependent Pro- and Antiinflammatory Cytokine Response in Ventilated Preterm Infants: A Prospective Cohort Study. Pediatric Research, 2004, 56, 547-552.	1.1	11
440	Sepsis-Induced Changes in Macrophage Co-Stimulatory Molecule Expression: CD86 as a Regulator of Anti-Inflammatory IL-10 Response. Surgical Infections, 2004, 5, 375-383.	0.7	39
441	Cutting Edge: Tumor-Specific CTL Are Constitutively Cross-Armed in Draining Lymph Nodes and Transiently Disseminate to Mediate Tumor Regression following Systemic CD40 Activation. Journal of Immunology, 2004, 173, 5923-5928.	0.4	68
442	Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing. Nucleic Acids Research, 2004, 32, 2695-2706.	6.5	44
443	Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5610-5615.	3.3	418
444	Differential Requirement for the CD40-CD154 Costimulatory Pathway during Th Cell Priming by CD8α+ and CD8αâ^' Murine Dendritic Cell Subsets. Journal of Immunology, 2004, 172, 4826-4833.	0.4	30
445	Expanding Role of Circulating Adhesion Molecules in Assessing Prognosis and Treatment Response in Human Immunodeficiency Virus Infection. Vaccine Journal, 2004, 11, 996-1001.	2.6	7
446	B cell signalling as therapeutic target. Annals of the Rheumatic Diseases, 2004, 63, ii65-ii66.	0.5	2
447	A Novel in Vivo Role for Osteoprotegerin Ligand in Activation of Monocyte Effector Function and Inflammatory Response. Journal of Biological Chemistry, 2004, 279, 30202-30209.	1.6	60
448	Pathogenâ€ s pecific Induction of CD154 Is Impaired in CD4+T Cells from Human Immunodeficiency Virus–Infected Patients. Journal of Infectious Diseases, 2004, 189, 61-70.	1.9	32
449	Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1132-9.	1.4	26
450	Role of TNF Receptor-Associated Factor 3 in the CD40 Signaling by Production of Reactive Oxygen Species through Association with p40phox, a Cytosolic Subunit of Nicotinamide Adenine Dinucleotide Phosphate Oxidase. Journal of Immunology, 2004, 172, 231-239.	0.4	51
451	Ectopic CD40 Ligand Expression on B Cells Triggers Intestinal Inflammation. Journal of Immunology, 2004, 172, 6388-6397.	0.4	31
453	Cutting Edge: T Cells Trigger CD40-Dependent Platelet Activation and Granular RANTES Release: A Novel Pathway for Immune Response Amplification. Journal of Immunology, 2004, 172, 2011-2015.	0.4	164
454	Requirement for Donor and Recipient CD40 Expression in Cardiac Allograft Rejection: Induction of Th1 Responses and Influence of Donor-Derived Dendritic Cells. Journal of Immunology, 2004, 172, 6626-6633.	0.4	15
455	BordetellaType III Secretion and Adenylate Cyclase Toxin Synergize to Drive Dendritic Cells into a Semimature State. Journal of Immunology, 2004, 173, 1934-1940.	0.4	48
456	The Role of TNF-Related Activation-Induced Cytokine–Receptor Activating NF-κB Interaction in Acute Allograft Rejection and CD40L-Independent Chronic Allograft Rejection. Journal of Immunology, 2004, 172, 1619-1629.	0.4	30

#	Article	IF	CITATIONS
457	Soluble CD40 Ligand, Soluble P-Selectin, Interleukin-6, and Tissue Factor in Diabetes Mellitus. Circulation, 2004, 109, 2524-2528.	1.6	164
458	FcR Interactions Do Not Play a Major Role in Inhibition of Experimental Autoimmune Encephalomyelitis by Anti-CD154 Monoclonal Antibodies. Journal of Immunology, 2004, 173, 993-999.	0.4	13
459	Novel Regulatory Mechanisms of CD40-Induced Prostanoid Synthesis by IL-4 and IL-10 in Human Monocytes. Journal of Immunology, 2004, 172, 2147-2154.	0.4	33
460	CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9345-9350.	3.3	14
461	Gene Therapy for Liver Transplantation Using Adenoviral Vectors: CD40–CD154 Blockade by Gene Transfer of CD40lg Protects Rat Livers from Cold Ischemia and Reperfusion Injury. Molecular Therapy, 2004, 9, 38-45.	3.7	21
462	Marginal Zone, but Not Follicular B Cells, Are Potent Activators of Naive CD4 T Cells. Journal of Immunology, 2004, 172, 803-811.	0.4	245
463	The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the immune challenge. International Immunology, 2004, 16, 1583-1594.	1.8	49
464	Sexual Dimorphism and the Immune System. , 2004, , 1071-1081.		Ο
465	In Vitro Immunomodulatory Activity of Boâ€Yangâ€Hwanâ€Oâ€Tang. Immunopharmacology and Immunotoxicology, 2004, 26, 631-644.	1.1	5
466	Initial experience with the human anti-human CD154 monoclonal antibody, ABI793, in pig-to-baboon xenotransplantation. Xenotransplantation, 2004, 11, 353-360.	1.6	23
467	T lymphocyte dependence of the antibody response to 'T lymphocyte independent type 2' antigens. Immunology, 2004, 111, 1-7.	2.0	47
468	CD40 is required for the optimal induction of protective immunity to Mycobacterium avium. Immunology, 2004, 111, 323-327.	2.0	22
469	Loss of CD154 impairs the Th2 extrafollicular plasma cell response but not early T cell proliferation and interleukin-4 induction. Immunology, 2004, 113, 187-193.	2.0	28
470	Interaction Between Natural Killer and Dendritic Cells: the Role of CD40, CD80 and Major Histocompatibility Complex Class I Molecules in Cytotoxicity Induction and Interferon-gamma Production. Scandinavian Journal of Immunology, 2004, 59, 356-362.	1.3	22
471	CD40 is Necessary for Activation of Naive T Cells by a Dendritic Cell Line In Vivo but not In Vitro. Scandinavian Journal of Immunology, 2004, 59, 237-245.	1.3	14
472	A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nature Immunology, 2004, 5, 583-589.	7.0	167
473	Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nature Medicine, 2004, 10, 540-544.	15.2	214
474	Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. Nature Medicine, 2004, 10, 835-841.	15.2	79

#	Article	IF	CITATIONS
475	Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Therapy, 2004, 11, 280-288.	2.2	29
476	Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles. Cancer Gene Therapy, 2004, 11, 808-818.	2.2	15
477	Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys. Gene Therapy, 2004, 11, 241-252.	2.3	23
478	Adenoviral vectors: Adenoviral vectors, breaking a barrier to gene therapy?. Gene Therapy, 2004, 11, 229-230.	2.3	2
479	Characterization of Colonic and Mesenteric Lymph Node Dendritic Cell Subpopulations in a Murine Adoptive Transfer Model of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, 834-847.	0.9	29
480	Decrease of CD154 intensity on peripheral CD4+ T cells in autoimmune thyroid disease. Clinical and Experimental Immunology, 2004, 136, 555-558.	1.1	10
481	CD40-CD154 interactions between macrophages and natural killer cells during sepsis are critical for macrophage activation and are not interferon gamma dependent. Clinical and Experimental Immunology, 2004, 137, 469-477.	1.1	40
482	Monoclonal Antibody Specific for TIRC7 Induces Donor-specific Anergy and Prevents Rejection of Cardiac Allografts in Mice. American Journal of Transplantation, 2004, 4, 505-514.	2.6	25
483	Multiple Combination Therapies Involving Blockade of ICOS/B7RP-1 Costimulation Facilitate Long-Term Islet Allograft Survival. American Journal of Transplantation, 2004, 4, 526-536.	2.6	68
484	Critical Role for CD8+ T Cells in Allograft Acceptance Induced by DST and CD40/CD154 Costimulatory Blockade. American Journal of Transplantation, 2004, 4, 1061-1070.	2.6	14
485	The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology, 2004, 326, 20-28.	1.1	70
486	Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning. Experimental Hematology, 2004, 32, 1110-1117.	0.2	13
487	Autoimmune rheumatic diseases days held in Athens in June 2004. Autoimmunity Reviews, 2004, 3, 7-73.	2.5	43
488	Behavioral effects of CD40–CD40L pathway disruption in aged PSAPP mice. Brain Research, 2004, 1015, 161-168.	1.1	37
489	New strategies in immune tolerance induction. Cell Biochemistry and Biophysics, 2004, 40, 27-48.	0.9	8
490	New strategies in immune tolerance induction. Cell Biochemistry and Biophysics, 2004, 2004, 25-48.	0.9	0
491	Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression. FEMS Microbiology Reviews, 2004, 28, 59-77.	3.9	104
492	Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. Current Opinion in Immunology, 2004, 16, 259-263.	2.4	87

#	Article	IF	CITATIONS
493	CD40 expression on human pancreatic duct cells: role in nuclear factor-kappa B activation and production of pro-inflammatory cytokines. Diabetologia, 2004, 47, 660-668.	2.9	27
494	Disruption of CD40/CD40L interaction influences the course ofCryptococcus neoformansinfection. FEMS Immunology and Medical Microbiology, 2004, 40, 63-70.	2.7	33
495	Augmented production of chemokines by the interaction of type II collagen-reactive T cells with rheumatoid synovial fibroblasts. Arthritis and Rheumatism, 2004, 50, 1146-1155.	6.7	35
496	Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key. European Journal of Immunology, 2004, 34, 317-326.	1.6	64
497	Pivotal role of nuclear factor ?B signaling in anti-CD40-induced liver injury in mice. Hepatology, 2004, 40, 1180-1189.	3.6	21
498	Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand. International Journal of Cancer, 2004, 108, 696-703.	2.3	24
499	Current developments of immunotherapy in the clinic. Current Opinion in Immunology, 2004, 16, 130-136.	2.4	72
500	Interactions between dendritic cells and bacteria in the regulation of intestinal immunity. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 255-270.	1.0	59
501	The Role of CD40–CD154 Interactions in Autoimmunity and the Benefit of Disrupting this Pathway. Autoimmunity, 2004, 37, 457-464.	1.2	144
502	Using antibodies in tumour immunotherapy. Expert Opinion on Biological Therapy, 2004, 4, 1265-1284.	1.4	9
503	T Lymphocyte–EndothelialCellInteractions. Annual Review of Immunology, 2004, 22, 683-709.	9.5	179
504	ImmunologicalMemory toViralInfections. Annual Review of Immunology, 2004, 22, 711-743.	9.5	191
505	Truncated Thioredoxin: Physiological Functions and Mechanism. Antioxidants and Redox Signaling, 2004, 6, 53-61.	2.5	100
506	The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut, 2004, 53, 1035-1043.	6.1	124
507	Potential use of CD40 ligand for immunotherapy of childhood B-cell precursor acute lymphoblastic leukaemia. Best Practice and Research in Clinical Haematology, 2004, 17, 465-477.	0.7	8
508	Immunotherapeutic approaches in multiple sclerosis. Journal of the Neurological Sciences, 2004, 223, 13-24.	0.3	35
509	GMP production and testing of Xcellerated T Cellsâ,,¢ for the treatment of patients with CLL. Cytotherapy, 2004, 6, 554-562.	0.3	60
510	Genetic medicine at the RNA level: modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing. Comptes Rendus - Biologies, 2004, 327, 695-709.	0.1	19

#	Article	IF	CITATIONS
511	Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine and Growth Factor Reviews, 2004, 15, 353-366.	3.2	246
512	Prolactin as a modulator of B cell function: implications for SLE. Biomedicine and Pharmacotherapy, 2004, 58, 310-319.	2.5	64
513	Role of T cell costimulation in anti-viral immunity. Seminars in Immunology, 2004, 16, 185-196.	2.7	86
514	CD8 T cell memory. Seminars in Immunology, 2004, 16, 305-314.	2.7	39
515	CD8 memory T cells: cross-reactivity and heterologous immunity. Seminars in Immunology, 2004, 16, 335-347.	2.7	112
516	The CD154-CD40 costimulation pathway in organ transplantation. Transplantation Reviews, 2004, 18, 10-19.	1.2	4
517	CD80 and CD86, but not CD154, augment DNA vaccine-induced protection in experimental bovine tuberculosis. Vaccine, 2004, 23, 769-779.	1.7	43
518	Selective depletion of activated T cells: the CD40L-specific antibody experience. Trends in Molecular Medicine, 2004, 10, 130-135.	3.5	17
519	Microenvironmental Interactions and Survival of CLL B-cells. Leukemia and Lymphoma, 2004, 45, 2365-2372.	0.6	118
520	Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation1. Transplantation, 2004, 77, 717-726.	0.5	80
521	An IL-12-Independent Role for CD40-CD154 in Mediating Effector Responses: Studies in Cell-Mediated Glomerulonephritis and Dermal Delayed-Type Hypersensitivity. Journal of Immunology, 2004, 173, 136-144.	0.4	15
522	Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens. Blood, 2004, 104, 2704-2713.	0.6	22
523	CD40-Dependent Activation of Phosphatidylinositol 3-Kinase/Akt Pathway Inhibits Apoptosis of Human Cultured Mesangial Cells Induced by Oxidized LDL. International Journal of Immunopathology and Pharmacology, 2005, 18, 327-337.	1.0	10
524	Dimeric but not Monomeric Soluble CD40 Prolongs Allograft Survival and Generates Regulatory T Cells that Inhibit CTL Function. Transplantation, 2005, 80, 1614-1622.	0.5	11
525	Disruption of CD40-CD40 ligand pathway inhibits the development of intestinal muscle hypercontractility and protective immunity in nematode infection. American Journal of Physiology - Renal Physiology, 2005, 288, G15-G22.	1.6	21
526	Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis. Expert Review of Neurotherapeutics, 2005, 5, 379-390.	1.4	7
527	Vaccine Therapies for Pediatric Malignancies. Cancer Journal (Sudbury, Mass), 2005, 11, 331-339.	1.0	24
528	Future therapies for hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2005, 17, 515-521.	0.8	9

		CITATION REPORT		
#	Article		IF	CITATIONS
529	Platelet-associated CD154 in immune thrombocytopenic purpura. Blood, 2005, 105, 2	15-218.	0.6	101
530	Preconditioning of NOD mice with anti-CD8 mAb and costimulatory blockade enhance tolerance and prevents diabetes, while depletion of $\hat{I}\pm\hat{I}^2$ -TCR+ and CD4+ cells negates 2005, 105, 2577-2584.	s chimerism and the effect. Blood,	0.6	29
531	Induction of tumor NK-cell immunity by anti-CD69 antibody therapy. Blood, 2005, 105	, 4399-4406.	0.6	57
532	LPS induces CD40 gene expression through the activation of NF-κB and STAT-1α in m microglia. Blood, 2005, 106, 3114-3122.	acrophages and	0.6	225
533	Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent su dendritic-cell maturation and trafficking. Blood, 2005, 106, 2409-2416.	uppressor of	0.6	69
534	Experimental mouse models of inflammatory bowel disease: new insights into pathoge , 2003, , 67-99.	nic mechanisms.		3
535	Role of costimulatory molecules in immune response of patients with cutaneous leish Microbes and Infection, 2005, 7, 86-92.	naniasis.	1.0	13
536	Multi-dysfunctional pathophysiology in ITP. Critical Reviews in Oncology/Hematology,	2005, 54, 107-116.	2.0	94
537	CD40 ligand (CD154) takes part in regulation of the transition to mononuclear cell do peritonitis. Kidney International, 2005, 67, 1340-1349.	minance during	2.6	13
538	Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved imm Immunology, 2005, 115, 215-222.	nunogen.	2.0	15
539	Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with m Crohn's disease. Alimentary Pharmacology and Therapeutics, 2005, 22, 111-122.	oderate to severe	1.9	78
540	Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-ovaccines in vivo. Nature Medicine, 2005, 11, 130-137.	cell cancer	15.2	79
541	Increased CD40 ligand in patients with acute anterior uveitis. Acta Ophthalmologica, 2	2005, 83, 370-373.	0.4	3
542	Isolation of viable antigen-specific CD4 T cells by CD40L surface trapping. Journal of In Methods, 2005, 302, 103-115.	nmunological	0.6	21
543	Effects of sex hormones on costimulatory molecule expression in multiple sclerosis. Jo Neuroimmunology, 2005, 167, 190-203.	urnal of	1.1	13
544	B7-H3 promotes acute and chronic allograft rejection. European Journal of Immunolog 428-438.	y, 2005, 35,	1.6	91
545	CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis. H 42, 372-380.	epatology, 2005,	3.6	34
546	Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD40: Relevance to Parkinson's disease. Journal of Neuroscience 81, 874-882.	Research, 2005,	1.3	48

#	Article	IF	CITATIONS
547	Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World Journal of Urology, 2005, 23, 166-174.	1.2	30
548	A functional CD40 receptor is expressed in pancreatic beta cells. Diabetologia, 2005, 48, 268-276.	2.9	35
549	Mucosal effector memory T cells: the other side of the coin. Cellular and Molecular Life Sciences, 2005, 62, 2853-2866.	2.4	26
550	CD40 signaling induces reciprocal outcomes in Leishmania-infected macrophages; roles of host genotype and cytokine milieu. Microbes and Infection, 2005, 7, 78-85.	1.0	16
551	Plasma membrane-focused proteomics: Dramatic changes in surface expression during the maturation of human dendritic cells. Proteomics, 2005, 5, 4001-4011.	1.3	47
552	CD40 Ligand Expression Correlates with Resolution of Peritonitis and Mononuclear Cell Recruitment. Peritoneal Dialysis International, 2005, 25, 240-247.	1.1	12
553	Soluble CD40L in peripheral artery disease. Thrombosis and Haemostasis, 2005, 93, 578-583.	1.8	43
554	Transfection of Trypanosoma cruzi with Host CD40 Ligand Results in Improved Control of Parasite Infection. Infection and Immunity, 2005, 73, 6552-6561.	1.0	14
555	Evidence for the requirement for CD40–CD154 interactions in resistance to infections with attenuated <i>Salmonella</i> . Journal of Endotoxin Research, 2005, 11, 395-399.	2.5	4
556	T cells from paroxysmal nocturnal haemoglobinuria (PNH) patients show an altered CD40-dependent pathway. Journal of Leukocyte Biology, 2005, 78, 27-36.	1.5	15
557	Drug-Induced Type 1 and Type 2 Immune Responses are Characterized by Distinct Profiles of Cell Kinetics, Cytokine Production, and Expression of Co-Stimulatory Molecules in the Popliteal Lymph Node Assay. Journal of Immunotoxicology, 2005, 2, 141-150.	0.9	4
558	Adenovirus-mediated Transgene-engineered Dendritic Cell Vaccine of Cancer. Current Gene Therapy, 2005, 5, 237-247.	0.9	27
559	Prevention of Relapse after Chemotherapy in a Chronic Intracellular Infection: Mechanisms in Experimental Visceral Leishmaniasis. Journal of Immunology, 2005, 174, 4916-4923.	0.4	52
560	Cyclophosphamide Inhibition of Anti-CD40 Monoclonal Antibody–Based Therapy of B Cell Lymphoma Is Dependent on CD11b+ Cells. Cancer Research, 2005, 65, 7493-7501.	0.4	9
561	TRAF2 Plays a Key, Nonredundant Role in LIGHT-Lymphotoxin β Receptor Signaling. Molecular and Cellular Biology, 2005, 25, 2130-2137.	1.1	46
563	Effector Mechanisms of Nonsuppurative Destructive Cholangitis in Graft-Versus-Host Disease and Allograft Rejection. Seminars in Liver Disease, 2005, 25, 281-297.	1.8	32
564	Genetically Engineered Myeloma Cell Vaccine. , 2005, 113, 235-244.		0
565	A Graves' Disease-Associated Kozak Sequence Single-Nucleotide Polymorphism Enhances the Efficiency of CD40 Gene Translation: A Case for Translational Pathophysiology. Endocrinology, 2005, 146, 2684-2691.	1.4	190

#	Article	IF	Citations
566	Interactions at the Dendritic Cell / T-Cell Interface Define the Balance between Immunity and Tolerance. Transfusion Medicine and Hemotherapy, 2005, 32, 373-383.	0.7	4
567	Multiple myeloma: an update of developments in targeted therapy. Expert Review of Anticancer Therapy, 2005, 5, 379-389.	1.1	4
568	Nonreplicating Recombinant Vaccinia Virus Expressing CD40 Ligand Enhances APC Capacity to Stimulate Specific CD4+ and CD8+ T Cell Responses. Human Gene Therapy, 2005, 16, 348-360.	1.4	42
569	PD-1/PD-L pathway and autoimmunity. Autoimmunity, 2005, 38, 353-357.	1.2	85
570	Antibodies and CD8+ T Cells Are Complementary and Essential for Natural Resistance to a Highly Lethal Cytopathic Virus. Journal of Immunology, 2005, 175, 6829-6836.	0.4	103
571	Identification of Stimulating and Inhibitory Epitopes within the Heat Shock Protein 70 Molecule That Modulate Cytokine Production and Maturation of Dendritic Cells. Journal of Immunology, 2005, 174, 3306-3316.	0.4	120
572	Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy. Journal of Immunology, 2005, 174, 817-826.	0.4	491
573	New Therapeutic Approaches to Parkinson's Disease Including Neural Transplants. Neurorehabilitation and Neural Repair, 2005, 19, 155-181.	1.4	21
574	Disruption of CD40/CD40-Ligand Interactions in a Retinal Autoimmunity Model Results in Protection without Tolerance. Journal of Immunology, 2005, 175, 124-130.	0.4	36
575	Short Communication: Impairment of Membrane Markers on Peripheral Blood Mononuclear Cells and Imbalance of Cytokine Secretion in the Pathogenesis of Multiple Sclerosis Active Phases. Journal of Interferon and Cytokine Research, 2005, 25, 661-665.	0.5	4
576	Potassium Channel-blockers as Therapeutic Agents to Interfere with Bone Resorption of Periodontal Disease. Journal of Dental Research, 2005, 84, 488-499.	2.5	30
577	Resistance to Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis by Death Receptor 6-Deficient Mice. Journal of Immunology, 2005, 175, 2286-2292.	0.4	18
578	Effect of B7-2 and CD40 Signals from Activated Antigen-Presenting Cells on the Ability of Zwitterionic Polysaccharides To Induce T-Cell Stimulation. Infection and Immunity, 2005, 73, 2184-2189.	1.0	34
579	Preclinical Antilymphoma Activity of a Humanized Anti-CD40 Monoclonal Antibody, SGN-40. Cancer Research, 2005, 65, 8331-8338.	0.4	127
580	THE NOD MOUSE: A Model of Immune Dysregulation. Annual Review of Immunology, 2005, 23, 447-485.	9.5	949
581	Anti-CD40 monoclonal antibody. Leukemia and Lymphoma, 2005, 46, 1105-1113.	0.6	24
582	The Role of ICOS in the CXCR5+ Follicular B Helper T Cell Maintenance In Vivo. Journal of Immunology, 2005, 175, 2340-2348.	0.4	322
583	Structureâ [~] 'Activity Relationship Study on a Simple Cationic Peptide Motif for Cellular Delivery of Antisense Peptide Nucleic Acid. Journal of Medicinal Chemistry, 2005, 48, 6741-6749.	2.9	32

#	Article	IF	CITATIONS
584	Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy. Trends in Molecular Medicine, 2005, 11, 322-326.	3.5	40
585	Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs. International Immunopharmacology, 2005, 5, 437-459.	1.7	41
586	Identification of novel genes in the memory response to Brucella infection by cDNA arrays. Molecular and Cellular Probes, 2005, 19, 341-348.	0.9	4
587	Signaling through CD40 ligand decreases CD80 expression on murine Langerhans cells and enhances IL-12 p40 production. Biochemical and Biophysical Research Communications, 2005, 331, 1045-1052.	1.0	3
588	Critical function of the CD40 pathway in parvovirus B19 infection revealed by a hypomorphic CD40 ligand mutation. Clinical Immunology, 2005, 117, 231-237.	1.4	21
589	The microglial "activation" continuum: from innate to adaptive responses. Journal of Neuroinflammation, 2005, 2, 24.	3.1	376
591	Genes and Susceptibility to Leishmaniasis. Advances in Parasitology, 2005, 59, 1-75.	1.4	20
592	Biology of Langerhans Cells and Langerhans Cell Histiocytosis. International Review of Cytology, 2006, 254, 1-43.	6.2	65
593	Tumor Immunology and Immunotherapy. , 2006, , 254-268.		0
594	Emerging drugs for chronic lymphocytic leukaemia. Expert Opinion on Emerging Drugs, 2006, 11, 167-189.	1.0	5
596	Pathogenic Role of B Cells in Anti-CD40-Induced Necroinflammatory Liver Disease. American Journal of Pathology, 2006, 168, 786-795.	1.9	32
597	Immunotherapy of hepatocellular carcinoma. Journal of Hepatology, 2006, 45, 868-878.	1.8	69
598	Human leukocyte antigen polymorphisms: variable humoral immune responses to viral vaccines. Expert Review of Vaccines, 2006, 5, 33-43.	2.0	34
599	COOPERATION BETWEEN CD4+AND CD8+T CELLS: When, Where, and How. Annual Review of Immunology, 2006, 24, 519-540.	9.5	332
600	Developmental Immunology and Role of Host Defenses in Fetal and Neonatal Susceptibility to Infection. , 2006, , 87-210.		41
601	Interactions between dendritic cells and epithelial cells in allergic disease. Toxicology Letters, 2006, 162, 71-82.	0.4	21
602	Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: Relationship to cholesterol turnover. Pharmacological Research, 2006, 54, 421-428.	3.1	28
603	Evaluation of Basic Amphipathic Peptides for Cellular Delivery of Antisense Peptide Nucleic Acids. Journal of Medicinal Chemistry, 2006, 49, 2534-2542.	2.9	26

#	Article	IF	CITATIONS
604	Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochemical and Biophysical Research Communications, 2006, 345, 106-117.	1.0	68
605	Anti-inflammatory effect of roasted licorice extracts on lipopolysaccharide-induced inflammatory responses in murine macrophages. Biochemical and Biophysical Research Communications, 2006, 345, 1215-1223.	1.0	126
606	Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer. European Journal of Cancer, 2006, 42, 981-987.	1.3	13
607	Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. Journal of Autoimmunity, 2006, 26, 165-171.	3.0	122
608	Panax notoginseng attenuates LPS-induced pro-inflammatory mediators in RAW264.7 cells. Journal of Ethnopharmacology, 2006, 106, 121-128.	2.0	147
609	Modulation of T cell function by TCR/pMHC binding kinetics. Immunobiology, 2006, 211, 47-64.	0.8	52
610	BANK Negatively Regulates Akt Activation and Subsequent B Cell Responses. Immunity, 2006, 24, 259-268.	6.6	86
611	BLyS receptor signatures resolve homeostatically independent compartments among naÃ ⁻ ve and antigen-experienced B cells. Seminars in Immunology, 2006, 18, 297-304.	2.7	40
612	Expression level of costimulatory receptor ICOS is critical for determining the polarization of helper T cell function. Transplant Immunology, 2006, 15, 255-263.	0.6	8
613	CD40L, CD28, and CTLA-4 expression on CD4+ T cells in kidney graft recipients: A relationship with post-transplantation clinical course. Transplant Immunology, 2006, 16, 32-40.	0.6	12
614	Expression of Costimulatory Molecules on Human Retinoblastoma Cells Y-79: Functional Expression of CD40 and B7H1. , 2006, 47, 4607.		14
615	Cognate Interaction Between Endothelial Cells and T Cells. , 2006, 43, 151-173.		11
616	Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood, 2006, 108, 1284-1290.	0.6	157
617	Functional Dichotomy in CD40 Reciprocally Regulates Effector T Cell Functions. Journal of Immunology, 2006, 177, 6642-6649.	0.4	32
618	Long-Term Survival of Xenogeneic Heart Grafts Achieved by Costimulatory Blockade and Transient Mixed Chimerism. Transplantation, 2006, 82, 275-281.	0.5	11
619	The Impact of Memory T Cells on Rejection and the Induction of Tolerance. Transplantation, 2006, 82, 1-9.	0.5	98
620	Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. Journal of Hypertension, 2006, 24, 117-121.	0.3	30
621	Short-Term Anti-CD40 Ligand Costimulatory Blockade Induces Tolerance to Peripheral Nerve Allografts, Resulting in Improved Skeletal Muscle Function. Plastic and Reconstructive Surgery, 2006, 117, 2250-2258	0.7	14

#	Article	IF	CITATIONS
622	The Tower of Babel of CD8 + Tâ€cell memory: known facts, deserted roads, muddy waters, and possible dead ends. Immunological Reviews, 2006, 211, 182-196.	2.8	31
623	Measurement of anti-CD154 monoclonal antibody in primate sera by competitive inhibition ELISA. Xenotransplantation, 2006, 13, 566-570.	1.6	10
624	CD40L is Critical for Protection from Demyelinating Disease and Development of Spontaneous Remyelination in a Mouse Model of Multiple Sclerosis. Brain Pathology, 2000, 10, 1-15.	2.1	15
625	Enhancement of binding activity of soluble human CD40 to CD40 ligand through incorporation of an isoleucine zipper motif1. Acta Pharmacologica Sinica, 2006, 27, 333-338.	2.8	6
626	The immunohistology of CD40 in human oral epithelium in health and disease. Journal of Oral Pathology and Medicine, 2006, 35, 268-273.	1.4	5
627	Sjögren's syndrome: why autoimmune epithelitis?. Oral Diseases, 2006, 12, 523-532.	1.5	80
628	Transfection of CD40 in a human oral squamous cell carcinoma keratinocyte line upregulates immune potency and costimulatory molecules. British Journal of Dermatology, 2006, 154, 231-238.	1.4	7
629	Primary immunodeficiencies and susceptibility to parasitic infections. Parasite Immunology, 2006, 28, 060608040039004-???.	0.7	5
630	Costimulatory Molecules and Cytokine Production by T Lymphocytes in Common Variable Immunodeficiency Disease. Scandinavian Journal of Immunology, 2006, 63, 383-389.	1.3	23
631	Revision of the antigen receptor of T-lymphocytes. Biochemistry (Moscow), 2006, 71, 827-837.	0.7	11
632	Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. British Journal of Pharmacology, 2006, 148, 1116-1123.	2.7	57
633	Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Research, 2006, 16, 241-259.	5.7	35
634	Inhibition of Pemphigus Vulgaris by Targeting of the CD40–CD154 Co-Stimulatory Pathway: A Step Toward Antigen-Specific Therapy?. Journal of Investigative Dermatology, 2006, 126, 11-13.	0.3	12
635	T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy. Leukemia, 2006, 20, 2015-2024.	3.3	14
636	The proportion of CD40+ mucosal macrophages is increased in inflammatory bowel disease whereas CD40 ligand (CD154)+ T cells are relatively decreased, suggesting differential modulation of these costimulatory molecules in human gut lamina propria. Inflammatory Bowel Diseases, 2006, 12, 1013-1024.	0.9	27
637	Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy. Journal of Cancer Research and Clinical Oncology, 2006, 132, 787-794.	1.2	9
638	Gene Therapy Strategies for Hepatocellular Carcinoma. Journal of Biomedical Science, 2006, 13, 453-468.	2.6	27
639	The generation of thymus-independent germinal centers depends on CD40 but not on CD154, the T cell-derived CD40-ligand, European Journal of Immunology, 2006, 36, 1665-1673.	1.6	42
ARTICLE IF CITATIONS # Potential role of CARMA1 in CD40-induced splenic B cell proliferation and marginal zone B cell 640 16 1.6 maturation. European Journal of Immunology, 2006, 36, 3033-3043. Current State and Perspectives of Dendritic Cell Vaccination in Cancer Immunotherapy. Skin 641 1.1 Pharmacology and Physiology, 2006, 19, 124-131. Distinctive role of donor strain immature dendritic cells in the creation of allograft tolerance. 642 1.8 6 International Immunology, 2006, 18, 1771-1777. Triggering CD40 on endothelial cells contributes to tumor growth. Journal of Experimental 643 Medicine, 2006, 203, 2441-2450. DC-SIGN on B Lymphocytes Is Required For Transmission of HIV-1 to T Lymphocytes. PLoS Pathogens, 644 2.1 98 2006, 2, e70. B cell proliferation following CD40 stimulation results in the expression and activation of Src protein tyrosine kinase. International Immunology, 2006, 18, 375-387. 1.8 Gene Therapy in Liver Ischemia and Reperfusion Injury. Current Pharmaceutical Design, 2006, 12, 646 0.9 28 2969-2975. 647 Gene Therapy in Lung Transplantation. Current Gene Therapy, 2006, 6, 439-458. The Dendritic Cell-T Cell Synapse as a Determinant of Autoimmune Pathogenesis. Current 648 0.9 35 Pharmaceutical Design, 2006, 12, 131-147. Differential expression and regulation of murine CD40 in regional vascular beds. American Journal of 649 1.5 Physiology - Heart and Circulatory Physiology, 2006, 290, H631-H639. IFNâ€Î²â€induced SOCSâ€1 negatively regulates CD40 gene expression in macrophages and microglia. FASEB 651 0.2 78 Journal, 2006, 20, 985-987. The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: lessons from 0.8 Sjögrenâ€[™]s syndrome (autoimmune epithelitis). Lupus, 2006, 15, 255-261. T Cell Costimulation in the Development of Cardiac Allograft Vasculopathy. Arteriosclerosis, 653 1.1 18 Thrombosis, and Vascular Biology, 2006, 26, 1447-1456. CD4 memory T cells survive and proliferate but fail to differentiate in the absence of CD40. Journal of 654 4.2 Experimental Medicine, 2006, 203, 897-906. CD40 Restrains In Vivo Growth of Toxoplasma gondii Independently of Gamma Interferon. Infection 655 1.0 39 and Immunity, 2006, 74, 1573-1579. CD154 Is Essential for Protective Immunity in Experimental <i>Salmonella</i> Infection: Evidence for a 36 Dual Role in Innate and Adaptive Immune Responses. Journal of Immunology, 2006, 176, 496-506. A New Memory CD27â[°]IgG+ B Cell Population in Peripheral Blood Expressing VH Genes with Low 657 0.4 257 Frequency of Somatic Mutation. Journal of Immunology, 2006, 177, 3728-3736. CD40 Ligand Enhances Dengue Viral Infection of Dendritic Cells: A Possible Mechanism for T Cell-Mediated Immunopathology. Journal of Immunology, 2006, 177, 6497-6503.

#	Article	IF	CITATIONS
659	Giving blood: a new role for CD40 in tumorigenesis. Journal of Experimental Medicine, 2006, 203, 2409-2412.	4.2	33
660	Increased CD154 Expression in Uninfected Infants Born to HIV-Positive Mothers Exposed to Antiretroviral Prophylaxis. Viral Immunology, 2006, 19, 363-372.	0.6	15
661	CXCR5 Identifies a Subset of Vγ9Vδ2 T Cells which Secrete IL-4 and IL-10 and Help B Cells for Antibody Production. Journal of Immunology, 2006, 177, 5290-5295.	0.4	133
662	Subepithelial Myofibroblasts are Novel Nonprofessional APCs in the Human Colonic Mucosa. Journal of Immunology, 2006, 177, 5968-5979.	0.4	100
663	IL-10- and IL-12-Independent Down-Regulation of Allergic Sensitization by Stimulation of CD40 Signaling. Journal of Immunology, 2006, 177, 5138-5144.	0.4	14
664	Differential Requirements of T Cell Subsets for CD40 Costimulation in Immunity toBlastomyces dermatitidis. Journal of Immunology, 2006, 176, 5538-5547.	0.4	15
665	IL-10 Inhibits Lipopolysaccharide-Induced CD40 Gene Expression through Induction of Suppressor of Cytokine Signaling-3. Journal of Immunology, 2006, 177, 7761-7771.	0.4	94
666	Immunomodulation with CD40 Stimulation and Interleukin-2 Protects Mice from Disseminated Cryptococcosis. Infection and Immunity, 2006, 74, 2161-2168.	1.0	27
667	Early Growth Response-1 Is Required for CD154 Transcription. Journal of Immunology, 2006, 176, 811-818.	0.4	26
668	Targeting Costimulatory Pathways for Tumor Immunotherapy. International Reviews of Immunology, 2007, 26, 161-196.	1.5	24
669	CD40 Ligand Mediates Inflammation Independently of CD40 by Interaction With Mac-1. Circulation, 2007, 115, 1571-1580.	1.6	209
670	Delivery of Antigen to CD40 Induces Protective Immune Responses against Tumors. Journal of Immunology, 2007, 178, 4169-4176.	0.4	66
671	Stimulation of Cell Surface CCR5 and CD40 Molecules by Their Ligands or by HSP70 Up-Regulates APOBEC3G Expression in CD4+ T Cells and Dendritic Cells. Journal of Immunology, 2007, 178, 1671-1679.	0.4	60
672	Chemokine-Guided CD4+T Cell Help Enhances Generation of IL-6RαhighIL-7RαhighPrememory CD8+T Cells. Journal of Immunology, 2007, 178, 778-787.	0.4	90
673	Cellâ€Đerived Microparticles and Exosomes in Neuroinflammatory Disorders. International Review of Neurobiology, 2007, 79, 227-268.	0.9	61
674	Differential Regulation of the Nature and Functions of Dendritic Cells and Macrophages by Cathepsin E. Journal of Immunology, 2007, 179, 5728-5737.	0.4	35
675	Regulation of Innate and Adaptive Immune Responses by a Novel Pattern Recognition Molecule Mindin. Current Immunology Reviews, 2007, 3, 233-239.	1.2	0
676	Artificial Pancreas to Treat Type 1 Diabetes Mellitus. Methods in Molecular Medicine, 2007, 140, 197-236.	0.8	18

ARTICLE IF CITATIONS High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet 1.0 186 677 Activation in 880 Patients With Nonvalvular Atrial Fibrillation. Stroke, 2007, 38, 1229-1237. Relationship of Soluble CD40 Ligand to Vascular Endothelial Growth Factor, Angiopoietins, and 678 0.4 39 Tissue Factor in Atrial Fibrillation. Chest, 2007, 132, 1913-1919. Increased Serum Levels of Circulating CD40 Ligand in Patients with Bullous Pemphigoid: Preliminary 679 0.9 2 Results. Dermatology, 2007, 215, 180-186. Cholesterol-Dependent and -Independent CD40 Internalization and Signaling Activation in Cardiovascular Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 680 2005-2013. TRAF-1, -2, -3, -5, and -6 Are Induced in Atherosclerotic Plaques and Differentially Mediate 681 Proinflammatory Functions of CD40L in Endothelial Cells. Arteriosclerosis, Thrombosis, and 1.1 97 Vascular Biology, 2007, 27, 1101-1107. Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody. Journal of Clinical Oncology, 2007, 25, 876-883. 0.8 458 A New Population of Cells Lacking Expression of CD27 Represents a Notable Component of the B Cell 683 0.4 512 Memory Compartment in Systemic Lupus Erythematosus. Journal of Immunology, 2007, 178, 6624-6633. Role of CD40-Dependent Down-Regulation of CD154 in Impaired Induction of CD154 in CD4+ T Cells 684 0.4 from HIV-1-Infected Patients. Journal of Immunology, 2007, 178, 1645-1653. CD40 Ligand Binds to 1 ± 51^{2} Integrin and Triggers Cell Signaling. Journal of Biological Chemistry, 2007, 685 93 1.6 282, 5143-5151. Prospect of Targeting the CD40 Pathway for Cancer Therapy. Clinical Cancer Research, 2007, 13, 3.2 1083-1088. Negative Regulation of CD40-Mediated B Cell Responses by E3 Ubiquitin Ligase Casitas-B-Lineage 687 0.4 37 Lymphoma Protein-B. Journal of Immunology, 2007, 179, 4473-4479. Frontiers in Nephrology: Heterologous Immunity, T Cell Cross-Reactivity, and Alloreactivity. Journal 688 3.0 of the American Society of Nephrology: JASN, 2007, 18, 2268-2277. Clinical Relevance of Cytokines and Inflammatory Molecules in Rheumatoid Vasculitis. Current 689 0.4 0 Rheumatology Reviews, 2007, 3, 309-316. Differential Virus Replication, Cytokine Production, and Antigen-Presenting Function by Microglia from Susceptible and Resistant Mice Infected with Theiler's Virus. Journal of Virology, 2007, 81, 1.5 11690-11702. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone 691 399 0.6 mass in vivo. Blood, 2007, 109, 3839-3848. Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood, 2007, 110, 89 2484-2493. Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells. 693 0.6 126 Blood, 2007, 110, 2736-2743. Molecular and Cellular Basis of Microflora-Host Interactions1, Journal of Nutrition, 2007, 137, 1.3 756S-772S.

#	Article	IF	CITATIONS
696	Immunomodulation by Adenoviral-Mediated SCD40-Ig Gene Therapy for Mouse Allogeneic Islet Transplantation. Transplantation, 2007, 84, 301-307.	0.5	15
697	Gene Transfer of Noncleavable Cell Surface Mutants of Human CD154 Induces the Immune Response and Diminishes Systemic Inflammatory Reactions. Journal of Immunotherapy, 2007, 30, 694-704.	1.2	5
698	A Novel Fully Human Anti-CD40 Monoclonal Antibody, 4D11, for Kidney Transplantation in Cynomolgus Monkeys. Transplantation, 2007, 84, 1020-1028.	0.5	81
699	Anti-CD40 agonist antibodies: Preclinical and clinical experience. Update on Cancer Therapeutics, 2007, 2, 61-65.	0.9	61
700	Long-term n-3 polyunsaturated fatty acids administration ameliorates arteriosclerosis by modulating T-cell activity in a rat model of small intestine transplantation. Clinica Chimica Acta, 2007, 381, 124-130.	0.5	12
701	Immunologic Approaches to Composite Tissue Allograft. Journal of Hand Surgery, 2007, 32, 1072-1085.	0.7	12
702	Germinal-Center Organization and Cellular Dynamics. Immunity, 2007, 27, 190-202.	6.6	838
703	Cloning, sequence analysis and expression of ovine CD154 (CD40 ligand). Molecular Immunology, 2007, 44, 741-746.	1.0	1
704	General Principles of Tumor Immunotherapy. , 2007, , .		3
707	High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance. Infectious Agents and Cancer, 2007, 2, 5.	1.2	21
708	Simultaneous Tether Extraction from Endothelial Cells and Leukocytes: Observation, Mechanics, and Significance. Biophysical Journal, 2007, 93, 4041-4052.	0.2	28
709	CD40–CD40 Ligand Mediates the Recruitment of Leukocytes and Platelets in the Inflamed Murine Colon. Gastroenterology, 2007, 132, 955-965.	0.6	64
710	Gene therapy and active immune therapy of hematologic malignancies. Best Practice and Research in Clinical Haematology, 2007, 20, 557-568.	0.7	14
711	Enhancement of Proliferation and Antigen Presentation of Human B Cells in Vitro by K562 Cells Expressing CD40L. Immune Network, 2007, 7, 80.	1.6	1
712	Endothelial Antigen Presentation. , 2007, , 1098-1108.		4
713	Up-regulation of stromal cell–derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: Role of interleukin-17 and CD40L–CD40 interaction. Arthritis and Rheumatism, 2007, 56, 1076-1086.	6.7	121
714	Identification and isolation of murine antigenâ€reactive T cells according to CD154 expression. European Journal of Immunology, 2007, 37, 2370-2377.	1.6	56

#	Article	IF	CITATIONS
716	Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40–CD40L interactions with T helper cells. Leukemia, 2007, 21, 2411-2419.	3.3	25
717	Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. British Journal of Pharmacology, 2007, 150, 248-248.	2.7	7
718	The half-life of the T-cell receptor/peptide?major histocompatibility complex interaction can modulate T-cell activation in response to bacterial challenge. Immunology, 2007, 121, 227-237.	2.0	25
719	Lipopolysaccharide desensitizes monocytes–macrophages to CD40 ligand stimulation. Immunology, 2007, 122, 362-370.	2.0	17
720	Interference with immuneâ€cellâ€mediated bone resorption in periodontal disease. Periodontology 2000, 2007, 45, 76-94.	6.3	49
721	Prostacyclin in sepsis: A systematic review. Prostaglandins and Other Lipid Mediators, 2007, 83, 1-24.	1.0	28
722	B cells play a cooperative role via CD40L–CD40 interaction in T cell-mediated experimental autoimmune neuritis in Lewis rats. Neurobiology of Disease, 2007, 25, 642-648.	2.1	11
723	Different patterns of activation markers expression and CD4+ T-cell responses to ex vivo stimulation in patients with clinically quiescent multiple sclerosis (MS). Journal of Neuroimmunology, 2007, 189, 137-146.	1.1	16
724	Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clinical Reviews in Allergy and Immunology, 2007, 32, 57-65.	2.9	26
725	Increases in circulating T lymphocytes expressing HLA-DR and CD40 ligand in patients with dilated cardiomyophthy. Heart and Vessels, 2007, 22, 316-321.	0.5	17
726	CD8 T cell memory development: CD4 T cell help is appreciated. Immunologic Research, 2007, 39, 94-104.	1.3	59
727	Inhibition of apoptosis, activation of NKT cell and upregulation of CD40 and CD40L mediated by M. leprae antigen(s) combined with Murabutide and Trat peptide in leprosy patients. Molecular and Cellular Biochemistry, 2008, 309, 87-97.	1.4	13
728	Genetic Polymorphisms in the CD40 Ligand Gene and Kawasaki Disease. Journal of Clinical Immunology, 2008, 28, 405-410.	2.0	21
729	Introduction of a CD40L genomic fragment via a human artificial chromosome vector permits cell-type-specific gene expression and induces immunoglobulin secretion. Journal of Human Genetics, 2008, 53, 447-453.	1.1	16
730	Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis. Pediatric Rheumatology, 2008, 6, 8.	0.9	25
731	A membrane-bound form of IL-4 enhances proliferation and antigen presentation of CD40-activated human B cells. Immunology Letters, 2008, 116, 33-40.	1.1	5
732	Targeting of the immune system in systemic lupus erythematosus. Expert Reviews in Molecular Medicine, 2008, 10, e2.	1.6	30
733	Twelve immunotherapy drugs that could cure cancers. Immunological Reviews, 2008, 222, 357-368.	2.8	297

#	Article	IF	CITATIONS
734	Characterization of pancreatic ductal cells in human islet preparations. Laboratory Investigation, 2008, 88, 1167-1177.	1.7	32
735	Future innovations in antiâ€platelet therapies. British Journal of Pharmacology, 2008, 154, 918-939.	2.7	135
736	Discrete Tollâ€ ŀ ike receptor agonists have differential effects on alloimmunization to transfused red blood cells. Transfusion, 2008, 48, 1869-1877.	0.8	50
737	CD28 downregulation on CD4+T cells is associated with age of kidney transplant recipient. Transplant International, 2008, 21, 661-668.	0.8	4
738	Adenovirusâ€mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma. Cancer Science, 2008, 99, 2097-2103.	1.7	10
739	RNA-electroporated CD40-activated B cells induce functional T-cell responses against HepG2 cells. European Journal of Cancer Care, 2008, 17, 404-411.	0.7	11
740	Functional analysis of a tripartite stability element within the CD40 ligand 3' untranslated region. Immunology, 2008, 124, 368-379.	2.0	8
741	Enhancement of T cell activation by immobilized hu5C8 (anti-CD40L) monoclonal antibody. European Journal of Haematology, 2008, 80, 322-330.	1.1	3
742	Transplant Acceptance Following Anti-CD4 Versus Anti-CD40L Therapy: Evidence for Differential Maintenance of Graft-Reactive T Cells. American Journal of Transplantation, 2008, 8, 2037-2048.	2.6	12
743	Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression. Journal of Neuroinflammation, 2008, 5, 41.	3.1	175
744	Chapter 4 CD8+ T Cells in Type 1 Diabetes. Advances in Immunology, 2008, 100, 79-124.	1.1	105
745	T-cell co-stimulatory pathways in autoimmunity. Arthritis Research and Therapy, 2008, 10, S3.	1.6	52
746	Characterization of natural human antagonistic soluble CD40 isoforms produced through alternative splicing. Molecular Immunology, 2008, 46, 250-257.	1.0	27
747	COX-2 and CCR2 induced by CD40 ligand and MCP-1 are linked to VEGF production in endothelial cells. Prostaglandins Leukotrienes and Essential Fatty Acids, 2008, 78, 137-146.	1.0	22
748	Peripherally Administered Human Umbilical Cord Blood Cells Reduce Parenchymal and Vascular <i>î²</i> -Amyloid Deposits in Alzheimer Mice. Stem Cells and Development, 2008, 17, 423-440.	1.1	110
749	CD4 T cells: Balancing the coming and going of autoimmune-mediated inflammation in the CNS. Brain, Behavior, and Immunity, 2008, 22, 421-430.	2.0	80
750	Soluble CD40 ligand as a biomarker for storage-related preanalytic variations of human serum. Cytokine, 2008, 44, 275-282.	1.4	33
751	CD40 ligand supports the long-term maintenance and differentiation of chicken B cells in culture. Developmental and Comparative Immunology, 2008, 32, 1015-1026.	1.0	30

#	Article	IF	CITATIONS
752	Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology, 2008, 48, 11-22.	0.9	159
753	CD40L+ CD4+ memory T cells migrate in a CD62P-dependent fashion into reactive lymph nodes and license dendritic cells for T cell priming. Journal of Experimental Medicine, 2008, 205, 2561-2574.	4.2	64
754	Full Development of Th2 Immunity Requires Both Innate and Adaptive Sources of CD154. Journal of Immunology, 2008, 180, 8083-8092.	0.4	21
755	Autoimmunity to Both Proinsulin and IGRP Is Required for Diabetes in Nonobese Diabetic 8.3 TCR Transgenic Mice. Journal of Immunology, 2008, 180, 4458-4464.	0.4	51
756	Strategic Nonmyeloablative Conditioning: CD154:CD40 Costimulatory Blockade at Primary Bone Marrow Transplantation Promotes Engraftment for Secondary Bone Marrow Transplantation after Engraftment Failure. Journal of Immunology, 2008, 181, 6616-6624.	0.4	4
757	Cancer Immunotherapy Using <i>In vitro</i> Genetically Modified Targeted Dendritic Cells. Cancer Research, 2008, 68, 3854-3862.	0.4	21
758	Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma. Gut, 2008, 57, 344-351.	6.1	19
759	Preclinical Assessment of Therapeutic Antibodies against Human CD40 and Human Interleukin-12/23p40 in a Nonhuman Primate Model of Multiple Sclerosis. Neurodegenerative Diseases, 2008, 5, 38-52.	0.8	29
760	Cutting Edge: The Transmembrane E3 Ligase GRAIL Ubiquitinates the Costimulatory Molecule CD40 Ligand during the Induction of T Cell Anergy. Journal of Immunology, 2008, 181, 1622-1626.	0.4	54
761	Separate cis-trans Pathways Post-transcriptionally Regulate Murine CD154 (CD40 Ligand) Expression. Journal of Biological Chemistry, 2008, 283, 25606-25616.	1.6	22
762	Foxp3 ⁺ regulatory T cells promiscuously accept thymic signals critical for their development. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 973-978.	3.3	67
763	The Agonists of TLR4 and 9 Are Sufficient to Activate Memory B Cells to Differentiate into Plasma Cells In Vitro but Not In Vivo. Journal of Immunology, 2008, 181, 1746-1752.	0.4	50
764	TLR4-mediated activation of dendritic cells by the heat shock protein DnaK from <i>Francisella tularensis</i> . Journal of Leukocyte Biology, 2008, 84, 1434-1446.	1.5	46
766	<i>Plasmodium falciparum</i> -free merozoites and infected RBCs distinctly affect soluble CD40 ligand-mediated maturation of immature monocyte-derived dendritic cells. Journal of Leukocyte Biology, 2008, 84, 244-254.	1.5	23
767	Characterization of phenotypically distinct B-cell subsets and receptor-stimulated mitogen-activated protein kinase activation in human cord blood B cells. Journal of Leukocyte Biology, 2008, 84, 1557-1564.	1.5	9
768	T-Cell Costimulation and Coinhibition in Atherosclerosis. Circulation Research, 2008, 103, 1220-1231.	2.0	123
770	CD20, CD3, and CD40 Ligand Microclusters Segregate Three-Dimensionally In Vivo at B-Cell-T-Cell Immunological Synapses after Viral Immunity in Primate Brain. Journal of Virology, 2008, 82, 9978-9993.	1.5	17
771	Downregulation of CD40 Ligand Response in Monocytes from Sepsis Patients. Vaccine Journal, 2008, 15, 1851-1858.	3.2	41

#	Article	IF	Citations
772	Intestinal Immune Response to Human <i>Cryptosporidium</i> sp. Infection. Infection and Immunity, 2008, 76, 23-29.	1.0	71
773	Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. Expert Opinion on Investigational Drugs, 2008, 17, 31-41.	1.9	14
774	Activin-A: a novel dendritic cell–derived cytokine that potently attenuates CD40 ligand–specific cytokine and chemokine production. Blood, 2008, 111, 2733-2743.	0.6	98
775	The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood, 2008, 111, 4596-4604.	0.6	80
776	A functional TNFRSF5 gene variant is associated with risk of lymphoma. Blood, 2008, 111, 4348-4354.	0.6	42
777	CD40: an upstream master switch for endothelial cell activation uncovered by RNAi-coupled transcriptional profiling. Blood, 2008, 112, 3624-3637.	0.6	36
778	Soluble CD40 Ligand, Platelet Surface CD40 Ligand, and Total Platelet CD40 Ligand in Atrial Fibrillation. Chest, 2008, 134, 574-581.	0.4	39
780	N-Acetylcysteine Derivative Inhibits CD40-Dependent Proinflammatory Properties of Human Pancreatic Duct Cells. Pancreas, 2008, 36, 363-368.	0.5	5
781	Impact of Donor Bone Marrow on Survival of Composite Tissue Allografts. Annals of Plastic Surgery, 2008, 60, 455-462.	0.5	29
782	Differential Impact of CD154 Costimulation Blockade on Alloreactive Effector and Regulatory T Cells in Murine Renal Transplant Recipients. Transplantation, 2008, 85, 1332-1338.	0.5	28
784	Characterization of Effector T Cells in Dry Eye Disease. , 2009, 50, 3802.		130
785	A Monoclonal Antibody Selection for Immunohistochemical Examination of Lymphoid Tissues From Non-human Primates. Journal of Histochemistry and Cytochemistry, 2009, 57, 1159-1167.	1.3	14
786	Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7513-7518.	3.3	127
787	Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges. Advances in Experimental Medicine and Biology, 2009, 647, 8-36.	0.8	88
788	The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thrombosis and Haemostasis, 2009, 102, 206-214.	1.8	117
789	High Levels of Human Antigen-Specific CD4+ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40). Journal of Immunology, 2009, 183, 2827-2836.	0.4	153
790	Anti-CD40 Monoclonal Antibody Synergizes with CTLA4-Ig in Promoting Long-Term Graft Survival in Murine Models of Transplantation. Journal of Immunology, 2009, 183, 1625-1635.	0.4	73
791	Oxaprozin-Induced Apoptosis on CD40 Ligand-Treated Human Primary Monocytes Is Associated with the Modulation of Defined Intracellular Pathways. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-9.	3.0	3

#	Article	IF	CITATIONS
792	Preliminary evidence for a matrix metalloproteinase-2 (MMP-2)-dependent shedding of soluble CD40 ligand (sCD40L) from activated platelets. Platelets, 2009, 20, 441-444.	1.1	33
793	Vaccination of chickens with recombinant Salmonella expressing M2e and CD154 epitopes increases protection and decreases viral shedding after low pathogenic avian influenza challenge. Poultry Science, 2009, 88, 2244-2252.	1.5	51
794	Activation-Induced CD154 Expression Abrogates Tolerance Induced by Apoptotic Cells. Journal of Immunology, 2009, 183, 6114-6123.	0.4	24
795	Suramin inhibits the CD40–CD154 costimulatory interaction: A possible mechanism for immunosuppressive effects. Biochemical Pharmacology, 2009, 77, 1236-1245.	2.0	28
796	<i>In vivo</i> postâ€transcriptional regulation of CD154 in mouse CD4 ⁺ T cells. European Journal of Immunology, 2009, 39, 2224-2232.	1.6	18
797	Critical role of microglial CD40 in the maintenance of mechanical hypersensitivity in a murine model of neuropathic pain. European Journal of Immunology, 2009, 39, 3562-3569.	1.6	30
798	Analysis of gene expression profiles in the liver and spleen of mice infected with Trypanosoma evansi by using a cDNA microarray. Parasitology Research, 2009, 104, 385-397.	0.6	7
799	Inhibition of cytokine and surface antigen expression in LPS-stimulated murine macrophages by triethylene glycol dimethacrylate. Biomaterials, 2009, 30, 1665-1674.	5.7	51
800	Dendritic cell-based cancer immunotherapies. Archivum Immunologiae Et Therapiae Experimentalis, 2009, 57, 189-198.	1.0	17
801	Innate and adaptive immunity in atherosclerosis. Seminars in Immunopathology, 2009, 31, 5-22.	2.8	154
802	Immunotherapy for liver tumors: present status and future prospects. Journal of Biomedical Science, 2009, 16, 30.	2.6	23
803	Peripheral blood CD27 ⁺ lgG ⁺ B cells rapidly proliferate and differentiate into immunoglobulinâ€secreting cells after exposure to low CD154 interaction. Immunology, 2009, 128, e353-65.	2.0	25
804	Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clinical and Experimental Immunology, 2009, 156, 69-77.	1.1	97
805	Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases. Clinical and Experimental Immunology, 2009, 157, 181-190.	1.1	9
806	Costimulatory pathways in transplantation: challenges and new developments. Immunological Reviews, 2009, 229, 271-293.	2.8	189
807	Autoantibodies to β ₁ â€adrenoceptors in human chronic periodontitis induce overexpression of fibroblast CD40 and trigger prostaglandin E ₂ generation. Journal of Periodontal Research, 2009, 44, 330-337.	1.4	8
808	Dendritic cell activation by combined exposure to antiâ€CD40 plus interleukin (IL)â€12 and ILâ€18 efficiently stimulates antiâ€tumor immunity. Experimental Dermatology, 2009, 18, 78-87.	1.4	19
809	Immunomodulation by blockade of the TRANCE co-stimulatory pathway in murine allogeneic islet transplantation. Transplant International, 2009, 22, 931-939.	0.8	8

#	Article	IF	CITATIONS
810	Effects of 7,8â€dihydroâ€8â€oxoâ€deoxyguanosine on antigen challenge in ovalbuminâ€sensitized mice may be mediated by suppression of Rac. British Journal of Pharmacology, 2009, 158, 1743-1752.	2.7	20
811	Protective effect of epigallocatechin gallate on the immune function of dendritic cells after ultraviolet B irradiation. Journal of Cosmetic Dermatology, 2009, 8, 174-180.	0.8	9
812	TNF superfamily: Costimulation and clinical applications. Cell Biology International, 2009, 33, 453-465.	1.4	20
813	Involvement of CD40 Targeting miR-224 and miR-486 on the Progression of Pancreatic Ductal Adenocarcinomas. Annals of Surgical Oncology, 2009, 16, 2339-2350.	0.7	123
814	Cationic liposome-mediated transfection of CD40 ligand gene inhibits hepatic tumor growth of hepatocellular carcinoma in mice. Journal of Zhejiang University: Science B, 2009, 10, 7-13.	1.3	3
815	1α,25-Dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in Human Monocytes. Cytokine, 2009, 45, 190-197.	1.4	192
816	Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. Cytokine, 2009, 47, 132-136.	1.4	54
817	CD40 ligation converts TGF-Î ² -secreting tolerogenic CD4â [~] 8â [~] dendritic cells into IL-12-secreting immunogenic ones. Biochemical and Biophysical Research Communications, 2009, 379, 954-958.	1.0	10
819	The immunobiology of CD154–CD40–TRAF interactions in atherosclerosis. Seminars in Immunology, 2009, 21, 308-312.	2.7	65
820	Upregulation of interferon-Î ³ and interleukin-4, Th cell-derived cytokines by So-Shi-Ho-Tang (Sho-Saiko-To) occurs at the level of antigen presenting cells, but not CD4 T cells. Journal of Ethnopharmacology, 2009, 123, 6-14.	2.0	27
821	Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Molecular Immunology, 2009, 46, 1654-1662.	1.0	47
822	Impaired immune responses in the lungs of aged mice following influenza infection. Respiratory Research, 2009, 10, 112.	1.4	207
824	Activation-Induced Cytidine Deaminase Expression and Activity in the Absence of Germinal Centers: Insights into Hyper-IgM Syndrome. Journal of Immunology, 2009, 183, 3237-3248.	0.4	48
825	Can peripheral leukocytes be used as Alzheimer's disease biomarkers?. Expert Review of Neurotherapeutics, 2009, 9, 1623-1633.	1.4	34
826	Generation of Human Dendritic Cells That Simultaneously Secrete IL-12 and Have Migratory Capacity by Adenoviral Gene Transfer of hCD40L in Combination With IFN-γ. Journal of Immunotherapy, 2009, 32, 524-538.	1.2	33
827	Enhanced platelet responsiveness due to chilling and its relation to CD40 ligand level and platelet–leukocyte aggregate formation. Blood Coagulation and Fibrinolysis, 2009, 20, 176-184.	0.5	10
828	Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus. Current Drug Targets, 2009, 10, 26-37.	1.0	32
829	Virosomal influenza-vaccine induced immunity in HIV-infected individuals with high versus low CD4+ T-cell counts: clues towards a rational vaccination strategy. Aids, 2010, 24, 2287-2289.	1.0	9

#	Article	IF	Citations
830	Impact of Immunosuppressants on the Therapeutic Efficacy of In Vitro-Expanded CD4+CD25+Foxp3+ Regulatory T Cells in Allotransplantation. Transplantation, 2010, 89, 928-936.	0.5	44
831	Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood, 2010, 116, 3004-3012.	0.6	67
832	CD40L induces inflammation and adipogenesis in adipose cells – a potential link between metabolic and cardiovascular disease. Thrombosis and Haemostasis, 2010, 103, 788-796.	1.8	61
833	Polysaccharides PS-G and Protein LZ-8 from Reishi (<i>Ganoderma lucidum</i>) Exhibit Diverse Functions in Regulating Murine Macrophages and T Lymphocytes. Journal of Agricultural and Food Chemistry, 2010, 58, 8535-8544.	2.4	71
834	Melanoma Immunotherapy. Mount Sinai Journal of Medicine, 2010, 77, 620-642.	1.9	13
835	Immunology of Î ² -Cell Destruction. Advances in Experimental Medicine and Biology, 2010, 654, 537-583.	0.8	27
836	Platelets and innate immunity. Cellular and Molecular Life Sciences, 2010, 67, 499-511.	2.4	277
837	Hypophysectomy and neurointermediate pituitary lobectomy decrease humoral immune responses to T-independent and T-dependent antigens. Journal of Physiology and Biochemistry, 2010, 66, 7-13.	1.3	16
838	CD40 expression in Wehi-164 cell line. Cytotechnology, 2010, 62, 195-199.	0.7	1
839	Biology and Clinical Applications of CD40 in Cancer Treatment. Seminars in Oncology, 2010, 37, 517-523.	0.8	41
840	Immunogene therapy against colon cancer metastasis using an adenovirus vector expressing CD40 ligand. Surgery, 2010, 148, 925-935.	1.0	7
841	Alloimmune Activation Enhances Innate Tissue Inflammation/Injury in a Mouse Model of Liver Ischemia/Reperfusion Injury. American Journal of Transplantation, 2010, 10, 1729-1737.	2.6	17
842	Nef-specific CD45RA+ CD8+ T cells secreting MIP-11 ² but not IFN-1 ³ are associated with nonprogressive HIV-1 infection. AIDS Research and Therapy, 2010, 7, 20.	0.7	8
843	CD40 ligand shedding is regulated by interaction between matrix metalloproteinaseâ€2 and platelet integrin αIlbβ3. Journal of Thrombosis and Haemostasis, 2010, 8, 1364-1371.	1.9	51
844	CD40 signalling induces ILâ€10â€producing, tolerogenic dendritic cells. Experimental Dermatology, 2010, 19, 44-53.	1.4	36
845	Activation of antigen receptor genes rearrangement in peripheral blood T lymphocytes as a possible mechanism of autoimmunity induction. Doklady Biological Sciences, 2010, 435, 387-389.	0.2	2
846	The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nature Medicine, 2010, 16, 713-717.	15.2	264
847	Structure and Function of Tumor Necrosis Factor (TNF) at the Cell Surface. , 2010, , 265-275.		4

		CITATION REPORT	
# 848	ARTICLE Soluble CD40 Ligand Impairs the Function of Peripheral Blood Angiogenic Outgrowth Cells and Increases Neointimal Formation After Arterial Injury. Circulation, 2010, 121, 315-324.	IF 1.6	CITATIONS 43
849	The Role of Costimulatory Molecules in Allergic Disease and Asthma. International Archives of Allergy and Immunology, 2010, 151, 179-189.	0.9	70
850	Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer. Cancer Research, 2010, 70, 99-108.	0.4	398
851	Evaluation of recombinant Salmonella expressing CD154 for persistence and enhanced antibody response in commercial turkeys. Poultry Science, 2010, 89, 1399-1405.	1.5	6
853	CD137 Promotes Proliferation and Survival of Human B Cells. Journal of Immunology, 2010, 184, 787-795.	0.4	60
854	A novel allergen-specific therapy for allergy using CD40-silenced dendritic cells. Journal of Allergy and Clinical Immunology, 2010, 125, 737-743.e6.	1.5	29
856	Effect of the administration of Lactobacillus paracasei subsp. paracasei NTU 101 on Peyer's patch-mediated mucosal immunity. International Immunopharmacology, 2010, 10, 791-798.	1.7	51
857	Vaccination with immature dendritic cells combined with CD40mAb induces protective immunity against B lymphoma in hu-SCID mice. Biomedicine and Pharmacotherapy, 2010, 64, 487-492.	2.5	6
858	T cells: Critical bone regulators in health and disease. Bone, 2010, 47, 461-471.	1.4	86
859	Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine, 2010, 28, 6757-6764.	1.7	52
860	Immunogenicity and protective efficacy of a DNA vaccine encoding a chimeric protein of avian influenza hemagglutinin subtype H5 fused to CD154 (CD40L) in Pekin ducks. Vaccine, 2010, 28, 8147-8156.	1.7	30
861	Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis, 2010, 209, 585-591.	0.4	105
862	<i>CD40</i> -1C>T polymorphism (rs1883832) is associated with brain vessel reocclusion after fibrinolysis in ischemic stroke. Pharmacogenomics, 2010, 11, 763-772.	0.6	16
863	Development and evaluation of candidate recombinant Salmonella-vectored Salmonella vaccines. Poultry Science, 2010, 89, 2370-2379.	1.5	14
864	Regulatory B cells in autoimmune diseases and mucosal immune homeostasis. Autoimmunity, 2011, 44, 58-68.	1.2	13
865	CD40L coâ€stimulation from CD8 ⁺ to CD4 ⁺ effector memory T cells supports CD4 ⁺ expansion. Immunology and Cell Biology, 2011, 89, 670-680.	1.0	9
866	TNFR1 is essential for CD40, but not for lipopolysaccharide-induced sickness behavior and clock gene dysregulation. Brain, Behavior, and Immunity, 2011, 25, 434-442.	2.0	17
867	TIM-1 signaling in B cells regulates antibody production. Biochemical and Biophysical Research Communications, 2011, 406, 223-228.	1.0	25

#	Article	IF	CITATIONS
868	The Adjuvant Effects of Antibodies. Science, 2011, 333, 944-945.	6.0	24
869	Tight Regulation of Memory CD8+ T Cells Limits Their Effectiveness during Sustained High Viral Load. Immunity, 2011, 35, 285-298.	6.6	141
870	A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNARâ^'/â^' mice upon lethal virus challenge. Vaccine, 2011, 29, 4469-4475.	1.7	52
871	Cantharidin modulates development of human monocyte-derived dendritic cells. Toxicology in Vitro, 2011, 25, 1740-1747.	1.1	10
872	Delivery of Alloantigens via Apoptotic Cells Generates Dendritic Cells With an Immature Tolerogenic Phenotype. Transplantation Proceedings, 2011, 43, 2325-2333.	0.3	17
873	Adenovirus vectors can induce activation of endothelial cells: CD40-CD40L interactions partly participate in the endothelial cells activation induced by adenovirus vectors in an NF-kappaB-dependent manner. African Journal of Biotechnology, 2011, 10, 13705-13713.	0.3	0
874	The Role of CD40/CD40 Ligand Interactions in Bone Marrow Granulopoiesis. Scientific World Journal, The, 2011, 11, 2011-2019.	0.8	22
875	Effect of Enhanced Glycemic Control with Saxagliptin on Endothelial Nitric Oxide Release and CD40 Levels in Obese Rats. Journal of Atherosclerosis and Thrombosis, 2011, 18, 774-783.	0.9	52
876	Chemokines: A New Dendritic Cell Signal for T Cell Activation. Frontiers in Immunology, 2011, 2, 31.	2.2	56
877	Cell-to-Cell Interactions and Signals Involved in the Reconstitution of Peripheral CD8+ TCM and TEM Cell Pools. PLoS ONE, 2011, 6, e17423.	1.1	8
878	The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clinical and Experimental Immunology, 2011, 164, 145-157.	1.1	25
879	Construction of the HBV S-ecdCD40L fusion gene and effects of HBV S-ecdCD40L modification on function of dendritic cells. Journal of Viral Hepatitis, 2011, 18, e461-e467.	1.0	5
880	How do pleiotropic kinase hubs mediate specific signaling by TNFR superfamily members?. Immunological Reviews, 2011, 244, 29-43.	2.8	24
881	Membrane-bound CD40 ligand on T cells from mice injected with lipopolysaccharide accelerates lipopolysaccharide-induced osteoclastogenesis. Journal of Periodontal Research, 2011, 46, 464-474.	1.4	18
882	Platelets and the immune continuum. Nature Reviews Immunology, 2011, 11, 264-274.	10.6	1,361
883	Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome. Genes and Immunity, 2011, 12, 100-109.	2.2	113
884	Modulation of the humoral immune response by targeting CD40 and FcÎ ³ RII/III; delivery of soluble but not particulate antigen to CD40 enhances antibody responses with a Th1 bias. Molecular Immunology, 2011, 49, 155-162.	1.0	4
885	Impaired in vivo CD4+ T cell expansion and differentiation in aged mice is not solely due to T cell defects: Decreased stimulation by aged dendritic cells. Mechanisms of Ageing and Development, 2011,	2.2	68

#	Article	IF	CITATIONS
886	Potentiation strategies of dendritic cell-based antitumor vaccines: combinational therapy takes the front seat. Drug Discovery Today, 2011, 16, 733-740.	3.2	16
888	Avian CD154 enhances humoral and cellular immune responses induced by an adenovirus vector-based vaccine in chickens. Comparative Immunology, Microbiology and Infectious Diseases, 2011, 34, 259-265.	0.7	28
889	Immunoglobulin Responses at the Mucosal Interface. Annual Review of Immunology, 2011, 29, 273-293.	9.5	309
890	A Prospective Study of Influenza Vaccination and a Comparison of Immunologic Parameters in Children and Adults with Chromosome 22q11.2 Deletion Syndrome (DiGeorge) Tj ETQq1 1 0.784314 rgBT /Over	lo ckol OTf	5 & £17 Td (S
891	Influence of sCD40L on gastric cancer cell lines. Molecular Biology Reports, 2011, 38, 5459-5464.	1.0	9
892	Tuning of CD40–CD154 Interactions in Human B-Lymphocyte Activation: A Broad Array of In Vitro Models for a Complex In Vivo Situation. Archivum Immunologiae Et Therapiae Experimentalis, 2011, 59, 25-40.	1.0	29
893	Immunoregulatory effects of AFP domains on monocyte-derived dendritic cell function. BMC Immunology, 2011, 12, 4.	0.9	12
894	A functional TNFRSF5 polymorphism and risk of nonâ€Hodgkin lymphoma, a pooled analysis. International Journal of Cancer, 2011, 128, 1481-1485.	2.3	12
895	Cell Surface Signaling Molecules in the Control of Immune Responses: A Tide Model. Immunity, 2011, 34, 466-478.	6.6	152
896	Resistance of canine lymphoma cells to adenoviral infection due to reduced cell surface RGD binding integrins. Cancer Biology and Therapy, 2011, 11, 651-658.	1.5	9
897	Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency Virus Increases CD40 Ligand Expression and IL-12 Production in CellsEx Vivo. Viral Immunology, 2011, 24, 281-289.	0.6	4
898	Effects of environmentally-relevant levels of perfluorooctane sulfonate on clinical parameters and immunological functions in B ₆ C ₃ F ₁ mice. Journal of Immunotoxicology, 2011, 8, 17-29.	0.9	49
899	A Pilot Study of the ELFE Longitudinal Cohort: Feasibility and Preliminary Evaluation of Biological Collection. Biopreservation and Biobanking, 2011, 9, 223-227.	0.5	9
900	Role of interleukin-18 in intrahepatic inflammatory cell recruitment in acute liver injury. Journal of Leukocyte Biology, 2010, 89, 433-442.	1.5	12
901	Involvement of calcitonin gene-related peptide and CCL2 production in CD40-mediated behavioral hypersensitivity in a model of neuropathic pain. Neuron Glia Biology, 2011, 7, 117-128.	2.0	18
902	Development of Memory-Like Autoregulatory CD8+ T Cells Is CD4+ T Cell Dependent. Journal of Immunology, 2011, 187, 2859-2866.	0.4	13
903	mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment. Cancer Research, 2011, 71, 4074-4084.	0.4	75
904	Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody. Clinical Cancer Research, 2011, 17, 2270-2280.	3.2	147

#	Article	IF	CITATIONS
905	Low Levels of NF-κB/p65 Mark Anergic CD4 + T Cells and Correlate with Disease Severity in Sarcoidosis. Vaccine Journal, 2011, 18, 223-234.	3.2	37
906	Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 768-773.	3.3	165
907	Interaction with Fcl ³ RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody. Journal of Immunology, 2011, 187, 1754-1763.	0.4	202
908	CD154-CD40 interactions in the control of murine B cell hematopoiesis. Journal of Leukocyte Biology, 2011, 89, 697-706.	1.5	10
909	A Self-Reactive TCR Drives the Development of Foxp3+ Regulatory T Cells That Prevent Autoimmune Disease. Journal of Immunology, 2011, 187, 861-869.	0.4	30
910	Polypyrimidine Tract-Binding Protein Is Critical for the Turnover and Subcellular Distribution of CD40 Ligand mRNA in CD4+ T Cells. Journal of Immunology, 2011, 186, 2164-2171.	0.4	17
911	Evaluation of <i>Salmonella</i> -Vectored <i>Campylobacter</i> Peptide Epitopes for Reduction of <i>Campylobacter jejuni</i> in Broiler Chickens. Vaccine Journal, 2011, 18, 449-454.	3.2	62
912	Involvement of CD40–CD40 Ligand in Uncomplicated and Refractory Celiac Disease. American Journal of Gastroenterology, 2011, 106, 519-527.	0.2	14
913	Th Subset Balance in Lupus Nephritis. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-7.	3.0	66
914	Single Amino Acid Modification of Adeno-Associated Virus Capsid Changes Transduction and Humoral Immune Profiles. Journal of Virology, 2012, 86, 7752-7759.	1.5	84
915	Synergistic CD40 signaling on APCs and CD8 T cells drives efficient CD8 response and memory differentiation. Journal of Leukocyte Biology, 2012, 91, 859-869.	1.5	18
916	Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice. Journal of Immunology, 2012, 188, 6156-6164.	0.4	46
917	Stromal Endothelial Cells Establish a Bidirectional Crosstalk with Chronic Lymphocytic Leukemia Cells through the TNF-Related Factors BAFF, APRIL, and CD40L. Journal of Immunology, 2012, 188, 6071-6083.	0.4	76
918	Reciprocal Regulation of Protein Kinase C Isoforms Results in Differential Cellular Responsiveness. Journal of Immunology, 2012, 188, 2328-2337.	0.4	42
919	Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection. Biologics: Targets and Therapy, 2012, 6, 355.	3.0	14
920	CD154: An Immunoinflammatory Mediator in Systemic Lupus Erythematosus and Rheumatoid Arthritis. Clinical and Developmental Immunology, 2012, 2012, 1-11.	3.3	32
921	The Role of Costimulatory Receptors of the Tumour Necrosis Factor Receptor Family in Atherosclerosis. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-16.	3.0	11
922	Primary Sjogren's Syndrome and the Type I Interferon System. Current Pharmaceutical Biotechnology, 2012, 13, 2054-2062.	0.9	28

#	Article	IF	CITATIONS
923	Sorting Through Subsets. Journal of Immunotherapy, 2012, 35, 651-660.	1.2	237
924	microRNA signature for human pancreatic cancer invasion and metastasis. Experimental and Therapeutic Medicine, 2012, 4, 181-187.	0.8	30
925	The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leukemia and Lymphoma, 2012, 53, 195-201.	0.6	50
926	The immunomodulatory effects of lactic acid bacteria for improving immune functions and benefits. Applied Microbiology and Biotechnology, 2012, 96, 853-862.	1.7	195
927	Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus. Cancer Research, 2012, 72, 2327-2338.	0.4	144
928	Prevention and synergistic control of Ph+ ALL by a DNA vaccine and 6-mercaptopurine. Vaccine, 2012, 30, 5949-5955.	1.7	7
929	Association between CD40 promoter polymorphism (rs1800686, â^'508 C/T) and ischemic stroke with hypertension in a Korean population. Molecular and Cellular Toxicology, 2012, 8, 257-262.	0.8	2
930	Znaczenie receptora programowanej Å›mierci 1 oraz jego ligandów w ukÅ,adzie immunologicznym oraz nowotworach. Acta Haematologica Polonica, 2012, 43, 132-145.	0.1	11
931	CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals. Vaccine, 2012, 30, 2768-2777.	1.7	14
932	Enhancement of the anti-Salmonella immune response in CD154-deficient mice by an attenuated, IFN-γ-expressing, strain of Salmonella enterica serovar Typhimurium. Microbial Pathogenesis, 2012, 52, 326-335.	1.3	4
933	Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4+ Th cells cytotoxic by activating both perforin- and FasL-pathways. Immunology Letters, 2012, 144, 7-15.	1.1	54
934	CD40 stimulation induces vincristine resistance via AKT activation and MRP1 expression in a human multiple myeloma cell line. Immunology Letters, 2012, 144, 41-48.	1.1	13
935	Emerging roles of cathepsin E in host defense mechanisms. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2012, 1824, 105-112.	1.1	34
936	Costimulatory molecule expression on human uveal melanoma cells: Functional analysis of CD40 and B7-H1. Experimental Eye Research, 2012, 96, 98-106.	1.2	18
937	Targeting TNF superfamily members for therapeutic intervention in rheumatoid arthritis. Cytokine, 2012, 57, 305-312.	1.4	28
938	Systemic biomarkers of inflammation and haemostasis in patients with chronic necrotizing pulmonary aspergillosis. BMC Infectious Diseases, 2012, 12, 144.	1.3	11
939	Plasmacytoid Dendritic Cells Are Inefficient in Activation of Human Regulatory T Cells. PLoS ONE, 2012, 7, e44056.	1.1	7
940	Interfering with CD40 ligation: a sensitive matter in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 2093-2094.	0.6	1

#	Article	IF	CITATIONS
941	Modeling and Experimental Analyses Reveals Signaling Plasticity in a Bi-Modular Assembly of CD40 Receptor Activated Kinases. PLoS ONE, 2012, 7, e39898.	1.1	17
942	T Cell Costimulatory and Coinhibitory Pathways in Vascular Inflammatory Diseases. Frontiers in Physiology, 2012, 3, 18.	1.3	27
943	Cell-Based Therapies in the Prevention of Solid Organ Transplant Rejection. American Journal of Immunology, 2012, 8, 52-64.	0.1	0
944	Microenvironment Interactions in Chronic Lymphocytic Leukemia: A Delicate Equilibrium Linking the Quiescent and the Proliferative Pool. , 0, , .		1
945	Role of T cells in ovariectomy induced bone loss—revisited. Journal of Bone and Mineral Research, 2012, 27, 231-239.	3.1	123
946	CD40 signal expression in gastric cancer tissue and its correlation with prognosis of gastric cancer patients. Molecular Biology Reports, 2012, 39, 8741-8747.	1.0	3
947	CD40 and tumour necrosis factorâ€Î± coâ€operate to upâ€regulate inducuble nitric oxide synthase expression in macrophages. Immunology, 2012, 135, 140-150.	2.0	38
948	Selection of regulatory T cells in the thymus. Nature Reviews Immunology, 2012, 12, 157-167.	10.6	382
949	lgM predominance in autoimmune disease: Genetics and gender. Autoimmunity Reviews, 2012, 11, A404-A412.	2.5	49
950	A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines. Virology, 2012, 424, 129-137.	1.1	14
951	Critical role of CD40â€mediated autocrine tumor necrosis factorâ€alpha in potentiation of cisplatinâ€induced cytotoxicity in cancer cells. Cancer Science, 2012, 103, 197-202.	1.7	8
952	Role of CD40-Dependent Signal in Induction of Recombinase RAG-1 Expression in Peripheral T Cells of Patients with Autoimmune Diabetes Mellitus. Bulletin of Experimental Biology and Medicine, 2012, 152, 336-339.	0.3	1
953	Estrogen Deficiency, Postmenopausal Osteoporosis, and Age-Related Bone Loss. , 2013, , 1113-1136.		11
955	Osteoimmunology. , 2013, , .		1
956	Peripheral blood CD40–CD40L expression in human breast cancer. Irish Journal of Medical Science, 2013, 182, 719-721.	0.8	11
957	Single nucleotide polymorphism of CD40 in the 5′-untranslated region is associated with ischemic stroke. Gene, 2013, 529, 257-261.	1.0	10
958	FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunology, Immunotherapy, 2013, 62, 941-948.	2.0	41
959	CD40 immunotherapy for pancreatic cancer. Cancer Immunology, Immunotherapy, 2013, 62, 949-954.	2.0	95

#	Article	IF	CITATIONS
960	CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunology, Immunotherapy, 2013, 62, 347-357.	2.0	47
961	Chronic Lymphocytic Leukemia Cells Are Activated and Proliferate in Response to Specific T Helper Cells. Cell Reports, 2013, 4, 566-577.	2.9	84
962	mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Letters, 2013, 340, 1-8.	3.2	128
963	Donor-specific Regulatory T Cells Generated on Donor B Cells Are Superior to CD4+CD25high Cells in Controlling Alloimmune Responses in Humanized Mice. Transplantation Proceedings, 2013, 45, 1832-1837.	0.3	19
964	Identification of a novel CD40 ligand for targeted imaging of inflammatory plaques by phage display. FASEB Journal, 2013, 27, 4136-4146.	0.2	7
965	Osteoimmunology and Its Implications for Transplantation. American Journal of Transplantation, 2013, 13, 2245-2254.	2.6	37
966	Induction of recombinase activity in peripheral T cells in multiple sclerosis. Doklady Biological Sciences, 2013, 453, 391-393.	0.2	1
967	CD40 deficiency in mice exacerbates obesity-induced adipose tissue inflammation, hepatic steatosis, and insulin resistance. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E951-E963.	1.8	46
968	A novel Lynâ€protein kinase Cî´/εâ€protein kinase D axis is activated in B cells by signalosomeâ€independent alternate pathway BCR signaling. European Journal of Immunology, 2013, 43, 1643-1650.	1.6	6
969	Advances in targeting cell surface signalling molecules for immune modulation. Nature Reviews Drug Discovery, 2013, 12, 130-146.	21.5	229
970	Interactions Between Platelets, Leukocytes and the Endothelium. , 2013, , 295-312.		14
971	Agonistic CD40 Antibodies and Cancer Therapy. Clinical Cancer Research, 2013, 19, 1035-1043.	3.2	352
972	Importance of reverse signaling of the TNF superfamily in immune regulation. Expert Review of Clinical Immunology, 2013, 9, 335-348.	1.3	56
973	CD40 activation induces NREM sleep and modulates genes associated with sleep homeostasis. Brain, Behavior, and Immunity, 2013, 27, 133-144.	2.0	12
974	Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. Clinical Cancer Research, 2013, 19, 997-1008.	3.2	161
975	IL-4 Upregulates Igα and Igβ Protein, Resulting in Augmented IgM Maturation and B Cell Receptor–Triggered B Cell Activation. Journal of Immunology, 2013, 191, 670-677.	0.4	28
976	CD40 Therapy and Surgery. Journal of Immunotherapy, 2013, 36, 359-361.	1.2	5
977	Agonistic Anti-CD40 Induces Thyrocyte Proliferation and Promotes Thyroid Autoimmunity by Increasing CD40 Expression on Thyroid Epithelial Cells. Journal of Immunology, 2013, 190, 3928-3938.	0.4	13

#	Article	IF	CITATIONS
978	Modulation of Tumor Immunity by Soluble and Membrane-Bound Molecules at the Immunological Synapse. Clinical and Developmental Immunology, 2013, 2013, 1-19.	3.3	12
979	Costimulatory Molecules on Immunogenic Versus Tolerogenic Human Dendritic Cells. Frontiers in Immunology, 2013, 4, 82.	2.2	180
980	T-cell co-stimulatory blockade in transplantation: two steps forward one step back!. Expert Opinion on Biological Therapy, 2013, 13, 1557-1568.	1.4	23
981	Agonistic anti D40 promotes early development and increases the incidence of severe thyroid epithelial cell hyperplasia (TEC H/P) in CD4â^'/â^' mice. Immunity, Inflammation and Disease, 2013, 1, 14-25.	1.3	4
982	Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clinical and Experimental Immunology, 2013, 174, 364-371.	1.1	41
983	Effective Anti-Neu–Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells. Clinical Cancer Research, 2013, 19, 1476-1486.	3.2	54
984	CD40L expression permits CD8+ T cells to execute immunologic helper functions. Blood, 2013, 122, 405-412.	0.6	80
985	Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. Aids, 2013, 27, 2041-2051.	1.0	43
986	The Interplay between the Bone and the Immune System. Clinical and Developmental Immunology, 2013, 2013, 1-16.	3.3	153
987	New Insights into the Role of the Immune Microenvironment in Breast Carcinoma. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	50
988	Germinal Center Formation Controlled by Balancing Between Follicular Helper T Cells and Follicular Regulatory T Cells. Hanyang Medical Reviews, 2013, 33, 10.	0.4	1
989	ICAM-1-Based Rabies Virus Vaccine Shows Increased Infection and Activation of Primary Murine B Cells In Vitro and Enhanced Antibody Titers In-Vivo. PLoS ONE, 2014, 9, e87098.	1.1	11
990	TL1A Increases Expression of CD25, LFA-1, CD134 and CD154, and Induces IL-22 and GM-CSF Production from Effector CD4 T-Cells. PLoS ONE, 2014, 9, e105627.	1.1	7
991	The Humoral Immune Response to Streptococcus Pneumoniae. , 2014, , 367-381.		0
992	The Use of Anti-CD40 mAb in Cancer. Current Topics in Microbiology and Immunology, 2014, 405, 165-207.	0.7	21
993	Anti-HER2/Neu passive-aggressive immunotherapy. Oncolmmunology, 2014, 3, e27296.	2.1	3
994	The Majority of Human Memory B Cells Recognizing RhD and Tetanus Resides in IgM+ B Cells. Journal of Immunology, 2014, 193, 1071-1079.	0.4	34
995	CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus SIV239 Vaccine Enhances SIV-Specific Humoral and Cellular Immunity and Improves Protection against a Heterologous SIVE660 Mucosal Challenge. Journal of Virology, 2014, 88, 9579-9589.	1.5	53

		CITATION R	EPORT	
#	Article		IF	CITATIONS
996	Antibodies in the Pathogenesis of Hypertension. BioMed Research International, 2014, 2014	4, 1-9.	0.9	31
997	Cytomegalovirus-specific responses of CD38+ memory T cells are skewed towards IFN-Î ³ an from CD154 in HIV-1 infection. Aids, 2014, 28, 311-316.	d dissociated	1.0	8
998	<i>Ex Vivo</i> Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of <i>I Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial. Cancer Immu Research, 2014, 2, 229-240.</i>	n Vivo nology	1.6	21
999	A CD40/CD40L feedback loop drives the breakdown of CD8 ⁺ <scp>T</scp> following depletion of suppressive CD4 ⁺ T cells. European Journal of Immunolo 44, 1099-1107.	cell tolerance ogy, 2014,	1.6	7
1000	The Signaling Role of CD40 Ligand in Platelet Biology and in Platelet Component Transfusio International Journal of Molecular Sciences, 2014, 15, 22342-22364.	'n.	1.8	140
1001	Tfh Cell Differentiation and Their Function in Promoting B-Cell Responses. Advances in Expe Medicine and Biology, 2014, 841, 153-180.	rimental	0.8	10
1002	CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8+ T cell fre and patient survival. Human Immunology, 2014, 75, 614-620.	quency	1.2	28
1003	Targeted immunomodulation using antigen onjugated nanoparticles. Wiley Interdisciplir Nanomedicine and Nanobiotechnology, 2014, 6, 298-315.	iary Reviews:	3.3	37
1004	HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathv dysregulation. Brain, 2014, 137, 819-833.	way	3.7	147
1005	CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune respon- tumor imaging. Gene Therapy, 2014, 21, 195-204.	se and	2.3	32
1006	Lack of association between CD40 polymorphisms and acute rejection in German liver trans recipients. Human Immunology, 2014, 75, 1123-1127.	splant	1.2	1
1007	CD40 Signaling Drives B Lymphocytes Into an Intermediate Memoryâ€Like State, Poised Be Plasma Cells. Journal of Cellular Physiology, 2014, 229, 1387-1396.	tween NaÃ⁻ve and	2.0	17
1008	Immunoglobulin class switch recombination deficiency type 1 or CD40 ligand deficiency: fro to bench and back again. Expert Review of Clinical Immunology, 2014, 10, 91-105.	om bedside	1.3	26
1009	T Helper Cell Differentiation and Their Function. Advances in Experimental Medicine and Bio	logy, 2014,	0.8	7
1010	Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celec induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Ca Immunology, Immunotherapy, 2014, 63, 847-857.	oxib ncer	2.0	82
1011	Thymic stromal lymphopoietin links keratinocytes and dendritic cell–derived IL-23 in patie psoriasis. Journal of Allergy and Clinical Immunology, 2014, 134, 373-381.e4.	ents with	1.5	74
1013	A new Tâ€cell activation mode for suboptimal doses of antigen under the full activation of different specificity. European Journal of Immunology, 2015, 45, 1643-1653.	lÂcells with	1.6	5
1014	T Cell–Expressed CD40L Potentiates the Bone Anabolic Activity of Intermittent PTH Treat of Bone and Mineral Research, 2015, 30, 695-705.	ment. Journal	3.1	33

		CITATION RE	EPORT	
#	Article		IF	CITATIONS
1015	Adeno-associated Virus as a Mammalian DNA Vector. Microbiology Spectrum, 2015, 3,		1.2	68
1016	Latent virus infection upregulates CD40 expression facilitating enhanced autoimmunity multiple sclerosis. Scientific Reports, 2015, 5, 13995.	in a model of	1.6	33
1017	Tumor necrosis factor receptor―associated factor 6 (<scp>TRAF</scp> 6) regulation o function, and homeostasis of the immune system. Immunological Reviews, 2015, 266,	f development, 72-92.	2.8	330
1018	The role of platelets in inflammation. Thrombosis and Haemostasis, 2015, 114, 449-458	3.	1.8	391
1019	Enhanced Protective Immunity Derived from Dendritic Cells with Phagocytosis of CD40 Transgene-engineered Apoptotic Tumor Cells via Increased Dendritic Cell Maturation. To 101, 637-643.	Ligand umori, 2015,	0.6	5
1020	Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 ir 2015, 29, 1287-1296.	ifection. Aids,	1.0	19
1021	Serum-Soluble CD40 Ligand Level in MPO-ANCA-Associated Renal Vasculitis. Journal of Audiology, 2015, 1, .	Phonetics &	0.2	0
1022	Adeno-associated Virus as a Mammalian DNA Vector. , 0, , 827-849.			4
1023	Atherosclerosis: a chronic inflammatory disease mediated by mast cells. Central-Europe Immunology, 2015, 3, 380-386.	an Journal of	0.4	99
1024	Increase in Anti-Gal IgM Level is Associated With Early Graft Failure in Intraportal Porcin Xenotransplantation. Annals of Laboratory Medicine, 2015, 35, 611-617.	e Islet	1.2	15
1025	An inflammatory link in atherosclerosis and obesity. Hamostaseologie, 2015, 35, 272-2	78.	0.9	12
1026	Introduction to Costimulation and Costimulatory Molecules. , 2015, , 1-43.			15
1027	Nouvelle Cuisine: Platelets Served with Inflammation. Journal of Immunology, 2015, 194	4, 5579-5587.	0.4	170
1028	Eliminating Schistosomes through Vaccination: What are the Best Immune Weapons?. Immunology, 2015, 6, 95.	Frontiers in	2.2	35
1029	Animal Models Correlating Immune Cells for the Development of NAFLD/NASH. Journal Experimental Hepatology, 2015, 5, 239-245.	of Clinical and	0.4	17
1030	Current concepts of immune based treatments for patients with HCC: from basic science treatment approaches. Gut, 2015, 64, 842-848.	ce to novel	6.1	155
1031	Platelets promote allergic asthma through the expression of CD154. Cellular and Molec Immunology, 2015, 12, 700-707.	ular	4.8	24
1032	Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic My Cells and Causes Immune-Mediated Liver Damage. Cancer Immunology Research, 2015	eloid-Suppressive , 3, 557-566.	1.6	44

#	Article	IF	CITATIONS
1033	Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment. Cancer Immunology Research, 2015, 3, 236-244.	1.6	117
1034	CD72 negatively regulates mouse mast cell functions and down-regulates the expression of KIT and FcÂRIÂ. International Immunology, 2015, 27, 95-103.	1.8	12
1035	Innate immune response of pullets fed diets supplemented with prebiotics and synbiotics. Poultry Science, 2015, 94, 1802-1811.	1.5	29
1036	CD40-TNF activation in mice induces extended sickness behavior syndrome co-incident with but not dependent on activation of the kynurenine pathway. Brain, Behavior, and Immunity, 2015, 50, 125-140.	2.0	31
1037	Emerging molecular networks common in ionizing radiation, immune and inflammatory responses by employing bioinformatics approaches. Cancer Letters, 2015, 368, 164-172.	3.2	60
1038	Immunogenicity and protective efficacy of an Eimeria vaccine candidate based on Eimeria tenella immune mapped protein 1 and chicken CD40 ligand. Veterinary Parasitology, 2015, 210, 19-24.	0.7	26
1039	Novel Immunosuppressive Drugs. , 2015, , 1332-1342.		0
1040	New frontiers for platelet CD154. Experimental Hematology and Oncology, 2015, 4, 6.	2.0	25
1041	Oleic acid nanoemulsion for nasal vaccination: Impact on adjuvanticity based immune response. Journal of Drug Delivery Science and Technology, 2015, 28, 56-63.	1.4	19
1042	Interleukin-10–producing CD5 ⁺ B cells inhibit mast cells during immunoglobulin E–mediated allergic responses. Science Signaling, 2015, 8, ra28.	1.6	24
1043	Inhibition of CD40-Induced N-Ras Activation Reduces <i>Leishmania major</i> Infection. Journal of Immunology, 2015, 194, 3852-3860.	0.4	22
1044	FUNCTIONAL MECHANISMS OF PROBIOTICS. Journal of Microbiology, Biotechnology and Food Sciences, 2015, 4, 321-327.	0.4	59
1045	Repertoires of Autophagy in the Pathogenesis of Ocular Diseases. Cellular Physiology and Biochemistry, 2015, 35, 1663-1676.	1.1	11,181
1046	Co-expression of CD40/CD40L On XG1 Multiple Myeloma Cells Promotes IL-6 Autocrine Function. Cancer Investigation, 2015, 33, 6-15.	0.6	7
1047	Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study. Clinical Cancer Research, 2015, 21, 1321-1328.	3.2	81
1048	Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance. Immunotherapy, 2015, 7, 399-410.	1.0	56
1049	CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells. Cell Death and Disease, 2015, 6, e1864-e1864.	2.7	21
1050	Blockade of <scp>CD</scp> 40– <scp>TRAF</scp> 2,3 or <scp>CD</scp> 40– <scp>TRAF</scp> 6 is sufficient to inhibit proâ€inflammatory responses in nonâ€haematopoietic cells. Immunology, 2015, 144, 21-33.	2.0	23

#	Article	IF	Citations
1051	Soluble CD40 ligand: a novel biomarker in the pathogenesis of periodontal disease. Clinical Oral Investigations, 2015, 19, 45-52.	1.4	10
1052	Mechanisms of Inflammatory Atherosclerosis in Rheumatoid Arthritis. Current Immunology Reviews, 2016, 12, 35-46.	1.2	12
1053	Nanoparticle Coated Viral Vectors for Gene Therapy. Current Biotechnology, 2016, 5, 44-53.	0.2	11
1054	Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis. Frontiers in Pharmacology, 2016, 7, 455.	1.6	81
1055	An Update on Calcineurin Inhibitor–Free Regimens. Transplantation, 2016, 100, 836-843.	0.5	27
1056	JAK3-STAT pathway blocking benefits in experimental lupus nephritis. Arthritis Research and Therapy, 2016, 18, 134.	1.6	35
1057	Platelet Functions Beyond Hemostasis. , 2016, , 221-237.		3
1058	TRAF3 as a powerful and multitalented regulator of lymphocyte functions. Journal of Leukocyte Biology, 2016, 100, 919-926.	1.5	26
1059	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. Leukemia and Lymphoma, 2016, 57, 1269-1280.	0.6	4
1060	The nonhemostatic immune functions of platelets. Seminars in Hematology, 2016, 53, S2-S6.	1.8	26
1061	Macrophage effector responses of horses are influenced by expression of CD154. Veterinary Immunology and Immunopathology, 2016, 180, 40-44.	0.5	2
1062	KLF10 Mediated Epigenetic Dysregulation of Epithelial CD40/CD154 Promotes Endometriosis. Biology of Reproduction, 2016, 95, 62-62.	1.2	10
1064	TÂcells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone. Annals of the New York Academy of Sciences, 2016, 1364, 11-24.	1.8	56
1065	Acute Virus Control Mediated by Licensed NK Cells Sets Primary CD8+ T Cell Dependence on CD27 Costimulation. Journal of Immunology, 2016, 197, 4360-4370.	0.4	6
1066	Current status of costimulatory blockade in renal transplantation. Current Opinion in Nephrology and Hypertension, 2016, 25, 583-590.	1.0	23
1067	Adaptive Immunity. , 2016, , 206-224.e3.		1
1068	p-Cresyl sulfate suppresses lipopolysaccharide-induced anti-bacterial immune responses in murine macrophages in vitro. Toxicology Letters, 2016, 245, 24-30.	0.4	18
1069	Intrinsic immunogenicity of rapidly-degradable polymers evolves during degradation. Acta Biomaterialia, 2016, 32, 24-34.	4.1	81

#	Article	IF	CITATIONS
1070	Aging Converts Innate B1a Cells into Potent CD8+ T Cell Inducers. Journal of Immunology, 2016, 196, 3385-3397.	0.4	27
1071	The delta 6 desaturase knock out mouse reveals that immunomodulatory effects of essential n-6 and n-3 polyunsaturated fatty acids are both independent of and dependent upon conversion. Journal of Nutritional Biochemistry, 2016, 32, 29-38.	1.9	37
1072	Utility of Adenoviral Vectors in Animal Models of Human Disease III. , 2016, , 675-690.		0
1073	Expression, purification and biological characterization of the extracellular domain of CD40 from Pichia pastoris. BMC Biotechnology, 2016, 16, 8.	1.7	3
1074	γδΤeells enhance B cells for antibody production in Hashimoto's thyroiditis, and retinoic acid induces apoptosis of the γδΤeell. Endocrine, 2016, 51, 113-122.	1.1	16
1075	CD4+ T-cell dependence of primary CD8+ T-cell response against vaccinia virus depends upon route of infection and viral dose. Cellular and Molecular Immunology, 2016, 13, 82-93.	4.8	24
1076	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. Breast Cancer, 2017, 24, 111-120.	1.3	21
1077	Immunotherapy in pancreatic cancer treatment: a new frontier. Therapeutic Advances in Gastroenterology, 2017, 10, 168-194.	1.4	73
1078	Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. British Journal of Pharmacology, 2017, 174, 3940-3955.	2.7	48
1079	Platelet–Leukocyte Interactions. , 2017, , 407-433.		3
1080	Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. OncoImmunology, 2017, 6, e1265717.	2.1	25
1081	Platelets modulate endothelial cell response to dynamic shear stress through PECAM-1. Thrombosis Research, 2017, 150, 44-50.	0.8	27
1082	Mechanisms regulating T-cell infiltration and activity in solid tumors. Annals of Oncology, 2017, 28, xii18-xii32.	0.6	276
1083	Dendritic Cell-Based Cancer Therapies: Current Status and Future Directions. Molecular and Translational Medicine, 2017, , 99-120.	0.4	1
1084	Co-stimulatory function in primary germinal center responses: CD40 and B7 are required on distinct antigen-presenting cells. Journal of Experimental Medicine, 2017, 214, 2795-2810.	4.2	54
1085	T cellâ€dependent antigen adjuvanted with DOTAPâ€CpGâ€B but not DOTAPâ€CpGâ€A induces robust germinal center responses and high affinity antibodies in mice. European Journal of Immunology, 2017, 47, 1890-1899.	1.6	16
1087	CD40L is transferred to antigenâ€presenting B cells during delivery of Tâ€cell help. European Journal of Immunology, 2017, 47, 41-50.	1.6	44
1088	Soluble CD40 ligand derived from serum is not correlated with early MS. Multiple Sclerosis and Related Disorders, 2017, 14, 29-31.	0.9	4

#	Article	IF	CITATIONS
1089	A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis. Oncogene, 2017, 36, 2515-2528.	2.6	22
1090	Peptides Against Autoimmune Neurodegeneration. Current Medicinal Chemistry, 2017, 24, 1761-1771.	1.2	4
1091	Gene Expression Contributes to the Recent Evolution of Host Resistance in a Model Host Parasite System. Frontiers in Immunology, 2017, 8, 1071.	2.2	36
1092	CD40L Expression Allows CD8+ T Cells to Promote Their Own Expansion and Differentiation through Dendritic Cells. Frontiers in Immunology, 2017, 8, 1484.	2.2	37
1093	The CD40–CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Frontiers in Immunology, 2017, 8, 1791.	2.2	56
1094	A Role for CD154, the CD40 Ligand, in Granulomatous Inflammation. Mediators of Inflammation, 2017, 2017, 1-14.	1.4	3
1095	Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. Mediators of Inflammation, 2017, 2017, 1-21.	1.4	131
1096	Effect of the hepatitis B virus S-ecdCD40L vaccine therapy in HBV transgenic mice: A vaccine-induced activation of antigen presenting dendritic cells. Molecular Medicine Reports, 2017, 16, 6102-6108.	1.1	2
1097	Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40. Journal of Immunotherapy, 2017, 40, 39-50.	1.2	12
1098	Determination of Genes Related to Uveitis by Utilization of the Random Walk with Restart Algorithm on a Protein–Protein Interaction Network. International Journal of Molecular Sciences, 2017, 18, 1045.	1.8	23
1099	CD40, a Novel Inducer of Purinergic Signaling: Implications to the Pathogenesis of Experimental Diabetic Retinopathy. Vision (Switzerland), 2017, 1, 20.	0.5	3
1100	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. Journal of Experimental Medicine, 2018, 215, 859-876.	4.2	150
1101	Isorhamnetin, the active constituent of a Chinese herb Hippophae rhamnoides L, is a potent suppressor of dendritic-cell maturation and trafficking. International Immunopharmacology, 2018, 55, 216-222.	1.7	18
1102	Therapeutic approaches for induction of tolerance and immune quiescence in corneal allotransplantation. Cellular and Molecular Life Sciences, 2018, 75, 1509-1520.	2.4	15
1103	Elevated expression of activated T H 2 cells and milk-specific T H 2 cells in milk-induced eosinophilic esophagitis. Annals of Allergy, Asthma and Immunology, 2018, 120, 177-183.e2.	0.5	43
1104	Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies. Cancer Cell, 2018, 33, 664-675.e4.	7.7	78
1105	Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer: Where Do We Stand?. Clinical Lung Cancer, 2018, 19, 1-11.	1.1	48
1106	Evolving Immunotherapy Approaches for Hepatocellular Carcinoma. Current Human Cell Research and Applications, 2018, , 93-110.	0.1	0

#	Article	IF	CITATIONS
1108	Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome. Innate Immunity, 2018, 24, 4-10.	1.1	12
1109	Modulation of fatty acid metabolism and immune suppression are features of in vitro tumour sphere formation in ontogenetically distinct dog cancers. Veterinary and Comparative Oncology, 2018, 16, E176-E184.	0.8	8
1110	Potential Markers of Autoimmune Diseases, Alleles rs115662534(T) and rs548231435(C), Disrupt the Binding of Transcription Factors STAT1 and EBF1 to the Regulatory Elements of Human CD40 Gene. Biochemistry (Moscow), 2018, 83, 1534-1542.	0.7	8
1111	Rosuvastatin stabilizes atherosclerotic plaques by reducing CD40L overexpression-induced downregulation of P4Hα1 in ApoEâ^'/â^' mice. International Journal of Biochemistry and Cell Biology, 2018, 105, 70-77.	1.2	3
1112	Increased expression of the membrane-bound CD40 ligand on peripheral CD4+ T cells in the acute phase of AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. Journal of Neuroimmunology, 2018, 325, 64-68.	1.1	6
1113	Regulatory T Cell Modulation of Cytokine and Cellular Networks in Corneal Graft Rejection. Current Ophthalmology Reports, 2018, 6, 266-274.	0.5	16
1116	Viral- and Non-viral-Based Hybrid Vectors for Gene Therapy. , 2018, , 111-130.		2
1117	ExÂvivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy. Kidney International, 2018, 93, 1452-1464.	2.6	20
1118	Hematobin is a novel immunomodulatory protein from the saliva of the horn fly Haematobia irritans that inhibits the inflammatory response in murine macrophages. Parasites and Vectors, 2018, 11, 435.	1.0	8
1119	Platelets and Hemostasis. , 2018, , 60-113.		Ο
1120	The ferroptosis inducer erastin promotes proliferation and differentiation in human peripheral blood mononuclear cells. Biochemical and Biophysical Research Communications, 2018, 503, 1689-1695.	1.0	40
1121			(
	Emerging Concepts in Immune Thrombocytopenia. Frontiers in Immunology, 2018, 9, 880.	2.2	155
1122	Emerging Concepts in Immune Thrombocytopenia. Frontiers in Immunology, 2018, 9, 880. CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. Oncolmmunology, 2018, 7, e1490856.	2.2	155 28
1122 1123	Emerging Concepts in Immune Thrombocytopenia. Frontiers in Immunology, 2018, 9, 880. CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. Oncolmmunology, 2018, 7, e1490856. Gene expression profiles of <scp>CD</scp> 4/ <scp>CD</scp> 8 doubleâ€positive T cells in porcine peripheral blood. Animal Science Journal, 2018, 89, 979-987.	2.2 2.1 0.6	155 28 19
1122 1123 1124	Emerging Concepts in Immune Thrombocytopenia. Frontiers in Immunology, 2018, 9, 880. CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. Oncolmmunology, 2018, 7, e1490856. Gene expression profiles of <scp>CD</scp> 4/ <scp>CD</scp> 8 doubleâ€positive T cells in porcine peripheral blood. Animal Science Journal, 2018, 89, 979-987. Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401. Cancer Gene Therapy, 2019, 26, 26-31.	2.2 2.1 0.6 2.2	155 28 19 16
1122 1123 1124 1125	 Emerging Concepts in Immune Thrombocytopenia. Frontiers in Immunology, 2018, 9, 880. CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. Oncolmmunology, 2018, 7, e1490856. Gene expression profiles of <scp>CD</scp>4/<scp>CD</scp>8 doubleâ€positive T cells in porcine peripheral blood. Animal Science Journal, 2018, 89, 979-987. Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401. Cancer Gene Therapy, 2019, 26, 26-31. Bovine κ-Casein Fragment Induces Hypo-Responsive M2-Like Macrophage Phenotype. Nutrients, 2019, 11, 1688. 	2.2 2.1 0.6 2.2 1.7	155 28 19 16 7
1122 1123 1124 1125 1126	Emerging Concepts in Immune Thrombocytopenia. Frontiers in Immunology, 2018, 9, 880. CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. Oncolmmunology, 2018, 7, e1490856. Gene expression profiles of <scp>CD</scp> 4/ <scp>CD</scp> 8 doubleâ€positive T cells in porcine peripheral blood. Animal Science Journal, 2018, 89, 979-987. Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401. Cancer Gene Therapy, 2019, 26, 26-31. Bovine κ-Casein Fragment Induces Hypo-Responsive M2-Like Macrophage Phenotype. Nutrients, 2019, 11, 1688. Overâ€expression of p190Rho GEF enhances Bâ€cell activation and germinal center formation in Tâ€cellâ€dependent humoral immune responses. Immunology and Cell Biology, 2019, 97, 877-887.	2.2 2.1 0.6 2.2 1.7	155 28 19 16 7 4

#	Article	IF	CITATIONS
1128	The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma. Frontiers in Immunology, 2019, 10, 2457.	2.2	16
1129	CD40 polymorphisms were associated with HCV infection susceptibility among Chinese population. BMC Infectious Diseases, 2019, 19, 840.	1.3	5
1130	Deep learning-based model for predicting progression in patients with head and neck squamous cell carcinoma. Cancer Biomarkers, 2019, 27, 19-28.	0.8	15
1131	CD40 in Endothelial Cells Restricts Neural Tissue Invasion by Toxoplasma gondii. Infection and Immunity, 2019, 87, .	1.0	8
1132	A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. Nature Communications, 2019, 10, 2236.	5.8	65
1133	Interactions Between Platelets, Leukocytes, and the Endothelium. , 2019, , 295-310.		5
1134	Polysaccharide Nanoparticles Can Efficiently Modulate the Immune Response against an HIV Peptide Antigen. ACS Nano, 2019, 13, 4947-4959.	7.3	61
1135	Reverse Signaling of Tumor Necrosis Factor Superfamily Proteins in Macrophages and Microglia: Superfamily Portrait in the Neuroimmune Interface. Frontiers in Immunology, 2019, 10, 262.	2.2	25
1136	Current Status of Vascularized Composite Allotransplantation. American Surgeon, 2019, 85, 631-637.	0.4	31
1137	Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity. International Journal of Molecular Sciences, 2019, 20, 5821.	1.8	23
1138	Identification of genetic overlap and novel risk loci for attention-deficit/hyperactivity disorder and bipolar disorder. Molecular Psychiatry, 2021, 26, 4055-4065.	4.1	31
1139	Macrophage CD40 signaling drives experimental autoimmune encephalomyelitis. Journal of Pathology, 2019, 247, 471-480.	2.1	21
1140	A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity. Cancer Immunology Research, 2019, 7, 428-442.	1.6	92
1141	Congenital neutropenia and primary immunodeficiency diseases. Critical Reviews in Oncology/Hematology, 2019, 133, 149-162.	2.0	35
1142	T follicular helper cells restricted by IRF8 contribute to T cell-mediated inflammation. Journal of Autoimmunity, 2019, 96, 113-122.	3.0	21
1143	CD40 Agonist Antibodies in Cancer Immunotherapy. Annual Review of Medicine, 2020, 71, 47-58.	5.0	327
1144	Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Scientific Reports, 2020, 10, 92.	1.6	122
1145	Costimulation Blockade in Kidney Transplant Recipients. Drugs, 2020, 80, 33-46.	4.9	21

#	Article	IF	CITATIONS
1146	Key Players and Biomarkers of the Adaptive Immune System in the Pathogenesis of Sarcoidosis. International Journal of Molecular Sciences, 2020, 21, 7398.	1.8	24
1147	Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Cancers, 2020, 12, 1872.	1.7	18
1148	Association between platelet count and mucosal healing in Japanese patients with ulcerative colitis: a cross-sectional study. BMC Gastroenterology, 2020, 20, 384.	0.8	14
1149	CD40/CD40L Signaling as a Promising Therapeutic Target for the Treatment of Renal Disease. Journal of Clinical Medicine, 2020, 9, 3653.	1.0	13
1150	Development of CD40L-modified tumor small extracellular vesicles for effective induction of antitumor immune response. Nanomedicine, 2020, 15, 1641-1652.	1.7	9
1151	Platelets as Mediators of Neuroinflammation and Thrombosis. Frontiers in Immunology, 2020, 11, 548631.	2.2	72
1152	Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors. Neuro-Oncology, 2020, 22, 1757-1770.	0.6	7
1153	Modeling human pediatric and adult gliomas in immunocompetent mice through costimulatory blockade. Oncolmmunology, 2020, 9, 1776577.	2.1	8
1154	Age-Dependent Differences in T-Cell Responses to Influenza A Virus. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 415-423.	1.4	7
1155	Selfâ€Assembling Glycopeptide Conjugate as a Versatile Platform for Mimicking Complex Polysaccharides. Advanced Science, 2020, 7, 2001264.	5.6	9
1156	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. Cell Reports, 2020, 30, 1553-1569.e6.	2.9	21
1157	Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer. Cell, 2020, 181, 442-459.e29.	13.5	741
1158	Blockade of CD40L inhibits immunogenic maturation of lung dendritic cells: Implications for the role of lung iNKT cells in mouse models of asthma. Molecular Immunology, 2020, 121, 167-185.	1.0	7
1159	An Improved DNA Vaccine Against Bovine Herpesvirus-1 Using CD40L and a Chemical Adjuvant Induces Specific Cytotoxicity in Mice. Viral Immunology, 2021, 34, 68-78.	0.6	5
1160	Estrogen deficiency and the pathogenesis of osteoporosis. , 2021, , 773-797.		2
1161	Protective effect of dietary supplementation of Bupleurum falcatum L saikosaponins on ammonia exposure–induced ileum injury in broilers. Poultry Science, 2021, 100, 100803.	1.5	8
1162	APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunology, Immunotherapy, 2021, 70, 1853-1865.	2.0	20
1163	Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response. Cancers, 2021, 13, 257.	1.7	10

#	Article	IF	CITATIONS
1164	Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies. Chemical Science, 2021, 12, 6929-6948.	3.7	85
1165	A Critical Review about Different Vaccines against Classical Swine Fever Virus and Their Repercussions in Endemic Regions. Vaccines, 2021, 9, 154.	2.1	32
1167	Agonistic CD40 Antibodies in Cancer Treatment. Cancers, 2021, 13, 1302.	1.7	50
1168	Protective effect of Polygonatum sibiricum polysaccharide on cyclophosphamide-induced immunosuppression in chickens. Research in Veterinary Science, 2021, 135, 96-105.	0.9	23
1169	Bayesian analysis of cytokines and chemokine identifies immune pathways of HBsAg loss during chronic hepatitis B treatment. Scientific Reports, 2021, 11, 7455.	1.6	2
1170	New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis. Frontiers in Immunology, 2021, 12, 631055.	2.2	12
1171	Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far. Seminars in Oncology, 2021, 48, 57-68.	0.8	5
1172	CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors. Clinical Cancer Research, 2021, 27, 4054-4065.	3.2	18
1173	Pancreas cancer: Therapeutic trials in metastatic disease. Journal of Surgical Oncology, 2021, 123, 1475-1488.	0.8	11
1174	Identification and functional characterization of CD154 in T cell-dependent immune response in Nile tilapia (Oreochromis niloticus). Fish and Shellfish Immunology, 2021, 111, 102-110.	1.6	8
1175	Ostertagia ostertagi Mediates Early Host Immune Responses via Macrophage and Toll-Like Receptor Pathways. Infection and Immunity, 2021, 89, .	1.0	2
1176	TLR9- and CD40-Targeting Vaccination Promotes Human B Cell Maturation and IgG Induction via pDC-Dependent Mechanisms in Humanized Mice. Frontiers in Immunology, 2021, 12, 672143.	2.2	5
1178	Macrophage Plasticity and Polarization Are Altered in the Experimental Model of Multiple Sclerosis. Biomolecules, 2021, 11, 837.	1.8	22
1179	Proinflammatory oscillations over the menstrual cycle drives bystander CD4 T cell recruitment and SHIV susceptibility from vaginal challenge. EBioMedicine, 2021, 69, 103472.	2.7	4
1180	Caspase-11 regulates lung inflammation in response to house dust mites. Cellular Immunology, 2021, 370, 104425.	1.4	4
1181	Mast Cell Modulation of B Cell Responses: An Under-Appreciated Partnership in Host Defence. Frontiers in Immunology, 2021, 12, 718499.	2.2	12
1182	Autoimmunity in dry eye disease – An updated review of evidence on effector and memory Th17 cells in disease pathogenicity. Autoimmunity Reviews, 2021, 20, 102933.	2.5	30
1184	CD40 plays roles in T cell-dependent response and B cell activation and differentiation in Nile tilapia (Oreochromis niloticus). Aquaculture, 2021, 544, 737063.	1.7	0

	CITATION	Report	
#	Article	IF	CITATIONS
1185	Immunotherapy as a boon in cancer treatment. , 2021, , 207-226.		0
1186	IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn's disease and new therapeutic targets. Archives of Pharmacal Research, 2021, 44, 117-132.	2.7	7
1187	Soluble CD40L activates soluble and cell-surface integrin αvβ3, α5β1, and α4β1 by binding to the allosteric ligand-binding site (site 2). Journal of Biological Chemistry, 2021, 296, 100399.	1.6	8
1188	Overview of Hematopoietic Cell Transplantation Immunology. , 0, , 16-30.		1
1189	Dendritic Cell Vaccines in Cancer: Obstaclesto Overcome. , 2009, , 309-330.		2
1190	Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology, 2009, , .	0.8	6
1191	Experimental mouse models of inflammatory bowel disease: new insights into pathogenic mechanisms. , 2003, , 67-99.		3
1192	Memory T Cells in Rhesus Macaques. Advances in Experimental Medicine and Biology, 2010, 684, 126-144.	0.8	14
1193	Immunobiology of \hat{I}^2 -Cell Destruction. Advances in Experimental Medicine and Biology, 2013, 771, 194-218.	0.8	13
1194	Immunoregulation by Cytokines in Autoimmune Diabetes. Advances in Experimental Medicine and Biology, 2003, 520, 159-193.	0.8	21
1195	Heat shock protein receptors, functions and their effect on monocytes and dendritic cells. , 2003, , 193-216.		3
1196	B-Lymphocyte Signaling Receptors and the Control of Class-II Antigen Processing. Current Topics in Microbiology and Immunology, 2000, 245, 101-126.	0.7	17
1197	The Relationship of Inflammation and Initiation of Autoimmune Disease: Role of TNF Super Family Members. Current Topics in Microbiology and Immunology, 2002, 266, 1-9.	0.7	30
1198	Mechanisms in Allergic Contact Dermatitis. , 2001, , 13-58.		22
1199	Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8+ cytotoxic T-cell activation and antitumor immunity. , 0, .		1
1200	Basic mechanisms and clinical implications of oral tolerance. Current Opinion in Gastroenterology, 1999, 15, 546.	1.0	25
1201	CONTRIBUTION OF CD40-CD154-MEDIATED COSTIMULATION TO AN ALLORESPONSE IN VIVO1. Transplantation, 1999, 67, 1284-1287.	0.5	16
1202	CD8+ T CELLS CONTRIBUTE TO THE DEVELOPMENT OF TRANSPLANT ARTERIOSCLEROSIS DESPITE CD154 BLOCKADE1. Transplantation, 2000, 69, 2609-2612.	0.5	70

#	Article	IF	CITATIONS
1203	TREATMENT WITH ANTI-CD154 ANTIBODY AND DONOR-SPECIFIC TRANSFUSION PREVENTS ACUTE REJECTION OF MYOBLAST TRANSPLANTATION1. Transplantation, 2002, 73, 453-461.	0.5	27
1204	Inhibition of CD40-mediated endothelial cell activation with antisense oligonucleotides. Transplantation, 2002, 73, 635-642.	0.5	1
1205	Treatment of multiple sclerosis: recent trials and future perspectives. Current Opinion in Neurology, 1999, 12, 279-293.	1.8	55
1206	Induction therapy with new monoclonal antibodies. Current Opinion in Organ Transplantation, 1999, 4, 326.	0.8	2
1207	African swine fever virus: a B cell-mitogenic virus in vivo and in vitro Journal of General Virology, 1999, 80, 1453-1461.	1.3	21
1208	Structural and Biochemical Analysis of Signal Transduction by the TRAF Family of Adapter Proteins. Cold Spring Harbor Symposia on Quantitative Biology, 1999, 64, 551-562.	2.0	12
1210	Acquired Immunity against Viral Infections. , 0, , 247-265.		2
1211	CD40 Ligation Prevents <i>Trypanosoma cruzi</i> Infection through Interleukin-12 Upregulation. Infection and Immunity, 1999, 67, 1929-1934.	1.0	44
1212	CD40-Mediated Induction of CD4 and CXCR4 on B Lymphocytes Correlates with Restricted Susceptibility to Human Immunodeficiency Virus Type 1 Infection: Potential Role of B Lymphocytes as a Viral Reservoir. Journal of Virology, 1999, 73, 7972-7980.	1.5	61
1213	Blockade of LIGHT/LTÎ ² and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. Journal of Clinical Investigation, 2002, 109, 549-557.	3.9	68
1214	Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2002, 109, 233-241.	3.9	19
1215	Rescue of CD8 T cell–mediated antimicrobial immunity with a nonspecific inflammatory stimulus. Journal of Clinical Investigation, 2002, 110, 1493-1501.	3.9	12
1216	Blockade of LIGHT/LTÎ ² and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. Journal of Clinical Investigation, 2002, 109, 549-557.	3.9	32
1217	CD4+ T cell–independent vaccination against Pneumocystis carinii in mice. Journal of Clinical Investigation, 2001, 108, 1469-1474.	3.9	96
1218	The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. Journal of Clinical Investigation, 2003, 112, 234-243.	3.9	50
1220	The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. Journal of Clinical Investigation, 2003, 112, 234-243.	3.9	114
1221	CD4+ T cell-independent DNA vaccination against opportunistic infections. Journal of Clinical Investigation, 2005, 115, 3536-3544.	3.9	65
1222	DC-based cancer vaccines. Journal of Clinical Investigation, 2007, 117, 1195-1203.	3.9	502

#	Article	IF	CITATIONS
1223	Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. Journal of Clinical Investigation, 1999, 103, 1151-1158.	3.9	101
1224	CTLA4Ig inhibits T cell–dependent B-cell maturation in murine systemic lupus erythematosus. Journal of Clinical Investigation, 2000, 106, 91-101.	3.9	147
1225	The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. Journal of Clinical Investigation, 2000, 106, 63-72.	3.9	125
1226	TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. Journal of Clinical Investigation, 2018, 128, 4387-4396.	3.9	55
1227	Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood, 2000, 96, 218-223.	0.6	76
1228	Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood, 2000, 96, 91-99.	0.6	15
1229	Optimal induction of antigenâ€specific CD8+ T cell responses requires bystander cell participation. Journal of Leukocyte Biology, 2002, 72, 1164-1171.	1.5	7
1230	Apoptosis Induced by Pseudomonas aeruginosa in Antigen Presenting Cells Is Diminished by Genetic Modification with CD40 Ligand. , 0, .		2
1231	Comparison of a Static Process and a Bioreactor-based Process for the GMP Manufacture of Autologous Xcellerated T Cells for Clinical Trials. BioProcessing: Advances and Trends in Biological Product Development, 2003, 2, 23-34.	0.1	13
1232	CD40 Signaling Synergizes with TLR-2 in the BCR Independent Activation of Resting B Cells. PLoS ONE, 2011, 6, e20651.	1.1	46
1233	Design of Targeted B Cell Killing Agents. PLoS ONE, 2011, 6, e20991.	1.1	41
1234	CD40 Gene Silencing Reduces the Progression of Experimental Lupus Nephritis Modulating Local Milieu and Systemic Mechanisms. PLoS ONE, 2013, 8, e65068.	1.1	26
1235	Downregulation of Immunoglobulin-Like Transcript-4 (ILT4) in Patients with Psoriatic Arthritis. PLoS ONE, 2014, 9, e92018.	1.1	9
1236	Soluble CD40 Ligand in Sera of Subjects Exposed to Leishmania infantum Infection Reduces the Parasite Load in Macrophages. PLoS ONE, 2015, 10, e0141265.	1.1	16
1237	Inhibition of Autoimmune Diabetes in NOD Mice by miRNA Therapy. PLoS ONE, 2015, 10, e0145179.	1.1	7
1238	T Cell Costimulatory Blockade. Journal of the American Society of Nephrology: JASN, 1999, 10, 1356-1365.	3.0	69
1239	CD40 Ligation Enhances IL-15 Production by Tubular Epithelial Cells. Journal of the American Society of Nephrology: JASN, 2001, 12, 80-87.	3.0	34
1240	An immunocompetent mouse model of human glioblastoma. Oncotarget, 2017, 8, 61072-61082.	0.8	30

#	Article	IF	CITATIONS
1241	Mucosal Tolerance to Prevent Type 1 Diabetes: Can the Outcome Be Improved in Humans?. Review of Diabetic Studies, 2004, 1, 113-113.	0.5	16
1242	CD40 Expression in Human Esophageal Squamous Cell Carcinoma Is Associated with Tumor Progression and Lymph Node Metastasis. Anticancer Research, 2016, 36, 4467-4476.	0.5	27
1243	Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Frontiers in Bioscience - Landmark, 2008, 13, 1813.	3.0	356
1244	Severity of Experimental Autoimmune Uveitis Is Reduced by Pretreatment with Live Probiotic Escherichia coli Nissle 1917. Cells, 2021, 10, 23.	1.8	15
1245	Construction of recombinant eukaryotic expression plasmid containing murine CD40 ligand gene and its expression in H22 cells. World Journal of Gastroenterology, 2005, 11, 182.	1.4	6
1246	Curcumin improves regulatory T cells in gut-associated lymphoid tissue of colitis mice. World Journal of Gastroenterology, 2016, 22, 5374.	1.4	43
1247	Therapeutic effect of curcumin on experimental colitis mediated by inhibiting CD8+CD11c+cells. World Journal of Gastroenterology, 2017, 23, 1804.	1.4	13
1248	Characteristics and clinical trial results of agonistic anti‑CD40 antibodies in the treatment of malignancies (Review). Oncology Letters, 2020, 20, 1-1.	0.8	44
1249	Dysfunction of Dendritic and T Cells as the Cause of Immune Suppression in HTLV-I Infected Individuals. Journal of Clinical and Experimental Hematopathology: JCEH, 2003, 43, 43-48.	0.3	11
1250	Requirement for CD40/CD40L Interactions for Development of Autoimmunity Differs Depending on Specific Checkpoint and Costimulatory Pathways. ImmunoHorizons, 2018, 2, 54-66.	0.8	14
1251	Peptide immunotherapy in experimental autoimmune encephalomyelitis. Biomedical Journal, 2015, 38, 206.	1.4	10
1252	Role for CD40 and CD40L Expression in Generating CD8 T Cell Response to Minor Histcompatibility Antigen, H60. Immune Network, 2007, 7, 173.	1.6	5
1253	Clinical Relevance of Cytokines, Chemokines and Adhesion Molecules in Systemic Vasculitis. , 0, , .		5
1254	Prognostic values of GMPS, PR, CD40, and p21 in ovarian cancer. PeerJ, 2019, 7, e6301.	0.9	12
1255	T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients. Journal of Experimental Medicine, 2021, 218, .	4.2	18
1256	DNA Vaccination Against Cancer Antigens. , 2000, , 119-136.		2
1257	HLA and Transplantation I: Allorecognition of HLA Molecules in Transplantation. , 2000, , 387-404.		1
1258	Blockade of cytokine activity by soluble cytokine receptors. , 2000, , 157-176.		0

#	Article	IF	CITATIONS
1259	Factors Contributing to Autoimmune Disease. Advances in Experimental Medicine and Biology, 2001, 490, 7-19.	0.8	0
1260	Bioartificial Pancreas. , 2001, , .		0
1261	Utility of Adenoviral Vectors in Animal Models of Human Disease III. , 2002, , 595-613.		0
1263	Contribution of LCMV Transgenic Models to Understanding T Lymphocyte Development, Activation, Tolerance, and Autoimmunity. Current Topics in Microbiology and Immunology, 2002, 263, 119-143.	0.7	3
1264	Aktivierende anti-CD4O-Antikörper führen zu intratumoraler T-Lymphozytenmigration und Wachstumshemmung beim experimentellen Leberkarzinom. Langenbecks Archiv Ful^r Chirurgie Supplement, 2002, , 65-67.	0.0	0
1265	Cellular effects of HMG-CoA reductase inhibitors on blood cells (monocytes, macrophages, platelets). , 2002, , 55-80.		0
1266	DENOUEMENT&OV0093Continued from p. 259. Pediatric Infectious Disease Journal, 2002, 21, 268-269.	1.1	0
1267	Blockade of CD40/CD154 signal as a therapeutic strategy for autoimmune diseases. Japanese Journal of Clinical Immunology, 2003, 26, 259-266.	0.0	0
1268	Mechanisms of CD40 Signaling in the Immune System. , 2003, , 319-322.		0
1269	Costimulatory Molecules in T Cell Activation and Transplantation. , 2004, , 291-312.		0
1270	Gene-Modified Tumor-Cell Vaccines. , 2004, , 253-273.		0
1272	Interaction of Innate and Acquired Immune Response: Toll Receptors— Potential Link of Infection to Rejection. , 2004, , 459-475.		0
1273	B-Type Natriuretic Peptides in Acute Coronary Syndromes. , 2004, , 323-338.		0
1274	Lymphocyte Subpopulations of the Skin. , 2004, , 101-122.		2
1275	Adjuvants and the Initiation of T-Cell Responses. , 2006, , 49-67.		2
1276	Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma. Cancer Science, 2008, , .	1.7	0
1277	Gene Therapy, Vaccines and Immune Modulation. , 2008, , 201-215.		0
1278	Immune Adjuvants. , 2009, , 627-652.		0

#	Article	IF	CITATIONS
1279	CD40 Stimulation and Antitumor Effects. , 2009, , 227-239.		0
1280	Monoclonal Antibody Therapy for Hematologic Malignancies. , 2010, , 493-536.		0
1281	Immunoisolation in Cell Transplantation. , 2010, , 241-262.		0
1282	Adaptive Immunity. , 2010, , 285-313.		0
1285	Treatment of Melanoma with Agonist Immune Costimulatory Agents. , 2012, , 307-331.		0
1286	T Cells Mediate the Effects of PTH in Bone. , 2013, , 81-90.		0
1287	Mechanism of inflammatory bone resorption. Journal of Japanese Society of Periodontology, 2014, 56, 5-11.	0.1	0
1289	Signaling through adhesion molecules in inflammatory processes Ensho, 1999, 19, 179-190.	0.0	0
1290	Tolerance induction in cardiac transplantation. Current Opinion in Organ Transplantation, 1999, 4, 219-226.	0.8	0
1291	Interaction of Pathogens with the Innate and Adaptive Immune System. , 0, , 425-449.		0
1292	T Cell Immune Responses in Skin. , 2017, , 121-135.		0
1294	Germinal Center Formation with Retrovirally Transduced B Cells for Determining the Role of Specific Molecules In Vivo. Methods in Molecular Biology, 2017, 1623, 147-158.	0.4	1
1295	The Effects of Checkpoint Blockade and a CD40 Agonist on Tindependent and T-dependent Antibody Responses in Mice: Implications for Optimization of Vaccination Strategies in Patients Receiving Immunotherapies. Journal of Cancer Research and Immuno-Oncology, 2018, 04, .	0.0	0
1296	Non-immune Modulators of Cellular Immune Surveillance to HIV-1 and Other Retroviruses: Future Artificial Intelligence-Driven Goals and Directions. , 2019, , 41-57.		0
1297	Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clinical Reviews in Allergy and Immunology, 2007, 32, 57-65.	2.9	1
1298	Immune modulation by CD40L blockade. , 2008, , 71-86.		0
1299	Immunomodulatory Molecules of the Immune System. , 2007, , 67-121.		0
1300	Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2002, 109, 233-241.	3.9	10

#	Article	IF	CITATIONS
1301	Rescue of CD8 T cell–mediated antimicrobial immunity with a nonspecific inflammatory stimulus. Journal of Clinical Investigation, 2002, 110, 1493-1501.	3.9	6
1302	Immunological Tolerance in Allo- and Xenografts. , 2007, , 433-449.		0
1303	Composite Tissue Allotransplantation. Journal of Investigative Surgery, 2003, 16, 193-201.	0.6	5
1306	Identification of primary retinal cells and ex vivo detection of proinflammatory molecules using flow cytometry. Molecular Vision, 2009, 15, 1383-9.	1.1	35
1308	Focus: Immunology and immunotherapeutics. Introduction. Yale Journal of Biology and Medicine, 2011, 84, 331-2.	0.2	0
1309	Polymorphism of the IL-18 and CD40 genes and Liver Transplant Outcome in Iranian Patients. International Journal of Organ Transplantation Medicine, 2014, 5, 149-54.	0.5	1
1310	CD40/CD40 ligand interactions in immune responses and pulmonary immunity. Nagoya Journal of Medical Science, 2011, 73, 69-78.	0.6	49
1311	Efficacy of Hepatitis B Vaccination among Children in Special Region of Yogyakarta, Indonesia: Evaluation of Humoral and Cellular Immunity. Kobe Journal of Medical Sciences, 2018, 63, E92-E98.	0.2	1
1312	Regulatory T cell modulation of cytokine and cellular networks in corneal graft rejection. Current Ophthalmology Reports, 2018, 6, 266-274.	0.5	10
1313	Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis. Cells, 2021, 10, 3116.	1.8	8
1315	The role of immunoglobulin E and mast cells in hypertension. Cardiovascular Research, 2022, 118, 2985-2999.	1.8	15
1316	Platelets as Key Factors in Inflammation: Focus on CD40L/CD40. Frontiers in Immunology, 2022, 13, 825892.	2.2	48
1317	Thrombocytopenia in COVIDâ€ʿ19 and vaccineâ€ʿinduced thrombotic thrombocytopenia. International Journal of Molecular Medicine, 2022, 49, .	1.8	4
1318	Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nature Cancer, 2022, 3, 287-302.	5.7	29
1319	The Controversial Role of HCY and Vitamin B Deficiency in Cardiovascular Diseases. Nutrients, 2022, 14, 1412.	1.7	21
1320	Distinct Cellular Immune Responses to SARS-CoV-2 in Pregnant Women. Journal of Immunology, 2022, 208, 1857-1872.	0.4	16
1321	Immune regulation of the ocular surface. Experimental Eye Research, 2022, 218, 109007.	1.2	17
1322	CD40L protects against mouse hepatitis virus-induced neuroinflammatory demyelination. PLoS Pathogens, 2021, 17, e1010059.	2.1	12
ARTICLE IF CITATIONS Genetic Vaccination as a Flexible Tool to Overcome the Immunological Complexity of Invasive Fungal 1324 1.5 0 Infections. Frontiers in Microbiology, 2021, 12, 789774. The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. Cancers, 2022, 14, 1913. 1.7 A Polyvalent Peptide CD40 Nanoagonist for Targeted Modulation of Dendritic Cells and Amplified 1326 11.1 20 Cancer Immunotherapy. Advanced Materials, 2022, 34, e2109432. Genetics and epigenetics of autoimmune thyroid diseases: Translational implications. Best Practice and 1327 Research in Clinical Endocrinology and Metábolism, 2023, 37, 101661. The Shape of Nanostructures Encodes Immunomodulation of Carbohydrate Antigen and Vaccine 1328 1.6 13 Development. ACS Chemical Biology, 2022, 17, 1122-1130. Pathophysiology of Dry Eye Disease Using Animal Models., 2023, , 41-68. Safety and tumour-specific immunological responses of combined dendritic cell vaccination and 1332 anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a 0.8 4 phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial). BMJ Open, 2022, 12, e060431. Disruption of retinal inflammation and the development of diabetic retinopathy in mice by a 2.9 14 CD40-derived peptide or mutation of CD40 in MÃ1/4ller cells. Diabetologia, 2022, 65, 2157-2171. Bovine Immunity and Vitamin D3: An Emerging Association in Johne's Disease. Microorganisms, 2022, 10, 1334 1.6 0 1865. Differential involvement of CD40, CD80, and major histocompatibility complex class I molecules in cytotoxicity induction and interferon $\hat{a} \in \hat{I}^3$ production by human natural killer effectors. Journal of 1.5 Leukocyte Biology, 2002, 72, 305-311. Disruption of CD40/CD40 ligand interaction with cleavage of CD40 on human gingival fibroblasts by human leukocyte elastase resulting in down-regulation of chemokine production. Journal of 1336 11 1.5 Leukocyte Biology, 2002, 72, 538-545. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. Journal of 6.9 Hematology and Oncology, 2022, 15, . Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. 1338 1.7 9 Cancers, 2022, 14, 4209. Detection of rare autoreactive T cell subsets in patients with pemphigus vulgaris. Frontiers in 2.2 Immunology, 0, 13, . TRAF3/p38-JNK Signalling Crosstalk with Intracellular-TRAIL/Caspase-10-Induced Apoptosis Accelerates 1341 1.8 7 ROS-Driven Cancer Cell-Specific Death by CD40. Cells, 2022, 11, 3274. Osteopontin augments CD3-mediated interferon- \hat{I}^3 and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. Journal of Leukocyte Biology, 2002, 68, 1343 495-502 SJL and NOD macrophages are uniquely characterized by genetically programmed, elevated expression 1344 of the IL-12(p40) gene, suggesting a conserved pathway for the induction of organ-specific 1.531 autoimmunity. Journal of Leukocyte Biology, 2001, 69, 440-448. Natural Killer Cell Activation Primes Macrophages to Clear Bacterial Infection. American Surgeon, 1347 0.4 2003, 69, 679-687.

CITATION REPORT

#	Article	IF	CITATIONS
1348	Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis. Cell Communication and Signaling, 2022, 20, .	2.7	3
1349	Nanoparticle delivery of <i>CD40</i> siRNA suppresses alloimmune responses by inhibiting activation and differentiation of DCs and macrophages. Science Advances, 2022, 8, .	4.7	4
1350	Receptorâ€mediated effects of Δ ⁹ â€ŧetrahydrocannabinol and cannabidiol on the inflammatory response of alveolar macrophages. Immunology and Cell Biology, 2023, 101, 156-170.	1.0	6
1351	Cutting Edge Commentary: Immune Responses in the Absence of Costimulation: Viruses Know the Trick. Journal of Immunology, 1998, 161, 5791-5794.	0.4	92
1352	TRANCE, a TNF Family Member, Is Differentially Expressed on T Cell Subsets and Induces Cytokine Production in Dendritic Cells. Journal of Immunology, 1999, 162, 2562-2568.	0.4	237
1353	Pancreatic Infiltration But Not Diabetes Occurs in the Relative Absence of MHC Class II-Restricted CD4 T Cells: Studies Using NOD/CIITA-Deficient Mice. Journal of Immunology, 1999, 162, 4576-4588.	0.4	53
1354	B Lymphocytes as Antigen-Presenting Cells for CD4+ T Cell Priming In Vivo. Journal of Immunology, 1999, 162, 5695-5703.	0.4	165
1355	Human Vascular Endothelial Cells Favor Clonal Expansion of Unusual Alloreactive CTL. Journal of Immunology, 1999, 162, 7022-7030.	0.4	46
1356	Mechanisms of IL-10 Production in Human Microglia-T Cell Interaction. Journal of Immunology, 1999, 162, 6819-6828.	0.4	58
1357	In Vivo Polysaccharide-Specific IgG Isotype Responses to Intact <i>Streptococcus pneumoniae</i> Are T Cell Dependent and Require CD40- and B7-Ligand Interactions. Journal of Immunology, 1999, 163, 659-667.	0.4	61
1358	CD40 Ligand-Activated Human Monocytes Amplify Glomerular Inflammatory Responses Through Soluble and Cell-to-Cell Contact-Dependent Mechanisims. Journal of Immunology, 1999, 163, 2168-2175.	0.4	48
1359	Evidence That Langerhans Cells in Adult Pulmonary Langerhans Cell Histiocytosis Are Mature Dendritic Cells: Importance of the Cytokine Microenvironment. Journal of Immunology, 1999, 163, 3511-3515.	0.4	87
1360	Disruption of CD154:CD40 Blocks Generation of Allograft Immunity Without Affecting APC Activation. Journal of Immunology, 1999, 163, 2470-2477.	0.4	27
1361	Characterization of RNA Binding Proteins Associated with CD40 Ligand (CD154) mRNA Turnover in Human T Lymphocytes. Journal of Immunology, 1999, 163, 4199-4206.	0.4	23
1362	Hyperexpression of CD40 Ligand (CD154) in Inflammatory Bowel Disease and Its Contribution to Pathogenic Cytokine Production. Journal of Immunology, 1999, 163, 4049-4057.	0.4	111
1363	Cutting Edge: Thymic Selection and Autoreactivity Are Regulated by Multiple Coreceptors Involved in T Cell Activation. Journal of Immunology, 1999, 163, 3577-3581.	0.4	45
1364	CD4+ T Cell Responses to CD40-Deficient APCs: Defects in Proliferation and Negative Selection Apply Only with B Cells as APCs. Journal of Immunology, 1999, 163, 5250-5256.	0.4	26
1365	Toll-like Receptor 9 Induced Dendritic Cell Activation Promotes Anti-Myeloperoxidase Autoimmunity and Glomerulonephritis. International Journal of Molecular Sciences, 2023, 24, 1339.	1.8	2

CITATION REPORT

#	Article	IF	CITATIONS
1366	Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Advanced Science, 2023, 10, .	5.6	10
1367	Role of Monocyte-Derived Dendritic Cells (MoDCs) in Tumor Immune Response. , 2023, , 1-18.		0
1368	One Case of Ulcerative Colitis with Secondary Thrombocytosis and Literature Review. Advances in Clinical Medicine, 2023, 13, 2065-2070.	0.0	0
1369	Single-cell transcriptome profiling of the stepwise progression of head and neck cancer. Nature Communications, 2023, 14, .	5.8	17
1383	Same yet different — how lymph node heterogeneity affects immune responses. Nature Reviews Immunology, 0, , .	10.6	1
1385	Future developments: Xenotransplantation. , 2008, , 1467-1484.		0